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ABSTRACT
STRUCTURAL AND MECHANISTIC STUDIES OF α-GALACTOSIDASE A
AND PHARMACOLOGICAL CHAPERONES
FEBRUARY 2010
ABIGAIL IDA A. GUCE, B.S., UNIVERSITY OF THE PHILIPPINES-DILIMAN
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Scott C. Garman

Human α-galactosidase (α-GAL; EC 3.2.1.22) is a lysosomal enzyme that
hydrolyzes of terminal alpha-linked galactosyl residue of glycosphingolipids.
Deficiencies in α-GAL leads to Fabry disease, which is characterized by the build-up of
globotriaosylceramide and other neutral substrates in cells, ultimately leading to a multisystemic organ failure in patients. Hundreds of distinct mutations have been found in the
α-GAL gene of Fabry disease patients. One current treatment for Fabry disease is
Enzyme Replacement Therapy (ERT), which restores the missing α-GAL function. An
alternative treatment, called Pharmacological Chaperone Therapy (PCT), utilizes a small
molecule substrate analogue, 1-deoxygalactonojirimycin (DGJ).
In order to better understand molecular basis of Fabry disease, this work
addresses structural and mechanistic studies of the α-GAL glycoprotein. First, we have
determined crystal structures of each stage in the catalytic mechanism of the α-GAL
enzymatic reaction. These studies reveal a novel strained conformation of the sugar when
it is covalently bound to the enzyme. Second, we examine the molecular mechanism of
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chaperoning by pharmacological chaperones. A combination of biochemical and
biophysical approaches reveals that the high potency of the DGJ chaperone is due to an
interaction with α-GAL residue D170. Third, we have investigated mutant α-GAL
proteins for their response to pharmacological chaperones, leading to a set of structurebased rules for predicting the effect of pharmacological chaperone on every Fabry disease
patient. Fourth, we use rational design approaches to interconvert the specificity of αGAL into that of a related enzyme, α-N-acetylgalactosaminidase (α-NAGAL). Structural
and enzymatic experiments show that the engineered enzyme contains new substrate
specificity, as predicted by the design.
The structural and mechanistic details we present in this thesis provide better
understanding of the catalysis of the human α-galactosidase enzyme as well as define the
molecular basis for pharmacological chaperone therapy in Fabry patients. Since α-GAL
is one of the best studied lysosomal storage disease, it might be used as a model to better
understand other lysosomal storage diseases and as well as other diseases related to
misfolded proteins, including Alzheimer’s and Parkinson’s diseases.
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CHAPTER 1

STRUCTURE AND FUNCTION OF α-GALACTOSIDASE A

1.1. α-Galactosidase A and Fabry disease
Human α-galactosidase A (α-GAL: EC 3.2.1.22) is a lysosomal enzyme that
catalyzes the hydrolysis of a terminal alpha-linked galactosides from oligosaccharides,
glycoproteins and glycolipids in cells (Figure 1.1a) (Brady 1967; Desnick 2001). α-GAL
is also known to recognize the terminal α-galactosyl moiety of the human blood group B
antigen and enzymatically convert it to the universal donor, blood group O (Figure 1b)
(Wherett 1973; Zhu, Leng et al. 1996).
The 1.45 kb α-galactosidase A gene (GLA A, NM000169) is localized to the Xchromosome region, Xq22.1, and encodes a glycoprotein of 429 amino acids including a
31 amino acid signal sequence (Calhoun 1985; Bishop 1986). Molecular mass analysis by
gel filtration revealed α-GAL is a obligate homodimer with an apparent molecular weight
of about 100 kDa (Dean and Sweeley 1979; Dean and Sweeley 1979; Bishop and
Desnick 1981). Biochemical assays show a 46 kDa mature monomer polypeptide which
undergoes dimerization, co-translational cleavage of the secretion signal, N-linked posttranslational carbohydrate attachment at the ER, and glycosylation modification in the
Golgi before it traffics to the lysosome through the mannose-6-phosphate receptor (Dean
and Sweeley 1979; Lemansky 1987; Dahms, Lobel et al. 1989; Ioannou, Bishop et al.
1992).
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a.

b.
α-GAL
Blood group B

Blood group O

Figure 1.1 α-galactosidase A natural substrates
α-GAL catalyzes the hydrolysis of terminal α-linked galactosyl residue. (a) Fabry
disease substrate globotriaosylceramide is cleaved by α-GAL to form
lactosylceramide. (b) Industrial application for purified α-GAL is the conversion of
blood group B to the universal donor, blood group O.
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In humans, inherited mutations in GLA gene causes Fabry disease (FD), a
lysosomal storage disease, which is characterized by the absence or shortage of
functional α-GAL enzyme in cells. The deficiency of functional α-GAL enzyme leads to
the progressive build up of neutral substrates, predominantly globotriaosylceramide (GL3), in the plasma and in lysosomes of tissues throughout the body (Figure 1a) (Brady
1967; Desnick 2001).
Among more than 50 lysosomal diseases, Fabry disease is the second most
common disorder after Gaucher disease (a deficiency of β-glucosidase) (Brady 1965;
Platt 2004). Fabry disease is an X-linked recessive lysosomal storage disorder first
described in 1898, which affects 1 of every 40,000 males of all ethnic backgrounds
(Anderson 1898; Fabry 1898; Desnick 2001). This number may be a gross underestimate
due to a number of independent clinical studies showing that ~3-5% of men with left
ventricular hypertrophy (LVH), a condition with an enlarged heart (Nakao, Takenaka et
al. 1995; Sachdev, Takenaka et al. 2002); ~5% of men with acute cryptogenic stroke,
stroke with unknown or undetermined cause (Rolfs 2005); and ~1% of men undergoing
hemodialysis caused by renal failure (Utsumi 2000; Nakao 2003; Kotanko, Kramar et al.
2004), have been diagnosed with FD. More recently, a population of newborns at
northwestern Italy was screened, revealing a higher incidence of 1 in 3,000-4,000 males
are α-GAL deficient (Spada, Pagliardini et al. 2006). These reports demonstrate that
Fabry disease has a higher prevalence than previously thought, and there are potentially a
large number of undiagnosed cases of Fabry disease among the male population. This
makes it a focus of a number of clinical studies and pharmaceutical pursuits.
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1.1.1. Phenotype and symptoms
Affected individuals with Fabry disease could either have classical (also called
severe) or cardiac (also known as mild or variant) phenotype. The classical or severe
phenotype of the disease is characterized by little or no α-GAL enzyme activity detected
in the lysosome. Initial symptoms appear during childhood and early adolescence where
patients complain of episodes of nagging pain in their extremities such as hands and feet,
a condition known as acroparesthesia (Lockman 1973; Beck 2001; Desnick 2001). This is
a clinical hallmark of Fabry disease and is mostly referred to in clinical literature as the
episodic Fabry “crisis” (Mehta 2002). Acroparesthesia is later followed by the visible
symptom of developing skin lesions (angiokeratoma) that first manifest as a characteristic
skin rash throughout the body (Wise 1962; Desnick 2001). In addition, GL-3 build-up in
the blood vessels near the sweat glands and eye affects the patient’s ability to sweat
(hypohidrosis and anhidrosis) and causes benign corneal and lenticular opacities (Sher
1979; Desnick 2001). With age, the disease progresses with the accumulation of GL-3
substrate in various types of cells in organs, and patients develop major morbid
symptoms such as cardiomyopathy, gastrointestinal disturbances, kidney dysfunction and
cerebrovascular complications, typically leading to early demise in their forties (Desnick
1971; Rowe 1974; Nagao, Nakashima et al. 1991; Desnick 2001). Blood type has also
shown to influence the severity of the disease, where patients with B blood group antigen
tend to have a more rapid progression of the disease (Desnick, Brady et al. 2003; Hopkin,
Bissler et al. 2003).
In contrast, individuals who have the mild or cardiac form of Fabry disease have
mutations in the α-GAL gene that lead to less than 5-10% residual enzymatic activity

4

(Beck 2001). These patients are initially asymptomatic because the residual enzyme
activity is able to remove some of the substrate in the lysosome, preventing its initial
build up. However with time, slow progressive build up of the substrate causes disease
symptoms, including late onset of unexplained renal failure, cardiac disease, and/or GL-3
deposition in myocardial cells (Ferrans 1969; von Scheidt W. 1991; Germain 2002).
Surprisingly, only 1% of female carriers develop the severe form of Fabry disease
(MacDermot, Holmes et al. 2001). Most are asymptomatic until they develop symptoms
associated with the mild/cardiac form (MacDermot 2001; Teragaki 2004). The difference
between the hemizygote (XY) male and the heterozygote (XX) female in terms of disease
manifestation is a result of random X inactivation of any of the two X-chromosome in
females (Redonnet-Vernhet, Ploos van Amstel et al. 1996; Whybra, Kampmann et al.
2001). Mortality in their 50’s is a result of the mild form of Fabry disease (Desnick
2001).
Fabry disease is a multi-systemic disorder often very difficult to clinically
evaluate because the initial symptoms are broad and associated with a variety of organs.
Misdiagnosis or untimely diagnosis is common among Fabry disease making treatment of
the more complicated symptoms challenging due to disease progression (MacDermot
2001). Accurate diagnosis is also central to effective health maintenance, vital primary
care management and treatment choices. Correctly identifying the disease is done through
the analysis of GL-3 substrate levels in urinary sediments (isosthenuria) and blood; αGAL activity assay in plasma or tears; and confirmed through genetic testing to identify
mutations to the GLA gene (Weibel 2001).
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1.1.2. Mutations
Among the nearly 50 distinct lysosomal storage diseases, Fabry disease is one of
the best documented, with over 400 mutations reported in patients. To date, a variety of
mutations have been identified including missense, nonsense, splicing mutation, small
deletion and insertion as well as large gene rearrangement (Human Gene Mutation
Database) which frequently causes the severe form of Fabry disease. These mutations can
lead to a defective synthesis of the polypeptide chain, loss of catalytic capability,
degradation of unstable or misfolded protein or a combination of these possibilities (Fan
and Ishii 2007). Approximately 70% of the described mutations are single point amino
acid substitutions and are considered private mutations, those unique to a single or few
families. This complicates clinical predictions based on genotype-phenotype correlation
alone. What is clearly established however is that clinical manifestation is directly related
to the GL-3 substrate accumulation and the phenotype of the disease (severe or mild) is
directly related to the level of residual enzyme activity measured in patients (Schaefer
2005).
Genome sequencing and transcription studies of patient fibroblasts, insect cells,
and mammalian cells enabled researchers to investigate the effect of FD mutations on αGAL mRNA level (Ioannou, Bishop et al. 1992). Studies have shown that in most cases,
mRNA levels are comparable for both normal and the patients’ cells. Therefore, most
mutations that result in the disease affect protein levels and/or activities (Ishii, Sakuraba
et al. 1992; Ishii 2000; Kase, Bierfreund et al. 2000). Because the mRNA levels are
typically unaffected by the mutations, Fabry disease is caused by the non-transcription of
mRNA,

6

Figure 1.2 Fabry disease causing mutations
Amino acid sequence of wild-type α-GAL with the mutations reported by Fabry disease
patients listed below. Amino acid residues in red indicate the mild form of the disease.
This list shows the heterogeneity of the type and location of the mutations for Fabry
disease.
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defective biosynthesis, protein folding, loss of the catalytic capability of the enzyme, or a
combination of these effects. Figure 1.2 shows the wild-type human α-GAL sequence
and a current list of amino acid substitutions reported by patients, indicating the
heterogeneity of mutations causing Fabry disease (Garman 2006). For Fabry disease, the
connection or pattern between the nature of the inherited mutation (genotype) and the
symptoms of the disease (phenotype), organ involvement or disease severity is not very
obvious. Clearly, a better understanding of the genotype-phenotype relationship in αGAL would be of immense clinical benefit.

1.2. Fabry disease treatment
Prior to 2001, there was no specific treatment for Fabry disease, with patients
receiving entirely palliative treatment (also called supportive management treatment) to
either reduce the severity of the symptoms or alleviate the pain. Palliative care is the
standard treatment for other lysosomal storage diseases with no known cure (Fan 2003).
The goal of this type of treatment is to improve the quality of life of the patients but does
not address the source of the disease. Another option for end-stage symptoms such as
major organ failure is an invasive surgery such as kidney and heart transplant to replace
the damaged organ. Although these procedures have elevated risks associated with the
surgery, transplants have shown promising results with notable clinical improvement
(Erten 1998; Simonaro 1999; Desnick 2001). Other potential therapies include
experimental gene-mediated enzyme replacement therapy and adeno-associated virusmediated muscle-directed gene transfer. These trial treatments are done by using an
expression vector for α-GAL A to insert into the patient cells through bone marrow
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transplant or intravenous injection to the liver (Takenaka, Hendrickson et al. 1999;
Ziegler, Li et al. 2002). However, careful safety and toxicity studies have not been done
(Takahashi, Hirai et al. 2002). A different treatment option is prophylactic therapy to
prevent the progression of disease (Desnick 2001). The goal of a prophylactic treatment
is protective and preventative through lifestyle modifications to minimize harmful disease
progression (Weibel 2001). The aforementioned treatments are nonspecific, addressing
symptoms rather than curing Fabry disease. Although these interventions manage and
can mitigate the symptoms, these treatments do not increase enzyme concentration or
activity in the lysosome to break down accumulated GL-3 substrate in cells and tissue.

1.2.1. Enzyme replacement therapy (ERT)
For three decades now, research on lysosomal storage diseases has focused on a
disease-specific therapy that tackles the fundamental cause of the disease, explicitly the
deficiency of an active lysosomal enzyme that breaks down toxic substrates in the cell.
Enzyme replacement therapy (ERT) was first proposed by de Duve in the early 1960’s in
order to supplement missing or defective enzyme with a normal and functional
counterpart to potentially stop and reverse disease progression (Desnick 2004). The
groundwork of Brady and co-workers on Gaucher disease provided the “proof of
concept” of ERT, which was approved for Gaucher disease by the US FDA in 1991
(Barton, Brady et al. 1991; Parker, Barton et al. 1991). Clinical trials have successfully
established the positive correlation of the GL-3 substrate clearance and improvement of
clinical manifestation with enzyme replacement therapy for Fabry disease and other
lysosomal storage diseases (Ioannou 2001; Schiffmann 2001; Beck 2002; Germain 2002;
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Desnick, Brady et al. 2003). This paved the way for ERT as a treatment for Fabry
disease, which was approved by the FDA in 2003.
Currently Fabry disease patients’ main treatment is enzyme replacement therapy
where recombinant human α-GAL produced in CHO or engineered human cell lines is
intravenously administered to restore the missing enzyme function. ERT has successfully
demonstrated the reduction and clearance of accumulated glycosphingolopids in FD
patients accompanied by the reversible manifestation of the disease such as reducing
pain, heart and renal complications (Eng, Banikazemi et al. 2001; Beck 2002). The small
increase of intracellular α-GAL activity in the lysosome lessens metabolic defects and
significant improves the quality of life of patients (Schiffmann 2001; Germain 2002).
Preclinical studies have shown lowered GL-3 accumulation in major organs such as heart
and kidney (Eng, Banikazemi et al. 2001; Breunig, Weidemann et al. 2006). In addition,
the discovery of the mannose-6-phosphate receptor-mediated pathway allowed for
targeting of recombinant enzyme to the lysosome of cells and tissue (Lemansky, Bishop
et al. 1987; Dahms and Kornfeld 1989; Dahms, Lobel et al. 1989).
However, progress of ERT is still limited by the large quantity of enzyme needed.
The difficulty of expression of highly purified therapeutic enzymes results in high costs,
approximately $250,000/year/patient, one of the most expensive treatments available in
the US (Desnick, Brady et al. 2003). Another pitfall of replacement therapy is that when
enzyme is administered exogenously, only 1% of the injected enzyme makes it to specific
tissues such as the heart and kidney. Most of the enzymes have a short biological halflife, necessitating frequent injections of a high dose of enzyme. This is accompanied by a
high risk of developing immune reaction to the injected glycoprotein (Schellekens 2002).
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About 65-85% of Fabry disease patients can develop immune responses ranging from
mild to severe and as a consequence require additional medication with the infusion, such
as anti-histamine or steroids (Eng, Guffon et al. 2001; Vedder, Breunig et al. 2008).
Safety and toxicity studies have demonstrated that the majority of males receiving ERT
produce antibodies, rendering ERT less effective (Eng, Guffon et al. 2001; Schiffmann,
Ries et al. 2006; Vedder, Breunig et al. 2008). Lastly, ERT is limited to non-neurologic
symptoms due to the fact that enzymes are unable to cross the blood-brain barrier
(Desnick 2004). Although enzyme replacement therapy is a therapeutic option for both
phenotypes of Fabry disease, there are clearly limitations associated with this treatment
option.

1.2.2. Pharmacological chaperone therapy (PCT)
An alternative treatment for enzyme replacement therapy for Fabry disease is
pharmacological chaperone therapy (PCT). This treatment, which utilizes a small
molecule to help stabilize the mutant enzyme, is proposed for patients having residual αGAL activity (Asano, Ishii et al. 2000; Fan 2003). There are two types of
pharmacological chaperones, one called a chemical chaperone that binds non-specifically
to the enzyme and another known as active-site specific chaperone (ASSC) where the
small molecule binds to the active site. In both cases the small molecule binds to the
enzyme and prevents protein aggregation or assists the enzyme to fold to its proper
conformation ultimately leading to restoration of enzyme function (Kolter 2003). In
particular, ASSC’s are of interest to researchers and clinicians since these small
molecules are usually enzyme inhibitors or substrate analogues that bind with high
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affinity to the active site of a specific target enzyme. A potent inhibitor binds efficiently
to the specific enzyme at a lower concentration and therefore serves as a better folding
template for the unstable mutant (Fan, Ishii et al. 1999; Fan 2003). Studies have shown
that the binding affinity of a pharmacological chaperone is proportional to its ability to
chaperone proper folding (Asano, Ishii et al. 2000). Because lysosomal enzymes fold in
the ER, pharmacological chaperones must also cross lipid bilayers to be able to rescue
unstable mutant enzyme and promote proper folding (Yam, Bosshard et al. 2006).
Chapter 3 discusses in detail a model for the molecular mechanism of pharmacological
chaperone therapy.
A pharmacological chaperone, the tight binding substrate analogue, 1deoxygalactonojirimycin (DGJ), is currently in clinical trials for Fabry disease (Asano,
Ishii et al. 2000; Fan, Ishii et al. 2000; Sugawara, Tajima et al. 2009). Additionally, the
enzymatic product galactose has also been investigated for treatment of Fabry disease.
DGJ is an imino sugar with a similar structure to galactose, the α-GAL product (see
Figure 1.3) (Legler and Pohl 1986; Frustaci, Chimenti et al. 2001). Cellular uptake of
DGJ and galactose is independent of receptors and then diffuse easily in the cells. In vivo
and in vitro studies have demonstrated that sub-saturating amounts of DGJ bind to the
active site of the mutant enzyme, facilitating trafficking out of the ER and increasing
enzyme concentration and activity at the lysosome (Ishii, Chang et al. 2007; Shimatori
2007; Shin 2007; Shin 2008; Benjamin 2009; Ishii, Chang et al. 2009). This increase in
enzyme activity translates to the clearance of the accumulated substrate in cells and
organs, resulting in a positive clinical outcome for patients. For lysosomal enzymes in
vivo, normal substrate turnover occurs with a threshold level of greater than
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α-galactose

1-deoxygalactonojirimycin
(DGJ)

Figure 1.3 Galactose and DGJ structure
Both α-galactose and DGJ have very similar structure and are known to bind to the
active site of α-GAL however DGJ is known to bind tighter to the active site than
galactose.
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10-15% of normal enzyme activity (Leinekugel 1992; Ries, Gupta et al. 2005). Short and
long term toxicity studies have shown DGJ to be well tolerated and to have no known
adverse effect (Ishii, Chang et al. 2009). DGJ is also orally administered and could
potentially cross the blood-brain barrier and could have a significant therapeutic effect on
neurological symptoms (Desnick 2004).
FD is one of the first lysosomal storage diseases to show promising results with
PCT. However the biochemical mechanism of the compound is not fully understood.
Chapter 3 and 4 will focus on investigating the molecular mechanism of DGJ as a
pharmacological chaperone. Chapter 3 will focus on characterizing interaction of the
small molecule with wild-type α-GAL to improve our understanding on the basis of
chaperone therapy. Chapter 4 explores other chemical chaperones, focusing on known
Fabry-disease causing mutations. Since there are a large number of mutations that cause
Fabry disease, we also seek to identify mutations that would respond favorably to PCT
and determine the full clinical spectrum of DGJ therapy through existing mutant studies
and structural analysis.

1. 3. Overall structure of human α-galactosidase A
Interest in the molecular structure of human α-galactosidase A in order to
understand the mechanism, phenotype-genotype relationship and physiology of Fabry
disease has lead to several crystal structures of the enzyme since the first α-GAL
structure at 3.25 Å resolution was published in 2004 (Garman and Garboczi 2004; Guce
2009; Lieberman, D'Aquino J et al. 2009).
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Superposition of all the three-dimensional structures mentioned above reveals
similar overall tertiary and quaternary arrangement with a root mean square deviation
between 0.3 to 1.0 Å (for 390 Cα). The mature polypeptide comes together to form an
obligate homodimer, after removal of the N-terminal 31 amino acid signal sequence.
Each monomer is composed of two domains: the N-terminal, (β/α)8 domain and the Cterminal β sandwich domain. Residues 32-330 make up domain one with alternating β
strands and α helices to form a classic β	
  barrel. Eight parallel β strands make up the
center of the barrel where the active site is located.	
  In the C-terminal domain, residues
330-429 form eight anti-parallel β strands on two sheets in a β sandwich to make a Greek
key motif. This domain does not have any known function, but truncating the C-terminal
domain abolishs the catalytic activity (Miyamura, Araki et al. 1996). The C-terminal
domain packs against the (β/α)8 barrel,	
  burying an extensive surface area of 2500 Å2,
while the dimer interface is approximately 2200 Å2 with mostly hydrophobic contacts
(see Figure 1.4) (Garman and Garboczi 2002; Garman and Garboczi 2004; Garman 2006;
Guce 2009; Lieberman, D'Aquino J et al. 2009).
Each monomer contains 12 cysteines, 10 of which participate in disulfide bonds
(C52-C94, C56-C63, C142-C172, C202-C223, and C378-C382). C90 and C174 are free
cysteines. There are three sites for N-linked glycosylation (N139, N192 and N215),
located in the N-terminal domain, away from the active site (Garman and Garboczi 2002;
Garman and Garboczi 2004; Garman 2006). In humans and mammalian cell lines the
enzyme mass is approximately 5-15% carbohydrate in the form of N-linked
oligosaccharide chains, which make up 70 different glycoforms (Lee, Jin et al. 2003). The
heterogeneity at the glycosylation site makes crystallization of the protein challenging.
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Figure 1.4 Overall structure of human α-galactosidase A
The α-galactosidase A polypeptide trace is shown in rainbow from blue at the Nterminus to red at the C-terminus. The N-linked carbohydrates are shown as sticks,
and the galactose ligand is shown as spheres, marking the active site in the first
domain.
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However, these carbohydrates are physiologically important for the enzyme to target the
lysosome through the mannose-6-phosphate receptor pathway (Dahms, Lobel et al.
1989). The enzyme has 11 more acidic residues than basic residues per monomer,
generating an electrostatic surface potential that is highly negative (see Figure 1.5, red
patches), suitable for the acidic environment of the lysosome.
The structural fold of human α-GAL is also well conserved among the other
members of the α-galactosidase family, including rice and Trichoderma reesei αgalactosidases, which both share 34% amino acid sequence identity with the human
sequence respectively (Fujimoto, Kaneko et al. 2003; Golubev, Nagem et al. 2004).

1.3.1. Active site and ligand binding
α-GAL binds and selects terminal α-galactosides by making specific contacts
with the functional groups on the substrate. Residues from seven loops of domain one are
assembled to form the active site at the middle of the (β/α)8 barrel. The active site of αGAL is composed of 15 residues: W47, D92, D93, Y134, C142, K168, D170, C172,
E203, L206, Y207, R227, D231, D266, and M267. There is an internal disulfide bond
between C172 and C142. This disulfide bond and Y134 would clash with a terminal βlinked galactoside, thus human α-GAL selects and binds only α-galactosides. The related
enzyme α-N-acetylgalactosaminidase (α-NAGAL, E.C. 3.2.1.49) recognizes a similar
substrate except for an N-acetyl instead of a hydroxyl at position 2 on the sugar (Garman,
Hannick et al. 2002; Clark and Garman 2009). In α-GAL, the larger side chains E203 and
L206 recognize the smaller hydroxyl at the 2 position of the sugar, and the side chains
sterically occlude N-acetyl at position 2 on the larger substrate, α-N-
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Figure 1.5 The electrostatic potential surface of α-galactosidase A
The dimer surface is colored by electrostatic potential as calculated by the program
CCP4mg (from -10 kBT/e (red) to +10 kBT/e (blue), and with galactose and N-linked
carbohydrates colored green and yellow respectively. The overall dimer is markedly
negatively charged, consistent with a molecule that resides in the low pH of the
lysosome.
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acetylgalactosamine. E203 and L206 are located on the “recognition loop” that sets the
substrate specificity between the two related glycosidases. Other than those two residues,
α-GAL and	
  α-NAGAL share 13 active site residues in common. W47 packs against C4,
C5 and C6 and discriminate the 4-axial hydroxide of galactose from the equatorial
hydroxide of glucose. The rest of the residues make contact with the ligand, stabilizing
the terminal galactose in the active site pocket through an extensive H-bonding network
(see Figure 1.6). The two monomers come together placing the two active sites on the
same side of the dimer approximately 50 Å2 apart. Based on the structure, there is no
evidence of cooperativity between the two active sites (Garman and Garboczi 2002;
Garman and Garboczi 2004; Garman 2006). Chapter 5 will detail experiments probing
the recognition loop and its consequence to the activity, function and structure of the
enzyme. D170 and D231 are the two residues at the active site that catalyze the
hydrolysis of the terminal α-galactosyl moiety from α-GAL substrates.

1.3.2. Fabry disease mutation
The α-GAL structure solved in 2004 enabled for the first time mapping of the
Fabry disease-causing mutations and this provided insight into the nature of the enzyme
defect leading to the protein deficiency (Garman and Garboczi 2002; Garman and
Garboczi 2004). In this section we focus on and examine only the mutations that affect
the structure of the protein. Point mutations were mapped as substitutions in the protein,
allowing classification of the mutations by their expected effect on the protein. Three
groups of mutations emerged: First, those mutations that disrupt the active site of the
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Figure 1.6 The α-galactosidase A active site and binding interactions
Top: The α-galactosidase A active site is shown with a galactose ligand (green) bound.
The surface indicates the complimentary shapes of the protein and the ligand in the
active site. The residues in the active site and the interactions between the protein and
the ligand are shown as dash lines.
Bottom: The interaction between the protein and the ligand are detailed. Red dash lines
represents hydrogen bonds, and blue dash lines represent van der Waals interactions.
Note that the protein makes contacts to every functional group on the ligand.
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enzyme leading to loss of enzyme activity, second, those mutations that perturb the
hydrophobic core of the protein leading to folding defects and possible degradation of
unstably folded protein, and last in those mutations that have other effects on the folded
state of the protein, which include broken disulfide bonds, loss of N-linked glycosylation
site or exposed mutations with no obvious explanation. Figure 1.7 maps the point
mutations in the Fabry disease database revealing that the mutations are distributed
throughout the structure. About 90% of the missense mutations are buried residues that
might disrupt the three dimensional structure of the protein. Combining the genetic data,
the clinical phenotype classification data of Fabry disease mutations and the threedimensional structure of the glycoprotein, leads to new structural insights and gives a
better molecular understanding of the disease.

1.4. Catalytic mechanism
Based on the sequence and structure of α-GAL, it is classified into glycoside
hydrolase family 27 and clan D (in the systematic classification of glycoside hydrolases,
GH’s) (Vocadlo and Davies 2008). The reaction catalyzed by α-GAL is classified as a
retaining glycoside hydrolysis and uses a double displacement mechanism first described
by Koshland in 1953 (Koshland 1953). In the active site, two carboxylic acids (D170 and
D231) are positioned on opposite sides of the glycosidic bond to be cleaved (see Figure
1.8). The substrate undergoes two successive nucleophilic attacks on the anomeric
carbon. First, D170 makes a nucleophilic attack on the anomeric carbon and cleaves the
glycosidic bond of the bound galactose generating a galactosyl-enzyme intermediate.
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Figure 1.7 α-galactosidase A protein and Fabry disease mutations
The α-galactosidase A dimer is shown in cartoon form. The residues affected in the
severe form of Fabry disease are colored blue, and those affected in the variant
phenotypes of Fabry disease are colored yellow. Overall, more than half of the
residues in the protein have been implicated in Fabry disease. The residues affected in
the variant phenotypes tend to be more exposed than those found in the severe
phenotype.

22

Figure 1.8 The α-galactosidase A catalytic mechanism
α-galactosidase A uses a double displacement mechanism, where the substrate
undergoes two successive nucleophilic attacks on the same chiral carbon. First, D170
makes a nucleophilic attack on the anomeric C and cleaves the glycosidic bond of the
bound galactose generating a covalent intermediate. Second, D231 deprotonates water
that attacks C1, breaking the covalent bond, and resulting in the retention of the α
anomeric conformation of the product.
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Second, D231 deprotonates a water molecule, which in turn attacks the C1 of the
galactosyl-enzyme intermediate resulting in the cleavage of the covalent intermediate and
the retention of the α anomeric conformation (Hart 2000; Ly 2000). D170 of the active
site acts as a nucleophile and D231 as a proton donor and then acceptor. Prior to the
determination of the three- dimensional structure, covalent labeling of the nucleophile
with a mechanism-based inhibitor followed by proteolysis and LC/MS identified the
catalytic aspartic acid residue of a homologue α-GAL enzyme. This technique was used
to identify the nucleophile of other α retaining glycosydases (belonging to other GHclans), including α-glucosidase (family 13), α-mannosidase (family 38) and coffee αgalactosidase (family 27) (Ly 2000). Chapter 2 will present a snapshot of the stages of the
double displacement mechanism by a series of α-GAL structures. These new highresolution structures provide new insight and mechanistic detail into the entire α-GAL
family.

1.5. Statement of thesis
The clinical studies and structural knowledge serve as the groundwork for the
research described here. We seek to broaden our knowledge of one of the well-studied
lysosomal storage disorders, Fabry disease, through high-resolution crystal structures and
biophysical techniques. Despite the intense clinical interest in this enzyme or industrial
appeal for blood group conversion, high-resolution structures of the catalytic mechanism
remained elusive. We seek to characterize each step in the catalytic cycle of the enzyme
through x-ray crystallography. The high-resolution crystal structures of α-GAL at
different stages of the catalytic cycle provide structural insight into the double
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displacement mechanism for α-GAL as well as other proteins belonging to the same
family. The characterization of each step of the catalytic cycle of the enzyme is presented
in Chapter 2.
With the various treatments for Fabry disease, the research described here will
seek to define the molecular basis for pharmacological chaperone therapy in Fabry
disease patients. Little is know about the atomic basis as well as the biochemistry of
pharmacological chaperone therapy. Here, we studied the effects of the binding of the
small molecule to the stability of the enzyme under various pH conditions. The
characterization of the interaction between α-GAL and the small molecule DGJ is
described in Chapter 3. Biophysical techniques and mutagenesis identified the important
residue for binding the small molecule and its chaperoning effect. The analysis of DGJ
binding described in Chapter 3 is used as a model for other lysosomal storage disease and
protein misfolding diseases.
We extend the work on the pharmacological chaperone DGJ described for wildtype α-GAL to mutant enzymes that cause protein deficiency. We used the assay
established in Chapter 3 to assess DGJ chaperoning effect on mutant enzymes. In Chapter
4, predictions of the response of mutant enzyme to DGJ are presented. This gives an
indication of the applicability of DGJ therapy to various Fabry disease mutations.
Lastly, the recognition loop at the active site of α-GAL protein will be probed in
greater detail to determine the ligand specificity of two homologous enzymes, α-GAL
and α-NAGAL. α-GAL with an engineered recognition loop is an excellent tool to
investigate the structure-function of the protein. Chapter 5 presents the kinetic studies and
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the structure of the active site engineered α-GAL to provide an evidence for interconversion of the specificity of α-GAL.

26

CHAPTER 2

CATALYTIC MECHANISM OF HUMAN α-GALACTOSIDASE A
This work was performed in collaboration with Nathaniel Clark and Eric Salgado.
Portions of this chapter derive from a paper written in collaboration with them and other
collaborators (Abigail I. Guce, Nathaniel E. Clark, Eric N. Salgado, Ivanen, D.R.,
Kulminskaya, A.A., Harry Brumer 3rd, and Scott C. Garman. The catalytic mechanism of
human α-galactosidase. J. Biol. Chem. 2010)
2.1. Introduction
Degradation of macromolecules in the cells is essential for cell survival and proper
cellular functions. Selective cleavage of macromolecules in the lysosome is specifically
regulated and catalyzed by a number of enzymes, including glycosidases. The loss of
functional endo- and exoglycosidases in the lysosome results in the accumulation of
substrates in the cells, characteristic of a family of diseases collectively known as
lysosomal storage diseases (Platt 2004). One of these exoglycosidases is α-GAL, which
catalyzes the hydrolysis of a terminal alpha-linked galactosyl residue from
macromolecules such as oligosaccharides, glycoproteins and glycosphingolipids (Desnick
2001). Deficiency in α-GAL enzyme in humans causes Fabry disease, resulting in the
build up of a neutral substrate, globotriasylceramide, in the vascular endothelium and
other tissues (Brady 1967).
Mechanistically, glycosidases are generally classified according to the
stereochemistry of the anomeric carbon of the glycosidic bond (Hart, He et al. 2000). The
“inverting” glycosidases cleave the glycosidic bond in a one-step mechanism, with
simultaneous nucleophilic attacks and leaving group departure. The “retaining” enzymes
catalyze the cleavage via the double displacement mechanism where a covalently linked
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glycosyl-enzyme intermediate is formed (Sinnott 1990). α-GAL is considered an αretaining glycosidase, because it selectively binds substrates with terminal α-galactosidic
bonds and then releases α-galactose as product.
The double displacement mechanism first described in 1953 by Koshland
involves two successive nucleophilic attacks of the anomeric carbon of the terminal αgalactoside. D170 of the active site acts as a nucleophile and D231 as a proton donor
(acid) and then acceptor (base). D170 makes a nucleophilic attack on the anomeric
carbon and cleaves the glycosidic bond of the bound substrate. This results in a galactosyl
intermediate covalently linked to D170, and the release of the aglycone portion (R-OH).
Next, the negatively charged D231 deprotonates a nearby water molecule, which in turn
attacks C1 of the covalent intermediate, resulting in the breakage of the covalent bond to
D170. The two consecutive inversions of the anomeric carbon lead to an overall retention
of the α anomeric conformation in the product (see Figure 1.8).
A structural description of the steps in the catalytic mechanism has not been
studied in detail. The goal of this study is to elucidate the catalytic cycle of α-GAL using
three-dimensional crystal structures. The conformation change induced by the enzyme to
the ligand as the reaction proceeds is not known (Vasella, Davies et al. 2002). The
discovery of a new conformation of the covalent intermediate opens doors to rational
design of a more potent transition-like inhibitors. These inhibitors could be designed with
great selectivity and affinity towards the target enzyme. The recognition of role of αGAL in Fabry disease might lead to an alternative treatment that uses a small molecule
that binds tightly to the enzyme.
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2.2. Experimental Strategy
A series of four new structures of human α-GAL that represent each stage in the
double displacement mechanism provides a snapshot of the catalytic mechanism. In this
study, we determined crystal structures of α-GAL representing the four steps in the
double displacement mechanism (see Figure 2.1). A combination of genetic engineering,
microseeding techniques and synthetic mechanism-based inhibitors was used to improve
the resolution of human α-GAL crystals to 1.9 Å. These structures provide the first
complete picture of the structural mechanism of glycoside hydrolase family 27 enzymes.

2.3. Results
We determined the structures of an empty, substrate-bound, covalent intermediate
and product-soaked α-GAL. All of the structures show very little structural change with a
root mean square deviation of 0.4-0.5 Å for the 390 Cα. All four structures share a (β/α)8
barrel N-terminal fold with the active site at the center and the C-terminal β sandwich
(Garman and Garboczi 2004). Table 2.2 summarizes the structural statistics of the data
collection.

2.3.1. Empty enzyme
Using glycerol and ethylene glycol (a common choice for cryoprotectant) resulted
in the small cryoprotectant bound to the active site. Therefore, to obtain the empty
enzyme structure, it was necessary to use a cryoprotectant (lactose) sterically occluded
from the active site. Several water molecules mimic the positions of galactose atoms in
the active site instead. The water molecules are close to the positions of the O2 (0.92 Å

29

Figure 2.1 Trapping different steps in the catalytic cycle
Empty enzyme used cryoprotectants excluded from the active site. The substrate
bound structure used deletion of the active site nucleophile. The covalent intermediate
used a difluoro-substituted galactose compound. The product bound structure used
product inhibition on the enzyme. Color scheme are consistent with the succeeding
figures in this chapter.
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Table 2.1 Crystallographic statistics of the α-galactosidase A in the catalytic cycle
Active site:
PDB code:
Protein
Protein Sequence
Expression system
Cell lengths, Å
Cell angles, °
X-ray data
X-ray source
Wavelength, Å
Resolution (last shell)
Observations
Unique observations
Completeness, %
(last shell)
Multiplicity (last shell)
Rsym (last shell)
I/σI (last shell)
Refinement
Rwork/Rfree, %
No. of atoms
Protein
Carbohydrates
Water
•

Empty
3HG2

Substrate
3HG3

Intermediate
3HG4

Product
3HG5

Wild-type
P3221
90.8, 90.8, 217.2

Wild-type
P3221
90.2, 90.2, 216.6

Wild-type
P3221
90.8, 90.8, 217.2

90, 90, 120

D170A
P212121
59.5, 106.1,
181.7
90, 90, 90

90, 90, 120

90, 90, 120

Cu anode
1.54
50-2.3 (2.48-2.3)
637,404
45,612
97.2
(95.4)
14.0 (14.2)
0.115 (0.818)
25.2 (3.5)

BNL X25
1.0085
50-1.9 (1.97-1.9)
1,248,391
90,308
98.6
(88.4)
13.8 (9.9)
0.088 (0.755)
30.2 (3.1)

Cu anode
1.54
50-2.3 (2.38-2.3)
739,029
46,337
99.7
(100.0)
15.9 (16.0)
0.112 (0.944)
28.3 (3.4)

Cu anode
1.54
50-2.3 (2.38-2.3)
398,547
47,076
99.9
(100.0)
8.5 (8.4)
0.099 (0.989)
21.4 (2.3)

17.6/20.2
6767
6255
156
329

16.5/19.7
7539
6377
216
893

16.5/22.1
7251
6262
276
682

19.1/22.7
16694
6255
167
236

Table 2.1 is continued onto the next page
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Others
Ave. B, Å2

27
36.4

53
23.1

31
49.8

36
43.4

Ramachandran Plot
Favored (%)
Allow (%)
Generous (%)
Forbidden (%)

90.7
8.4
0.6
0.3

92.1
7.0
0.9
0.0

90.0
9.4
0.4
0.1

90.5
8.4
0.7
0.3

RMS deviations
Bonds (Å)
Angles (°)

0.008
1.128

0.006
1.058

0.008
1.159

0.008
1.175
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away), O3 (0.27 Å) and O6 (0.21 Å) oxygens of galactose, and two other water
molecules are close to the position of C1 (0.51 Å) and C4 (1.1 Å) carbons of the
galactose. The empty enzyme structure of α-GAL solved at 2.3 Å shows no global
movement as well as major rearrangements at the active site residues compared to the
earlier structures of α-GAL.

2.3.2. Substrate-bound
To trap an intact substrate in the active site, a D170A α-GAL mutant was
engineered to delete the nucleophilic residue that attacks the anomeric carbon. We
expressed and purified the mutant protein D170A α-GAL, which showed no detectable
enzyme activity. Melibiose, a D-galactose-α1-6-D-glucose disaccharide, was used as a
terminal α-galactose linked substrate. Melibiose binds to the active site of α-GAL with
the galactose saccharide in the active site and the glucose saccharide extending out of the
active site pocket. The galactoside portion of the melibiose substrate is in standard 4C1
chair conformation. Residues in the active site make specific interactions with the
galactoside of melibiose with no specificity beyond the glycosidic linkage. No interaction
between the residues in or near the active site is found making specific contacts to the
next sugar residue beyond the galactose. The 1.9 Å resolution structure shows that αGAL binds the terminal galactose and the sugar assumes the low-energy 4C1
conformation. This conformation aligns the anomeric carbon with the syn lone pair of the
catalytic nucleophile D170, allowing a direct in-line attack by the nucleophile. The 4C1
conformation of galactose is shown in Figure 2.2a. The 1.9 Å substrate-bound enzyme is
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the first structure of any enzyme from glycoside hydrolase family 27 that shows the
unprocessed substrate in the active site of the enzyme.

2.3.3. Covalent intermediate
To trap a covalent intermediate, a synthetic substrate 2’,4’,6’-trinitrophenyl-2deoxy-2, 2-difluoro-α-galactopyranoside (TNP-2,2-di-F-α-Gal, see Figure 2.2d) was
soaked into wild-type α-GAL crystals. TNP-2,2-di-F-α-Gal is a mechanism-based αGAL inhibitor used to trap transient intermediate species, analogous to other fluoro
sugars extensively studied in the Withers laboratory (Withers, Rupitz et al. 1988; Street,
Kempton et al. 1992). The fluoro substituted galactopyranoside ring destabilizes the
oxocarbenium ion-like transition state of the double displacement mechanism (Zechel
2000). TNP is an excellent leaving group that allows the first nucleophilic attack to
proceed. However, the second nucleophilic attack by the deprotonated water molecule is
slowed considerably by the inductive effects of the fluoro substituents, allowing capture
of the covalently linked intermediate at subsequent low temperature x-ray data collection
(see Figure 2.3d) (Ly 2000; Zechel 2000). The covalent intermediate is in a 1S3 twist boat
conformation with strain in the sugar ring. The high-energy conformation is covalently
bound to the Oδ2 of D170 and is held on the other end by van der Waals interaction
between W47 and the 4-, 5- and 6 carbons of the sugar.

2.3.4. Product-bound
To obtain a product bound enzyme, galactose was used as a cryoprotectant. Although the
galactose solution contains a 70:30 mixture of β and α anomers of galactose, the human
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a.

b.

c.

d.

Figure 2.2 Covalent intermediate and ligand deformation
(a), (b), and (c) show close up views of the substrate-bound, covalent intermediate,
and product-bound ligands. The catalytic nucleophile D170, the catalytic acid/base
D231, and the conserved W47 are labeled. (d) The reaction mechanism for the TNP2,2-di-F-α-Gal substrate. The first step of the reaction remains fast because of the
good leaving group, but the second step is slow, allowing for the trapping of the
covalent intermediate species.
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α-GAL active site selects for the α anomer only. The C142-C172 disulfide bond, Y134
and D170 would clash with a β-linked galactose at position 1 thus human α-GAL selects
and binds only to the α form (Garman and Garboczi 2004). The galactose in the active
site is in a standard 4C1 conformation (see Figure 2.2c). After the second anomeric attack
by deprotonated water molecule, the ligand returns to a low energy conformation from its
high-energy state in the covalent intermediate structure. The crystallographic snapshot of
the double displacement mechanism is summarized in Figure 2.3.

2.4. Discussion
Interest in using the molecular structure of human α-galactosidase to understand
the mechanism of α-GAL has lead to several crystal structures of the enzyme since the
first α-GAL structure at 3.25 Å resolution was published in 2004 (Garman and Garboczi
2004). Higher resolution α-GAL with different substrate soaks revealed molecular details
of the double displacement mechanism (recent α-GAL structures compiled in Table 2.2)
(Garman and Garboczi 2004; Guce 2009; Lieberman, D'Aquino J et al. 2009). The
substrate bound and covalent intermediate structures are among the first known structures
for glycosidase family 27. α-GAL belongs to the family 27 and clad D (representing over
1900 proteins from different species) of glycoside hydrolases with active site residues
strictly conserved, therefore the entire family is most likely to use an identical mechanism
(Cantarel, Coutinho et al. 2009).
The structures reveal there is no major rearrangement or movement of active site
residues upon binding of substrate and throughout the stages of the double displacement
mechanism, unlike what is seen in the β-glucocerebrosidase family, for example, where a
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Figure 2.3 Double displacement mechanism snapshot
*Figure 2.3 caption is continued on the next page
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Panels A and B shows side (A) and top (B) views of the electron density for the ligand
in the four different structures. The four rows correspond to the empty, substratebound, covalent intermediate, and product-bound structures respectively. The electron
density corresponds to a σA-weighted 2Fo-Fc omit map calculated in SFCHECK
(contoured at 1.5 σ in the first row and 2.0 σ in the other three rows) with a cover
radius drawn around residues and/or waters in the active site.
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Table 2.2 Human α-galactosidase A structures published
α-GAL structures
Empty
Substrate
Covalent
Intermediate
Product

Active site contents
Glycerol
Water(s)
Melibiose (D-Gal-α1-6-DGlu)
TNP-2,2-di-F-α-Gal

Inhibitor

Galactose

DGJ

* PDB code not yet available
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Resolution,
Å
3.25
3.0
2.3
1.9

PDB
code
1R46
3GXN
3HG2
3HG3

year
published
2004
2009
2009
2009

2.3

3HG4

2009

3.45
2.2
2.3
2.0
2.7
2.1

1R47
3GXP
3HG5
3GXT
-

2004
2009
2009
2009*
2008
2009*

flap closes down on the active site after substrate binding. Here we present the first
complete mechanism of a retaining α-galactosidase. The substrate binds to the active site
in a low-energy 4C1 conformation that allows the D170 nucleophile to have access to the
anomeric carbon. After cleavage of the substrate, the glycosyl-enzyme covalent
intermediate structure assumes a strained 1S3 twist boat conformation. Most of the known
β-retaining enzymes distort the substrate into a high energy 1S5 conformation to gain
assess to the anomeric carbon upon binding, and the covalent intermediate of those
enzymes have a 4C1 conformation. This high-energy 1S3 twist boat conformation is a
sharp contrast to the other low-energy 4C1 covalent intermediates seen in the α amylase
family (Uitdehaag, Mosi et al. 1999; Barends, Bultema et al. 2007). TNP-2,2-di-F-α-Gal
had been used to modify and identify the catalytic residue of other glycoside hydrolase
family 27 enzymes, but those studies were mass spectrometry studies, not
crystallographic experiments, so they did not show the distorted conformation of the
covalent intermediate until recently (Hart, He et al. 2000; Ly 2000).
We have also provided structural evidence of a transition-like inhibitor for α-GAL
and other alpha-retaining enzymes. A more potent inhibitor would be a great candidate to
as a pharmacological chaperone, which will be discussed in details in Chapter 3 and 4.
Additionally, the structures reveal a second sugar-binding site away from the active site.
In all the four structures, there is either a β-galactose or a PEG molecule that packs
against the plane of Y329 and hydrogen bonds with K374 and D255. Binding of the
second molecule buries about 107 Å2 surface area (see Figure 2.4). The interaction
between Y329 and the β-galactose is weak since the contacts are not optimized, and
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Figure 2.4 The second ligand-binding site in human α-GAL
The second ligand-binding site is centered on Y329, at the interface between domain 1
and domain 2 of the structure. A surface drawn around all the atoms reveals a pocket
that is selective for β-galactose. The electron density from the galactose-soaked crystal
shows a σA-weighted 2Fo-Fc omit map calculated in SFCHECK, contoured at 1.1 σ
with a cover radius drawn around the ligand. Residues E251, D255, Y329, and K374
are shown.
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the occupancy at this site is due to high concentration of the small molecule. The second
binding site could be a possible site pharmacological chaperone binding without
competitively inhibiting the enzyme function. The second binding site is in a location that
might be exploited for pharmacological chaperone therapy.

2.5. Methods
2.5.1. Wild-type α-GAL TOPO plasmid generation and amplification
The human α-galactosidase A gene (GLA) was obtained from an 8% glycerol
stock of a recombinant pOTB7 vector (OpenBiosystems) transformed into a culture of
DH5α e. coli. cells. These cells were re-streaked into a fresh LB/chloramphenicol (34
µg/mL) plates and used as a starter culture of sterile LB broth with 34 µg/mL
chloramphenicol. The stock pOTB7-α-GAL vector was extracted and purified from an
overnight culture using the Wizard® Plus SV Minipreps DNA Purification System
(Promega). The α-GAL gene was cloned out of pOTB7-α-GAL vector using Phusion

®

High-Fidelity DNA Polymerase (Finnzymes) with forward (5’ACAATGCAGCTGAGGAACCCAGAACTACAT-3’) and reverse (5’TTAATGATGATGATGATGATGAAGTAAGTCTTTTAATGACAT-3’) primers and
was purified using the Wizard® SV Gel and PCR Clean-Up System (Promega) according
to the manufacturer’s specifications. The PCR-purified amplification product was then
incubated at 72ºC for 15 minutes with Taq polymerase (New England Biolabs) in order to
ensure the addition of a single 3’-deoxyadenosine overhangs for subsequent TOPO TA
®

cloning experiments. The amplification product with single 3’-deoxyadenosine overhangs
were annealed into a pIB/V5-His-TOPO vector (Invitrogen), and One Shot® TOP10
®
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chemically competent E. coli (Invitrogen) was transformed with pIB/V5-His-TOPO

®

vector containing the α-GAL gene (pIB/V5-His-TOPO-α-GAL). The TOP10 cells were
plated on LB agar plates containing 100 µg/mL ampicillin (amp) and grown overnight at
37°C. Plasmid mini preps using the PureYield™ Plasmid Midiprep System (Promega)
were performed from a 50 mL LB (+ 100 µg/mL amp) overnight culture grown from a
single colony. pIB/V5-His-TOPO-α-GAL construct containing the α-GAL native signal
sequence and a C-terminal His6-tag was used as a parental DNA.

2.5.2. D170A α-GAL expression and purification
A mutation coding for replacement of D170 with Ala (D170A) was incorporated
into the pIB/V5-His-TOPO-α-GAL construct with PhusionTM site-directed mutagensis kit
(Finnzymes). PCR amplification using forward primer (5’[PO4]CTGCTAAAATTTGCTGGTTGTTACTGTGACAG-3’, bold letters highlights the
mutation) and reverse primer (5’-[PO4]ATCTACTCCCCAGTCAGCAAAGGTCTG-3’)
introduced the mutation to the parental DNA. Mutation was confirmed by sequencing the
isolated and purified pIB/V5-His-TOPO-D170A DNA.
Transfection of insect cells with pIB/V5-His-TOPO-D170A was initiated by
allowing approximately 2.0 x 106 Tn5 cells to adhere in a 60mm tissue culture plate.
Cells were transfected using 2 mL transfection mixture containing SFx media, 1.8 µg
plasmid DNA and Hilymax (Dojindo Labs). Transfection was performed following the
manufacturer’s specifications. Selection was done by adding 100 µg/mL blastocidin to
fresh Sfx media after 3 days of transfection. The supernatant were collected to test for
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protein expression. Stable adherent cells were re-suspended in SFx media and were
grown in suspension for scale up.
Stable cells were grown to 5-6 x 106 for three days and the supernatant was
collected after spinning down the cells. The supernatant was concentrated and buffer
exchanged with Ni-NTA binding buffer (50 mM sodium phosphate, 500 mM sodium
chloride and 20 mM imidazole, pH 7) using Millipore Prep/Scale TFF cartridge. The
sample was loaded onto a column containing Ni SepharoseTM 6 Fast Flow resin (GE
Healthcare). D170A α-GAL mutant was eluted using a gradient of 0-50% elution buffer
(50 mM sodium phosphate, 500 mM sodium chloride and 1 M imidazole, pH 7).
Fractions containing pure α-GAL, as determined by SDS-PAGE analysis, were pooled
and concentrated to 2.0 mg/mL by using Vivaspin spin concentrator with 10 kDa
molecular weigh cut off (Sartorius Biolab) and stored in 10 mM sodium phosphate
buffer, pH 6.5.

2.5.3. Crystallography and x-ray data collection
Empty, Intermediate and product: Crystals were grown as previously described,
except that macroseeding techniques were used (Garman and Garboczi 2004). In the
original report, the P3221 crystals were 100 µm in the longest dimension; macroseeding
techniques increased the size of the crystals to 400 µm, leading to a much-improved
diffraction. Small crystals were grown in 25% PEG 4000, 200 mM ammonium sulfate,
and 100 mM sodium acetate pH 4.6 mixed with 9 mg/mL α-GAL stock. The crystals
were crushed, diluted 1:100,000, and added to 1:1:1 mixture of crystallization buffer,
protein stock, and water. Crystals appeared in the seeded solution after a few days.
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Crystals were harvested into buffer containing 30% PEG 4000, 200 mM ammonium
sulfate, and 100 mM sodium acetate. Crystals were transferred to similar solutions
supplemented with ligand: 15% α-lactose (empty structure), 20 mM 2’,4’,6’trinitrophenyl-2-deoxy-2, 2-difluoro-α-galactopyranoside (covalent intermediate), or 5%
D-(+)-galactose (product bound). For the covalent intermediate structure, the soak salts
were reduced to 100 mM ammonium sulfate and 50 mM sodium acetate. Five crystals
were transferred into the TNP-2,2-di-F-α-Gal solution; all but one shattered immediately
after transfer. Ice rings limited the quality of the galactose soaked crystals. 180° of
diffraction data were collected on a RU-H3R rotating anode generator (Rigaku) and
processed with HKL2000 (Otwinowski 1997). The P3221 crystals diffracted highly
anisotropically, with approximately 1.9 Å resolution limit along the c axis compared to
approximately 2.8 Å diffraction limits in the perpendicular directions; we limited the
overall isotropic resolution to 2.3 Å based upon I/σI criteria. The isotropic integration of
the anisotropic diffraction data resulted in poor merging statistics. The structures were
phased by Fourier synthesis using the 3.25 Å human α-GAL coordinates (PDB code
1R46) (Garman and Garboczi 2004).
Substrate: The crystals of D170 α-GAL mutant were obtained by the hangingdrop vapor diffusion technique at 20°C. Crystals were obtained from 1:1 mixture of
reservoir solution (12% (w/v) PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 0.022 M
Magnesium acetate) with a 2.0 mg/mL protein solution (10 mM sodium phosphate buffer,
pH 6.5). Prior to freezing and data collection, crystals were transferred stepwise into a
reservoir solution with 100 mM melibiose (D-galactose-α1-6D-glucose, Sigma), and then
into a cryoprotectant solution containing 40% (w/v) PEG 8K, 22 mM magnesium acetate,
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100 mM sodium cacodylate pH 6.5, 20% ethylene glycol and 100 mM melibiose
(Sigma). Crystals were flash frozen in liquid nitrogen and x-ray data were collected at
100K at beamline X25 at the Brookhaven National Laboratory. X-ray images were
processed using HKL2000 software package. The diffraction data were scaled in space
group P212121, leading to a solvent content of 57% and a dimer in the asymmetric unit.
The structure was phased by molecular replacement in the CCP4 program AMoRe using
the coordinates of the galactose soaked crystals.
For all structures: Atomic models were built into electron density using the
program O, and refinement and water placement were done using REFMAC (Jones, Zou
et al. 1991). Coordinates were superimposed using LSQMAN, and surface accessible
areas were calculated in AREAIMOL (Kleywegt 1997). Molecular docking studies were
performed in O and in Pymol (Jones, Zou et al. 1991; DeLano 2008). Figures were made
in MolScript and POVScript+ (Kraulis, Fenn). Coordinates and structure factors are
under PDB accession codes 3HG2 (empty), 3HG3 (substrate-bound), 3HG4 (covalent
intermediate), and 3HG5 (product-bound).
Sugar and sugar analogues: TNP-2,2-di-F-α-Gal was prepared as described
previously (Brumer 1999; Hart, He et al. 2000). Thioethyl-α-galactose was prepared from
2,3,4,6-tetraacetyl-thioethyl-α-D-galactose (Toronto Research Chemicals) by treatment
with HCl for 1 hour Mass spectrometry was performed to confirm that the hydrolysis of
the four acetyls had run to completions. The thioethyl-α-Gal was lyophilized and used at
20 mM concentration for crystallization soaks. Galactose, lactose, and melibiose were
obtained from Sigma.
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CHAPTER 3

MECHANISM OF A SMALL MOLECULE DGJ AS
PHARMACOLOGICAL CHAPERONE FOR FABRY DISEASE
This chapter is part of a paper in preparation. (Abigail I. Guce and Scott C. Garman.
Mechanism of a small molecule DGJ for pharmacological chaperone)
3.1. Introduction
Lysosomal enzymes such as α-GAL are synthesized, folded and processed in the
endoplasmic reticulum (ER) at near neutral pH, then exported to the pH 6.5 Golgi
apparatus for carbohydrate modification and sorting, and finally trafficked to the pH 4.5
lysosome. α-GAL is among the many glycosidases in the lysosome that break down a
complex macromolecules into smaller components for the cells to reuse. Single point
mutations to the polypeptide chain of α-GAL are most likely to disrupt the hydrophobic
core of the protein leading to protein misfolding and degradation at the ER. Interestingly
most of these mutations are located far away from the active site and yield active or
partially active enzyme (Leinekugel 1992; Garman and Garboczi 2002; Sugawara,
Tajima et al. 2009). However, these misfolded enzyme fail to reach the lysosome due to
the quality control machinery of the ER (Remeo, D'Urso et al. 1975; Bishop and Desnick
1981; Okumiya 1995; Fan, Ishii et al. 1999). Protein deficiency due to degradation of
unstable protein is also common to other inherited disease, beyond Fabry disease.
Beyond enzyme replacement therapy, an alternative treatment, pharmacological
chaperone therapy (PCT), has been proposed for Fabry disease. PCT uses the enzyme
product, galactose, and a tight-binding substrate analogue inhibitor, 1deoxygalactonojirimycin (DGJ), as chaperones. The current model for the mechanism of
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pharmacological chaperoning hypothesizes that DGJ binds at neutral pH to the unstable
protein in the ER. By binding the native state, it shifts the folding equilibrium toward
properly folded protein, and thus the protein avoids ER-associated degradation (ERAD)
(Fan, Ishii et al. 1999; Asano, Ishii et al. 2000; Frustaci, Chimenti et al. 2001; Yam,
Zuber et al. 2005). The small molecule can then dissociates at low pH (Fan, Ishii et al.
1999; Asano, Ishii et al. 2000; Frustaci, Chimenti et al. 2001; Yam, Zuber et al. 2005).
Once the active site is free, α-GAL can now cleave its substrate. Based on the structure
and electrostatic potential of α-GAL, the protein is hypothesized to be more stable at
lower pH due to the excess of negative charge (Garman and Garboczi 2004; Yam,
Bosshard et al. 2006; Guce 2009). Pharmacological chaperone treatment is presumed to
rescue unstable protein from degradation at the ER, and improve the transport of mutant
α-GAL to the lysosome (Fan, Ishii et al. 1999; Cohen and Kelly 2003; Kolter 2003; Yam,
Bosshard et al. 2006).

3.2. Experimental Strategy
In this study, the effect of pH on the different binding affinities of galactose and
DGJ and its consequence on the stability of the wild-type enzyme will be examined. This
is the dilemma in pharmacological chaperone we want to focus, how a potent inhibitor
could increase the activity of an unstable enzyme. Here, evidence will be presented that
DGJ binds to and stabilizes α-GAL at neutral pH, the same pH where α-GAL protein is
synthesized. Most of these experiments are done at pH 6.5 instead of a more neutral pH
because α-GAL has very little activity at pH 7 and above (based on the optimal activity
profile, data not shown). We provide evidence that tighter binding between the inhibitor
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and the enzyme at neutral pH is vital for the chaperoning effect of DGJ. We developed
different assays to assess the kinetics of unfolding, stability and global conformation of
α-GAL in the presence of a pharmacological chaperone. Moreover we have solved the
structure of α-GAL with bound galactose and with DGJ at a higher resolution than
previously reported. These will give us a better insight into the molecular mechanism of
pharmacological chaperoning for Fabry disease. By studying the D170A mutant, we
identified a critical interaction responsible for the high potency of DGJ as a chaperone.

3.3. Results
3.3.1. Resistance to unfolding monitored by fluorescence
Fluorescence was employed to monitor the rate of unfolding of α-GAL under
various pH conditions (pH 6.5 where the enzyme is inactive and pH 4.5 where the
enzyme is optimally functional). The tryptophan fluorescence emission signals of α-GAL
at pH 6.5 and 4.5 are shown in Figure 3.1a and d. After addition of 7.5 M urea, the
fluorescence signal was measured over time. Upon unfolding, the fluorescence at λmax
shows a decrease intensity relative to the folded protein and a red shift from 335 nm to
350 nm. This assay allowed us to measure the rate of unfolding of α-GAL, which we fit
to a first order exponential. We calculated an unfolding half time t of 2.2 and 1.3 hours
for pH 6.5 and 4.5 respectively. This shows that at pH 6.5, α-GAL unfolds more slowly
than at pH 4.5, contrary to expectations. Next, we added DGJ and galactose to the
fluorescence experiment to measure the effect of the pharmacological chaperones on the
rate of unfolding of α-GAL at pH 6.5 and 4.5 (see Figure 3.1b, c and e, f respectively).
Upon the addition of 50 µM DGJ at pH 6.5, the unfolding is significantly slowed and the

49

Figure 3.1 Fluorescence signal of unfolding α-GAL in 7.5 M urea
(a), (b) and (c): Fluorescence measurement of 1.2 µM α-GAL over time in phosphate
buffer/urea solution, pH 6.5 without pharmacological chaperone, + 50 µM DGJ and
+50 mM Gal respectively; d, e and f: Fluorescence measurement of 1.2 µM α-GAL
over time in sodium acetate buffer/urea solution, pH 4.5 without pharmacological
chaperone, + 50 µM DGJ and +50 mM Gal respectively. Emission scans at 0 hrs (,
red) in buffer/urea solution, subsequent scans were measured each hour up to 8 hours,
and after 24 hrs (, blue) in buffer/urea solution.
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Fluorescence Intensity
@ 335 nm
Figure 3.2 First order kinetics of unfolding of α-GAL
Pharmacological chaperone slows down the kinetics of unfolding of α-GAL.
Rate of unfolding of α-GAL at pH 6.5 (a and b) and pH 4.5 (c and d) upon
addition of 50 µM DGJ and 50 mM galactose respectively.
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protein remains primarily folded even after 24 hours in urea (Figure 3.2a), so we
conclude the t > 24 hours. DGJ greatly slows the kinetics of unfolding because there is
little change in the fluorescence intensity at λmax over 24 hours in 7.5 M urea and 50 µM
DGJ at pH 6.5. In comparison, at pH 4.5, the addition of DGJ slows the rate of unfolding
of α-GAL from a t of approximately 1.3 hrs to 6.5 hrs (Figure 3.2c). The experimental
data demonstrate that, i) α-GAL unfolds more rapidly at pH 4.5 than at pH 6.5, ii) DGJ
slows down the rate of unfolding of α-GAL, and iii) DGJ is more effective in preventing
the decrease in the fluorescence signal of α-GAL at pH 6.5 than at acidic pH.
Next, we repeated the fluorescence experiments in the presence of 50 mM
galactose. Galactose also slows the unfolding of α-GAL, increasing the t from 2.2 to 8.0
hours at pH 6.5 and from 1.3 to 2.5 hours at pH 4.5 (see Figure 3.1 c and f; Figure 3.2b
and d). Although the same trend was also seen upon the addition of galactose to α-GAL it
is less potent and less effective at preventing unfolding than DGJ. Comparing the two pH
conditions, galactose slows the unfolding better at pH 6.5 than at pH 4.5. Galactose
requires higher concentrations than DGJ to slow the unfolding, 50 mM galactose
compared to 50 µM DGJ. In general, it is observed that addition of a pharmacological
chaperone to α-GAL has a considerable effect on the kinetics of unfolding of the enzyme
and resistance to unfolding of α-GAL is a consequence of the binding of DGJ and
galactose.

3.3.2. Increase in apparent thermal stability of α-GAL measured by CD
We developed an assay to measure the secondary structure of α-GAL under
different conditions by monitoring the CD signal of the protein from 210-240 nm. To
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evaluate the stability of α-GAL in the presence of varying concentrations of
pharmacological chaperone, the CD signal was measured at wavelength 222 nm as the
temperature was increased. The CD data allowed us to calculate the fraction denatured
(Fd), and the temperature where Fd equals 0.5 was labeled the apparent melting
temperature (Tm). The Tm value serves as a measure of the thermal stability of the protein
(Acosta, Beldarrain et al. 2000; Fitter and Haber-Pohlmeier 2004; Sanchez-Ruiz 2007).
To examine the effects of DGJ and galactose on the stability of wild-type α-GAL, the Tm
of α-GAL was measured with increasing concentration of the pharmacological chaperone
at pH 6.5 and pH 4.5. The CD data show that there is little difference in the thermal
stability of α-GAL at pH 6.5 and 4.5, but α-GAL is less stable at pH 7.2, in agreement
with differential scanning calorimetry studies (see Table 3.1) (Lieberman, D'Aquino J et
al. 2009).
We next tested the effect of pharmacological chaperones on the Tm of α-GAL.
Upon the addition of increasing concentrations of either DGJ or galactose, the Tm of αGAL significantly increases. Figure 3.3 illustrates the increasing Tm of α-GAL with
increasing concentrations of DGJ and galactose. At pH 7.2 and 6.5, a detectable increase
in the Tm of α-GAL is observed at concentrations as low as 500 nM DGJ and about 5 mM
galactose. When galactose is added to the enzyme, there is a smaller change in the Tm of
α-GAL (Figure 3.3; Table 3.1). This result suggests that DGJ is more potent and
efficacious than galactose at increasing the stability of the enzyme. To achieve the same
increase in α-GAL Tm, approximately 104 times more galactose than DGJ is required.
This trend is in agreement to the fluorescence experiments, where DGJ is markedly more
potent at decreasing the rate of unfolding of the enzyme.
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Figure 3.3 Apparent melting temperature of α-GAL as measured by CD
Increasing apparent melting temperature (Tm) of α-GAL (1.2 µM) in 10 mM
phosphate buffer (pH 7.2 and pH 6.5) and 10 mM sodium acetate (pH 4.5) in the
presence of pharmacological chaperone. (, black) – 0 DGJ or Gal; (, cyan) – 50
nM DGJ; (, green) – 500 nM DGJ or Gal; (, red) – 50 µM DGJ or Gal; (,
yellow) – 5 mM Gal; (, blue) – 50 mM Gal. Observed CD signal is measured at
222 nm at 1°/min.
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Table 3.1. Apparent melting temperature (°C) of α-galactosidase A with
pharmacological chaperones
[chaperone]
0
50 nM
500 nM
5 µM
50 µM
5 mM
50 mM

+DGJ
+Gal
pH 7.2
56
56
57
62
56
78

56
64

+DGJ
+Gal
pH 6.5
60
62
62
65
61
76
82
62
62
67
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+DGJ
+Gal
pH 4.5
61
60
61
63
62
70
74
62
62
69

Both the CD and fluorescence experiments show that the stabilizing effect of the
pharmacological chaperones is greater at higher pH than at pH 4.5. Although α-GAL is
less stable at pH 7.2 compared to pH 6.5 or 4.5, the effect of pharmacogical chaperone
(as measured by increase in Tm) is greater at pH 7.2. Table 3.1 summarizes the Tm of αGAL and highlights in bold the significant increase in thermal stability in comparison to
the Tm of α-GAL measured in the absence of a pharmacological chaperone.

3.3.3. Confers protection from protease digestion monitored by pulse proteolysis
A third assay we developed to measure the stability of α-GAL is pulse
proteolysis, which assesses the resistance to protease digestion, a measure of global
foldedness. We assessed the protease sensitivity of α-GAL after incubation with urea. We
first performed the experiment on α-GAL, and then we repeated the experiment in the
presence of pharmacological chaperones.
When incubated overnight with urea, α-GAL is susceptible to digestion by
thermolysin and pepsin in 5 minutes, suggesting that α-GAL is in a flexible conformation
that allows digestion by protease. However in the presence of pharmacological
chaperone, α-GAL resists digestion (see Figure 3.4). In these experiments, we interpret
protease sensitivity as unfolded/misfolded or flexible protein while protease resistance
implies a compact folded state. We quantified the intensity of the undigested α-GAL
band, allowing us to calculate the concentration of chaperone leading to 50% protection
from protease. DGJ is more potent at pH 6.5, because 50% protection from digestion
requires 400 nM DGJ at pH 6.5 and 3.0 µM DGJ at pH 4.5 (see Figure 3.4a and c). In
contrast, galactose shows similar potency in this assay at pH 6.5 and 4.5, where 3 mM
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pH 6.5 (+DGJ)

pH 6.5 (+Gal)

pH 4.5 (+DGJ)

pH 4.5 (+Gal)

Figure 3.4 Pulse proteolysis experiment
Effects of DGJ and galactose on α-GAL stability through resistance to protease. (a)
and (b): Thermolysin digestion (pH 6.5) of 1.2 µM α-GAL in 8M urea with DGJ
and galactose respectively; (c) and (d): Pepsin digestion (pH 4.5) of 1.2 µM α-GAL
in 3M urea with DGJ and Gal respectively.
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galactose is required to see 50% protection from digestion (see Figure 3.4b and d). Once
again, DGJ is vastly more potent than galactose, where 104-105 less concentration of DGJ
is required to see comparable protection.
3.3.4. Effect of pharmacological chaperones on enzymatic activity
A fourth assay we developed to examine the effect of pharmacological
chaperones is an enzymatic inhibition assay. We measured the enzymatic activity of αGAL in the presence of increasing amount of pharmacological chaperone. Since the
structure of DGJ is very similar to the α-GAL catalytic product galactose (with just imino
and hydroxyl group differences), it is expected to exhibit competitive inhibition of the
enzyme (Legler and Pohl 1986; Yoshimizu, Tajima et al. 2008; Sugawara, Tajima et al.
2009). One contradiction in the use of pharmacological chaperones for the treatment of
lysosomal storage diseases is that in order to increase the activity of a defective enzyme,
a competitive inhibitor is used. Since both DGJ and galactose are expected to be
competitive inhibitors of the enzyme, we measured the inhibition constant Ki for the
pharmacological chaperones at different pH values. When the enzyme activity is plotted
versus concentration of DGJ or galactose, increasing the concentration of the
pharmacological chaperone leads to a subsequent loss of enzyme activity. DGJ inhibits αGAL at a lower concentration than galactose. Similar to the results and observations
mentioned above, DGJ is approximately 105-fold more potent as an inhibitor than
galactose (Figure 3.5). However, we also have observed that at sub-stoichiometric
concentration of DGJ (~500 pM-100 nM), α-GAL activity increases (see Figure 3.5a).
Thus the effect of DGJ can be split into a chaperoning effect of DGJ at low concentration
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Figure 3.5 Inhibition assay of α-GAL with DGJ and galactose
(a) and (c) α-GAL activity is inhibited by DGJ at ~ 500 nM DGJ for both pH 6.5 and
4.5; while galactose (b) and (d) inhibits enzyme activity at ~ 300 mM galactose for
both pH 6.5 and 4.5. The specific activity of 1.2 µM enzyme was measured by the
absorbance of the para-nitrophenylate ion at 400 nm.
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Figure 3.6 Determination of DGJ and galactose Ki for α-GAL enzyme
Pharmacological chaperones are usually competitive inhibitors of the enzyme. αGAL is inhibited by the substrate analogue DGJ and the substrate galactose.
Based on the Ki values, DGJ is a more potent inhibitor than galactose.
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and an inhibitory effect at higher concentration. In the CD and pulse proteolysis
experiments above, there is a critical concentration (around 1 µM for DGJ and 10 mM for
galactose) above which α-GAL becomes more resistant to thermal and chemical
denaturation (Table 3.1 and Figure 3.4). These values are close to the concentrations
where enzyme inhibition is seen.
In addition to the activity assays, full enzyme kinetic measurements were made in
the presence of increasing concentrations of DGJ and galactose (Figure 3.6). Although
the activity assays above showed that the pharmacological chaperones were inhibitors of
α-GAL, they did not allow calculation of the Ki for the pharmacological chaperones. A
full treatment of the enzyme kinetics allowed for calculation of the Ki for DGJ as
approximately 150 nM while galactose is 105-fold less potent at around 20 mM.

3.3.5. Active-site nucleophile (D170) is responsible for the pharmacological
chaperoning effect of DGJ
The two pharmacological chaperones we have tested here differ by only two nonhydrogen atoms, yet they show very different potencies. Because the active site
nucleophile D170 interacts with a ring oxygen in galactose and with a ring nitrogen in
DGJ, we examined the role of the active-site nucleophile D170 in the binding of the
pharmacological chaperones. We engineered a mutant α-GAL D170A with the active site
nucleophile removed and replaced by an alanine, and measured the effect of the removal
of the carboxylate on the chaperoning effects of pharmacological chaperones. First, we
checked the stability of the D170A mutant using CD to measure the apparent melting
temperature (Tm) as described above. The D170A mutant shows comparable stability to
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the wild-type. This is consistent with surface exposed location of D170 in the active site,
where amino acid substitution is not expected to have a major effect on the conformation
of the protein. Next, the apparent melting temperature of D170A α-GAL mutant was
measured in the presence of DGJ. Contrary to the wild type α-GAL, the D170A mutant
shows no subsequent increase in Tm at 2 mM DGJ (Figure 3.7a). In comparison, the Tm
of the wild-type protein is raised by 20° at similar DGJ concentration.
Second, we tested the stability of the D170A mutant in the pulse proteolysis
experiment. The resistance of the D170A mutant to protease digestion was examined
through pulse proteolysis. Without pharmacological chaperone present, the D170A
mutant protein shows comparable digestion to wild type. However, in the presence of
DGJ, the D170A mutant shows resistance to protease only at a much higher concentration
of DGJ, where approximately 1.5 mM DGJ is required to achieve 50% resistance to
proteolytic digestion under the assay conditions (Figure 3.7b). Surprisingly, D170A
requires approximately 105-fold more DGJ than wild type α-GAL does. The D170A
mutant makes the pharmacological chaperone activity of DGJ approximately the same as
galactose.
When galactose is used in the pulse proteolysis experiment with the D170A
mutant, 5mM galactose is necessary to protect 50% of D170A mutant, so the D170A
mutant behaves similarly to wild type in the presence of galactose. When alanine replaces
aspartic acid 170, the DGJ chaperoning is affected but the galactose chaperoning is not.
Thus, we conclude that deletion of the carboxylic acid side chain of the aspartic acid
(D170  A) eliminates the specific protective effect of DGJ.

62

a

b

c

Figure 3.7 CD and pulse proteolysis experiments for D170A mutant
Effects of DGJ and galactose on α-GAL mutant D170A stability through resistance to
protease. (a) CD thermal melt of D170A in the absence () and presence (, 2mM)
of DGJ in 10 mM phosphate buffer pH 6.5; (b) and (c): Thermolysin digestion at pH
6.5 of α-GAL in 8M urea with DGJ and galactose respectively.
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Table 3.2: Crystallographic statistics of α-galactosidase A with
pharmacological chaperones bound
Active site contents:

DGJ

Galactose

Protein
Space group
Cell lengths, Å
Cell angles, °

P21212
136.8, 182,6, 47.7
90, 90, 00

C2221
89.3, 140.6, 182.5
90, 90, 90

X-ray data
X-ray source
Wavelength, Å
Resolution (last shell)
Observations
Unique Observations
Completeness, % (last shell)
Multiplicity (last shell)
Rsym (last shell)
I/σI (last shell)

BNL X6A
1.000
50-2.18 (2.18-2.1)
412,904
66,778
95.0 (92.4)
5.8 (6.2)
0.115 (0.818)
17.2 (2.1)

BNL X6A
1.000
50-2.0 (2.07-2.0)
1,058,992
77,091
99.4 (96.2)
13.7 (10.0)
0.115 (0.782)
23.3 (2.2)

Refinement
Rwork/Rfree , %
No. of atoms
Protein
Carbohydrate
Water
Other
Average B, Å2

18.8/23.6
7137
781
21
441
14
25.8

23.1/25.9
6913
780
21
298
53
25.3

Ramachandran Plot
Favored (%)
Allowed (%)
Generous (%)
Forbidden (%)

90.8
8.1
1.0
0.0

88.8
9.5
1.0
0.7

0.007

0.006

RMS deviations
Bonds (Å)
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3.3.6. Crystal structure of α-GAL bound to a pharmacological chaperone
To address the effect of the pharmacological chaperones on the structure of αGAL, we determined crystal structures of the enzyme with DGJ and with galactose bound
in the active site. The crystal structures of human α-galactosidase A with DGJ and
galactose bound were solved at 2.1 and 2.0 Å resolution respectively (see Table 2.2). We
compared those structures to the structure of the D170A mutant described in chapter 2.
Superimposition of the two structures, the high-resolution wild-type α-GAL (PDB
code 3GH2) and D170A mutant (PDB code 3GH3) shows no major structural
rearrangement upon binding DGJ and galactose with a root mean square deviation
(RMSD) of 0.22 Å for 736 Cα atoms of the dimer and 0.20 Å for the 15 active site
residues (Figure 3.8a, b and c). Although there are no large changes between the DGJand galactose-bound structures of α-GAL, there are slight differences around the D170
active site nucleophile. The N5(DGJ)- δO(170) distance is slightly shorter than the O5(Gal)δO(170) distance at 2.8 and 3.0 Å respectively (see Figure 3.8b and c). The O5(Gal) has two
lone pairs that are in close proximity to the deprotonated δO(170). The protonated N5(DGJ),
on the other hand, is able to form hydrogen bonding and electrostatic interactions with
the deprotonated δO(170). The protonated N5(DGJ) in the imino sugar is likely to interact
with the D170 carboxylate more favorably than the unprotonated O5(Gal) , thus the
greater potency of DGJ as a pharmacological chaperone for α-GAL.

3.4. Discussion
DGJ or 1-deoxygalactonojirimycin is an imino sugar with a structure very similar
to the α-GAL product, galactose (Legler and Pohl 1986; Yoshimizu, Tajima et al. 2008).
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a.

b.

c.

Figure 3.8 Overlay of α-GAL dimer and active site with DGJ and galactose
bound
(a) The superimposition of human α-GAL structures with DGJ (gray) and galactose
(yellow) soak and empty (magenta) shows an rsmd of 0.20 Å. DGJ (b) and galactose
(c) at the active site of α-GAL shows that the N5(DGJ)- δO(170) appears to be short than
the O5(Gal)- δO(170) at 2.8 and 3.0 Å respectively most likely due to the chemistry
between the small molecule and the D170.
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DGJ is a small molecule that belongs to a class of chaperones called active-site specific
chaperones (ASSC). As chaperones, these molecules help stabilize the native fold
conformation. For a small molecule to be an effective ASSC, it must be able to
selectively bind to the active site of an enzyme but not so tightly that it inhibits enzyme
activity. Enzyme inhibitors are especially good chaperones because of their strong
affinity and specificity for the active site of a particular enzyme. However, inhibitors
acting as chaperones must also be able to dissociate from the active site of the enzyme in
the presence of the substrate in order to allow substrate binding. Upon pharmacological
chaperone binding, the native state is stabilized, helping the protein avoid degradation by
ER-associated degradation (Fan, Ishii et al. 1999; Asano, Ishii et al. 2000; Frustaci,
Chimenti et al. 2001; Yam, Zuber et al. 2005). DGJ is hypothesized to bind only to the
native protein, lowering the energy of the protein. This shifts the folding equilibrium in
the ER toward the proper folded protein. The 15 residues at the active site from seven
different loops select and bind the substrate (Garman and Garboczi 2004). The energy
added by pharmacological chaperone binding helps hold the mutant protein in its proper
conformation allowing trafficking to the lysosome. Once the α-GAL molecule traffics to
the lysosome, it is stable for days (unpublished results by Khanna, R., et.al.; Desnick
1979; Eng, Banikazemi et al. 2001). Most α-GAL missense mutations that cause FD lead
to protein with an intact catalytic domain with some residual enzyme activity (Remeo,
D'Urso et al. 1975; Beck 2001). However, these mutations tend to lead to misfolded or
aggregated α-GAL, thus they would be good candidates for pharmacological chaperone
therapy.
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Even wild-type α-GAL shows dose-dependent increase in enzyme activity upon
addition of sub-stoichoimetric amounts of DGJ (Figure 3.5a). In vivo experiments
demonstrate that the observed improvement of enzyme activity of wild-type α-GAL is a
result of increased folding efficiency of a stably folded protein (Fan, Ishii et al. 1999). A
number of α-GAL mutants have also been assessed for activity enhancement by DGJ in
cell culture experiments (Spada, Pagliardini et al. 2006; Shimatori 2007; Shin 2007; Shin
2008; Benjamin 2009). For α-GAL, 10-15% of wild-type enzyme activity is sufficient to
prevent the appearance of Fabry disease symptoms (Desnick 2001; Ries, Gupta et al.
2005). Since FD symptoms vary depending on the amount of residual enzyme activity
(from no residual activity to 3-5%), even a small enhancement of the residual enzyme
activity will reduce FD substrate in cells and most likely alter the clinical manifestation
of the disease. A small increase in the residual activity of α-GAL greatly reduces the
progression of FD symptoms in patients (Desnick 2001; Eng, Banikazemi et al. 2001;
Eng, Guffon et al. 2001).
Our experiments identify four important observations supporting DGJ as an
effective active-site specific chaperone for α-GAL. First, DGJ binds to the wild-type αGAL and stabilizes the enzyme. It helps stabilize even the well-folded and stable wildtype α-GAL. The additional stability that DGJ provides is apparent by the rise in the
apparent melting temperature of α-GAL monitored by CD (see Figure 3.3 and Table 3.1).
This was paralleled with the noticeable resistance to protease digestion by pulse
proteolysis (Figure 3.4) and the slow unfolding kinetics by fluorescence (Figure 3.1 and
3.2) in the presence of pharmacological chaperone. Second, in all of the experiments
above, the pharmacological chaperone works better at neutral pH than at acidic pH.

68

Third, the pharmacological chaperone galactose works like DGJ but at a higher
concentration (about 105-fold more galactose than DGJ). This suggests that DGJ binds to
the active site of the enzyme more tightly than galactose. This suggests that only active
site specific chaperoning could stabilize α-GAL but not the more general non-specific
chemical chaperoning. Lastly, the higher potency of DGJ over galactose is due to the
tight binding of the chaperone, and this tight binding requires the active site nucleophile
D170. When we measured the chaperoning effect of DGJ to both wild-type and D170
mutant using our biochemical assays mentioned previously, we did not see the same
effect (the mutant requiring more DGJ to see chaperoning), indicating the importance of
the aspartic acid to the chaperoning effect of DGJ.
The standard model for the mechanism of chaperoning of α-GAL by DGJ
assumes that the imino nitrogen of DGJ is deprotonated in the ER and then protonates in
the low pH of the lysosome, leading to dissociation of the ligand from the protein.
However, our experiments contradict this model. First, a large fraction of DGJ remains
bound to α-GAL at the lysosomal pH 4.5, as shown by the thermal melt CD experiments.
Second, the pKa of DGJ is measured to be 7.1 in solution, so it is unlikely to undergo
change in protonation state as the pH goes from 6.5 in the Golgi to 4.5 in the lysosome
(Legler and Pohl 1986; Butters 2005). Third, the binding site of α-GAL contains an
excess of negative charges over positive charges, so it is not clear why protonation of the
DGJ would lead to dissociation of the sugar from the complex. Fourth, in the highresolution (1.65Å) structure of isofagomine bound to Thermotoga maritima family 1 αglucosidase, shows that the imino sugar is protonated and charged when bound to the
glycosidase (Gloster, Meloncelli et al. 2007).
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Our experiments lead us to propose a new model for the mechanism of
pharmacological chaperoning of α-GAL by DGJ. We predict that the DGJ remains
protonated and positively charged when bound to α-GAL, and that the pH dependence of
the interaction is due to protonation of the catalytic nucleophile D170 of α-GAL. In our
model, the pKa of the carboxylate of D170 is raised by the excess of negative charges in
the active site. We hypothesize that at ER and Golgi pH (pH 7.2 and 6.5 respectively), the
D170 carboxylate is deprotonated while DGJ is protonated and carries a positive charge,
and the ionic interaction leads to tight binding of DGJ to α-GAL. However, at lysosomal
pH (4.5), the D170 carboxylate protonates, leading to the loss of the ionic interaction and
weaker binding of the DGJ. Upon the removal of the carboxylic side chain of D170 in the
D170A mutant, the ion pair is lost and the potency of DGJ is greatly diminished. Thermal
denaturation of the D170A mutant monitored by CD (Figure 3. 6c) shows no increase in
Tm upon addition of DGJ.
An ideal lysosomal pharmacological chaperone candidate should be a small
molecule that could diffuse readily into the cell and ER membrane and must be able to
bind to the active site of a specific enzyme in the ER where proteins are folded. Once the
pharmacological chaperone-bound enzyme escapes the quality control of the ER and is
transported to the lysosome, the natural substrate must be able to out-compete the PC at
the active site (Figure 3.9).
The experiments mentioned above demonstrate the mechanism of action of DGJ
as a pharmacological chaperone. An enzyme bound to DGJ is very stable and unfolds at a
slow rate. Since the Ki for DGJ and the amount of enzyme is known, we could calculate
how much α-GAL enzyme that remains unbound to DGJ. Only unbound to DGJ α-GAL
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Figure 3.9 Pharmacological chaperone therapy for wild-type and mutant αGAL
Protein folding in the ER is an equilibrium process. As the wild-type polypeptide
chain is being synthesized in the ER, it folds to its proper conformation with the help
molecular chaperones. At time times the folding protein samples the wrong
conformation, misfolds and is degraded through ERAD. In the presence of the
pharmacological chaperones like DGJ, it binds more favorably to the active site at
neutral pH, shifts the folding equilibrium to proper folded and facilitates proper
trafficking of the fully function protein to the lysosome. Strong binding of the
pharmacological chaperone is key to the chaperoning effect of the small molecule.
This increases the folding efficiency of wild-type protein. Similarly when the
polypeptide chain with an amino acid substitute is being synthesized at the ER, it tries
folds to the proper conformation with the help molecular chaperones. The folding
equilibrium of a mutant protein is shifted more towards the non-native fold. Most of
these mutants have intact active site and remain active or partially active however due
to the amino acid substitution the mutant misfolds. The misfolded protein is
recognized by the cell and is degraded. In the presence of the pharmacological
chaperones like DGJ, it binds favorably to the active site at neutral pH, shifts the
folding equilibrium to proper folded and facilitates proper trafficking of the fully
function protein to the lysosome. This increases the folding efficiency of mutant
protein.
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unfolds. Given that DGJ is a potent inhibitor (Ki in the nanomolar range), most of α-GAL
in the solution is bound to DGJ thus slow rate of unfolding, increased thermal stability
and resistance to protease digestion is detected in the experiments mentioned above.
Additionally, this also suggests that the pharmacological chaperone is not limited to mild
phenotype as initially thought. Most mutant with intact active site and could bind DGJ
tightly could be rescued by DGJ from ERAD. Fabry disease is the first lysosomal storage
disease that shows promising results for PCT and could be used as a model for other
storage diseases as well as other protein-folding disease such as Alzheimer’s disease and
Parkinson’s disease.

3.5. Methods
3.5.1. D170A α-GAL expression and purification
α-GAL active site mutant, D170A was expressed and purified as previously
described in Chapter 2. 6. 1 and Chapter 2. 6. 2.

3.5.2. Fluorescence
To measure the kinetics of chemical denaturation of α-GAL in the presence of
pharmacological chaperones, tryptophan fluorescence measurements were carried out on
PTI QM1 spectrofluorometer (PTI, Inc., Birhamton, NJ). Recombinant WT α-GAL (12
µM; FabrazymeR, Genzyme Corp) was incubated with 500 µM DGJ (Toronto Research
Chemicals Inc., D236500) or 500 mM galactose (Sigma Aldrich, G5388). After 2-4
hours, chemical denaturation was initiated by ten-fold dilution into 10 mM sodium
phosphate/7.5M urea, pH 6.5 or into 10 mM sodium acetate/7.5M urea, pH 4.5. The
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kinetics of unfolding was measured by monitoring the fluorescence emission hourly for
10 hours after dilution and then at 24 hours. Tryptophan fluorescence signal was
monitored at 25°C by excitation at 295 nM (1 nm slit width) and emission at 300-400 nm
(3 nm slit width). Fluorescence intensity at 335nm, the peak in the spectrum of the folded
protein, was normalized against the initial reading (Io). The rate constant for unfolding
(kU) was obtained assuming first order kinetics from the exponential fit of the
fluorescence data using Igor Pro software:
kU = ln 2/t

(3.1)

where t is half-time of the unfolding.

3.5.3. Circular dichroism (CD)
To measure the stability of α-GAL in the presence of pharmacological
chaperones, we used circular dichroism (Jasco J715 spectropolarimeter) monitor the
secondary structure of α-GAL as the protein denatured. α-GAL samples were prepared by
incubating 12 µM protein alone and with varying concentrations of pharmacological
chaperone (50 nM - 50 µM DGJ and 50 nM - 50 mM galactose). The solutions were then
diluted ten-fold into 10 mM phosphate buffer (pH 6.5) or 10mM sodium acetate buffer
(pH 4.5) and incubated overnight at 20°C prior to CD analysis. CD wavelength scans and
thermal melts were carried out on a Jasco J715 spectropolarimeter equipped with a PTC348WI temperature controller. To examine the secondary structure of the samples, they
were first scanned from 190-240 nm at 25°C at a scan rate of 20 nm/min using a 0.1 cm
quartz cuvette. Then, the CD signal at 222 nm was monitored while raising the
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temperature from 25-90°C at a rate of 1°C/min. The molar ellipticity (Θ) of each solution
was calculated using:

Molar ellipticity, " =

CD signal @ 222 nm # 100
C#n#l

(3.2)

where C is the protein concentration in mM, n is 418, the number of amino acid residues
per monomer, and l is 0.1 cm, the cell path length. The molar ellipticity data was

!

converted into fraction denatured, Fd according to:

Fd =

"N # "obs
"N # "U

(3.3)

where Θobs is the calculated molar ellipticity and ΘN and ΘU are values characteristic of a
fully native and fully!denatured states respectively. The Tm is the temperature at which Fd
is equal to .

3.5.4. Pulse Proteolysis
To monitor the resistance of α-GAL to proteolytic digestion in the presence of
pharmacological chaperones, we adapted a published pulse proteolysis protocol (Park and
Marqusee 2005). For the pH 6.5 experiments, 1.2 - 2 µM α-GAL was incubated for 2-4
hours alone or with 0.5 nM-50 µM DGJ or 0.5 µM-50 mM galactose in 10 mM
phosphate buffer (pH 6.5). The solution was then diluted ten-fold into 10 mM
phosphate/8M urea and incubated at 20°C overnight. Digestion was initiated by the
addition of 0.13 mg/mL thermolysin (Sigma T7902) in 10 mM CaCl2, 50 mM NaCl, 20
mM Tris•HCl, pH 8.3. After 5 minutes at 37°C, the reaction was quenched by the
addition of 50 mM EDTA (pH 8.0) to a final concentration of 12.5 mM. For the pH 4.5
experiments, 1.2 - 2 µM was incubated for 2-4 hours alone or with 0.5 nM-50 µM DGJ or
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0.5 µm-50 mM galactose in 100 mM sodium acetate (pH 4.5). The solution was then
diluted ten-fold into 10 mM sodium acetate/3M urea, pH 4.5 and incubated at 20°C
overnight. Digestion was initiated by the addition of 0.16 - 0.25 mg/mL pepsin. After 5
min, the reaction was quenched by the addition of 2M Tris-HCl, pH 9.0 to a final
concentration of 0.25 M.
Samples were separated on a reducing 10% SDS/PAGE gel and stained with
GelCode Blue (Pierce 24592). Band intensities between 43 and 53 kDa were quantified
using the Syngene GeneTools gel analysis software. Each α-GAL band intensity was
normalized against the α-GAL band intensity in the absence of protease. The amount of
undigested protein in the presence of DGJ or galactose is a measure of the
pharmacological chaperone’s ability to stabilize the α-GAL and confer protease
resistance.

3.5.5. Activity Assay/Ki determination
To determine the enzymatic parameters of α-GAL in the presence of
pharmacological chaperones, the specific activity of the enzyme was measured using the
synthetic substrate para-nitrophenyl-α-galactopyranoside (pNP-α-gal; Sigma Aldrich, St.
Loius Mo, N0877). 1.2 µM α-GAL in 100 mM citrate/phosphate buffer, pH 6.5 or pH 4.5
was incubated with 0-100 µM DGJ or 0-2 M galactose for 2-4 hours at 20°C. The
solution was diluted 5-10 fold into 10 mM pNP-α-gal/100 mM citrate/phosphate buffer
pH 6.5 or pH 4.5. After 10 minutes at 37°C, the reaction was quenched by the addition of
250 µL of borate buffer, pH 9.8. Absorbance of the para-nitrophenylate ion at 400 nm
was measured using a microplate reader at room temperature and converted to amount
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product using 18 mM-1cm-1 as the extinction coefficient. Ki values for DGJ and galactose
were calculated using the Michaelis-Menten equation.
d[ pNP]
=
dt

v max "[ pNP - # - galactose]
$ [I] '
K M&1+ ) + [ pNP - # - galactose]
% KI (

(3.4)

In the presence of increasing concentration of inhibitor (I), DGJ and galactose, KM can be
replaced
with KM(app):
!
" [I] %
K M (app) = K M$1+ '
# KI &

(3.5)

where KM(app) is observed KM of enzyme in the presence of an inhibitor, [I] is the
!
inhibitor concentration,
and Ki is the inhibition constant. Upon plotting Km (app) vs [I], Ki

can be calculated from the slope of the linear fit of the data.

3.5.6. Crystallography
Wild-type human α-galactosidase A expressed in tobacco plants was a gift from
Large Scale Biology Corporation. Purified α-GAL protein was concentrated to ~8.0
mg/mL. Crystallization experiments were performed using the hanging-drop vapordiffusion method and were grown at 20°C in an incubator. Crystals of the wild-type αGAL were obtained by mixing 1µL of reservoir solution (20 mM magnesium acetate,
100 mM sodium cacodylate (pH 5.1) and 8-15% (w/v) PEG8K) with 1 µL of a protein
solution at ~8.0 mg/mL. Prior to freezing and data collection, the crystals were
transferred stepwise into a cryoprotectant and ligand solution containing 20% PEG400,
25% (w/v) PEG8K, 20 mM Mg(CH2COOH)2, 100 mM Na-cacodylate (pH 5.1) and
either 12 mM DGJ or 100 mM galactose.
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Data collection was performed at the National Synchrotron Light Source (NSLS)
beamline X6A at the Brookhaven National Laboratory. X-ray images were integrated,
indexed and scaled using HKL2000 software package (Otwinowski 1997). αgalactosidase A in space group P3221 (PDB code 3HG5) was used as a molecular
replacement model in the CCP4 program MolRep/AMoRe and rigid body refinement and
positional refinement were performed using Refmac5. The atomic models were built into
electron density using the program O, after which refinement and water placement were
done using REFMAC (Jones, Zou et al. 1991). Ramachandran plots were computed using
PROCHECK (Laskowski 1993). Coordinates were superimposed using LSQMAN; the
surface accessible are were calculated using AREAMIMOL in CCP4 and figures were
made in PyMOL (Kleywegt 1997; DeLano 2008).
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CHAPTER 4

SPECIFIC DEFECTS RESPONSIBLE FOR FABRY DISEASE RESCUED
BY PHARMACOLOGICAL CHAPERONE DGJ
This chapter is part of a paper in preparation. (Abigail I. Guce and Scott C. Garman.
2009)
4.1. Introduction
Fabry disease is a well-documented inherited disorder with over 400 missense
mutations reported in patients (Human Gene Mutation Database). Mapping the mutations
into the three-dimensional structure of human α-GAL indicates a breadth of the mutations
that cause Fabry disease (Garman and Garboczi 2002; Garman and Garboczi 2004; Guce
2009). Some of these mutations grossly alter the gene sequence such as splicing
mutations, small deletions & insertions and large gene rearrangements. These mutations
result in gross modification of the polypeptide product and typically result in a
completely non-functional protein. Patients with structure-altering mutations present the
severe form of the disease. The previous chapter focused on the molecular mechanism
and the interactions of the pharmacological chaperones with wild type α-GAL. This
chapter focuses on the point mutations that disrupt the α-GAL protein and how they
respond to DGJ. Most of the mutations lead to deficiency of α-GAL due to misfolding
and degradation of the mutant protein at the ER (Hartl and Hayer-Hartl 2002; Ellgaard
and Helenius 2003). The structure of α-GAL allows for the predictions of the effect of
hundreds of point mutations found in different Fabry patients on the structure of the
enzyme. Despite numerous effects to study these mutations, there is still no clear
genotype-phenotype connection established because of the diversity of the mutations.
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Fabry disease, a protein misfolding disorder, is an excellent candidate for
pharmacological chaperone therapy. Based on the work described in Chapter 3 on the
mechanism of the small molecule DGJ, this chapter describes similar approaches, but
focused on the various categories of mutations that cause Fabry disease. Studies on wild
type α-GAL and the pharmacological chaperone DGJ demonstrate that sub-inhibitory
amounts of DGJ stabilize α-GAL. DGJ binds more tightly at neutral pH, presumably
because of the presence of an extra H-bond and electrostatic interaction stabilizing the
interaction between the ligand and the protein. The increase in stability of α-GAL in the
presence of pharmacological chaperone is also demonstrated by the pulse proteolysis,
tryptophan fluorescence and CD experiments. Several studies have demonstrated an
increase in enzyme activity of some mutant α-GAL proteins upon addition of DGJ
(Spada, Pagliardini et al. 2006; Ishii, Chang et al. 2007; Shimatori 2007; Shin 2007; Shin
2008; Benjamin 2009). However it is not known how many of these mutations that cause
Fabry disease will respond favorably to pharmacological chaperone therapy (Fan, Ishii et
al. 1999; Asano, Ishii et al. 2000; Frustaci, Chimenti et al. 2001). Initially
pharmacological chaperone therapy was proposed exclusively for the mild phenotype of
the disease (Asano, Ishii et al. 2000; Fan 2003; Yam, Bosshard et al. 2006). However
recent studies show several severe α-GAL mutations respond favorably to DGJ treatment
resulting to an increase in enzyme activity or in the degradation of the accumulated
substrate at the lysosome.
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4.1.1. Structural analysis of Fabry disease mutants
First, we grouped the mutations into categories, and then chose representative
mutations from each of the categories. We examined representative mutations, (a) one
that is a surface exposed substitution and is unlikely to influence the fold of the protein
(E398K); (b) two that disrupt the enzyme active site (M51I, D170A); and (c) two that is
likely to affect the fold of the protein (L166V, M51I).

4.1.1.1. Glutamic acid 398 to lysine (E398K)
E398 is a surface-exposed residue with a side chain surface accessible area of
approximately 21.5Å2. It is located at the C-terminal domain at the end of β14 strand, and
at the edge of one of the two sheets of the β sandwich. It is also positioned at a small
positive patch in a surface loop of the protein and packs against atoms mostly from the
main chain carbonyl group of Thr 400 (see Figure 4.1). E398 is about 54 Å away from
the active site. Similarly is it also far away from the domain and dimer interface of the
protein. E398 is somewhat close to the C terminus of the monomer, about 16-18 Å away
from the last resolved residue Met 423 in the 1.9 Å D170A structure. The E398K
substitution changes the charge on the residue, but is considered a conservative
substitution in the BLOSSUM sequence alignment matrix (Needleman and Wunsch
1970). This residue is not conserved among consensus α-galactosidase sequences
(Thompson 1994). Structural alignment of four α-galactosidase structures from different
species (PDB ID: 1UAS, 3A5V, 1T0O, 1SZN) also shows no sequence conservation
(showing a Gln, Ser or His) at this position (Fujimoto, Kaneko et al. 2003; Golubev,
Nagem et al. 2004; Golubev, Nagem et al. 2004; DeLano 2008; Fujimoto, Kaneko et al.
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L166V

M51I

E398K

Figure 4.1 α-galactosidase A mutants
Shown are of the chosen Fabry disease-causing mutants and their location as mapped
to the monomer of α-GAL. E398K is located at the N-terminal loop, exposed to the
solvent. It is positioned between a cluster of acidic residues. E to K substitution
changes the charge of the residue but contact analysis show no clashes between other
nearby amino acid; M51I is a mutation of a buried residue that makes contacts with
active site residues D92 and D93, and a disulfide bond C52-C94. Although M to I
substitution is considered a conservative mutation, contact analysis show substitution
to I causes a structural clashes mostly from the disulfide bond; L166V is located at the
center of the (β/α)8 barrel at the opposite end of the active site pocket. L to V
substitution shows structural clash between the β strands that make up the center of the
barrel.
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2009). Changing the glutamic acid 398 to lysine changes the charge of the surface
however that is unlikely to be an adverse change in the structure. Since this mutation
islocated in an exposed loop that could accommodate a bigger residue and a change in the
charge, it is unknown why this particular mutation is reported to cause a severe type of
Fabry disease (Shabbeer, Yasuda et al. 2002).

4.1.1.2. Methionine 51 to isoleucine (M51I)
Patients reported with M51I have the severe form of Fabry disease (Spada,
Pagliardini et al. 2006). M51I is a buried residue near (~4.5 Å away) an active site
residue, W47. M51I is located near active site residues, Cys52-Cys94, D92 and D93 (see
Figure 4.2b). The Met to Ile change is a conservative substitution and when Ile is
modeled into the structure at this position it causes a small structural clash mostly from
the γ and δ carbons of Ile to the main chain of cysteine (see Figure 4.1). M51 also makes
contacts to residues at the dimer interface, with I359 at the loop connecting β11 and β12
of the C-terminal domain. However multiple sequence alignment and structural
alignment shows this residue is not conserved across related α-galactosidase sequence or
structures (Thompson 1994; Fujimoto, Kaneko et al. 2003; Golubev, Nagem et al. 2004;
Golubev, Nagem et al. 2004; DeLano 2008; Fujimoto, Kaneko et al. 2009). By analysis
of contacting residues, this mutation disrupts structurally important residues and could
influence the three-dimensional structure of the protein thus affecting the enzyme
activity.
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4.1.1.3. Leucine 166 to valine (L166V)
L166V mutation also causes the severe form of Fabry disease (Okumiya, Ishii et
al. 1995). L166 is another buried residue, with a side chain surface accessible area of only
1.0 Å2. It is located inside the (β/α)8 barrel at the opposite side of the active site pocket. It
is at the other end of the β4 strand, the same β strand where the nucleophile catalytic
residue D170 is located. It is about 13 Å from D170. Although L166V is considered a
conservative substitution, the branched β carbon of valine clashes with Tyr 88 on β2
strand and main chain atoms on β3 strand in the β barrel (see Figure 4.1). Sequence
alignment shows that although Y88 is not strictly conserved, it is most often a Tyr or Leu
(Thompson 1994; DeLano 2008). Based on the contact analysis, this mutation disrupts
the three-dimensional structure of the protein, also affecting enzyme activity. However
the sequence and structural alignment clearly suggests this position can accommodate a
bulkier group (Thompson 1994; Fujimoto, Kaneko et al. 2003; Golubev, Nagem et al.
2004; Golubev, Nagem et al. 2004; Fujimoto, Kaneko et al. 2009).

4.2. Experimental Strategy
In this section, we sought to test the effect of DGJ on the conformational stability
of the mutant proteins using pulse proteolysis. In the previous chapter, we described how
pulse proteolysis on the wild type α-GAL enzyme assessed the effect of DGJ on the
stability of the enzyme. We applied the assay (optimized against wild type α-GAL) to
selected mutant enzymes to study the response of the mutants to DGJ. We also
investigated the effect of other known chemical chaperones other than DGJ and galactose
on the stability of mutant α-GAL.
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Beyond these experimental approaches, we sought a general predictive model
relating changes in α-GAL sequence to response of these mutant proteins to
pharmacological chaperone. Based upon analysis of the structure and recent experimental
data on the responsiveness of individual α-GAL mutants to DGJ, we have created a set of
rules that predict the response of all known α-GAL mutants to DGJ. These predictions
aim to guide clinicians as to which patients are likely to respond to DGJ therapy,
depending on their individual DNA sequence, establishing a general genotype-DGJ
response relationship for Fabry disease.

4.3. Results
4.3.1. Characterization of the activity and kinetic properties of insect cell expressed
human α-GAL mutants
We expressed and purified wild type and mutant α-GAL enzymes, then tested
their specific activity, kinetic properties, thermal stability by CD, and resistance to
digestion in pulse proteolysis experiments. The apparent melting temperatures measured
by CD indicate the structural stability of the fold of the enzyme, while the kinetic
parameters report on the competence of the active site. We also performed these analyses
in the presence of DGJ, to indicate the effect of pharmacological chaperone on the
proteins. Wild type α-GAL and the catalytic inactive mutant D170A were used as
controls for the stability and activity of the other mutants. Table 4.1 summarizes the
biochemical and enzymatic characterization of the expressed mutants, E398K and M51I
(Figure 4.2a and b), as well the wild type and D170A controls. Because the L166V
mutant has a very low expression level, there is no quantification of the enzyme stability
and activity.

84

Table 4.1 Stability and kinetic parameters of expressed α-GAL
Protein

Type of

App Tm,

Spe. Act.,

mutation

°C

U/mg

KM, mM

kcat, sec-1

kcat/KM

E398K

Exposed

58 ± 1

415 ± 30

7.3 ± 0.3

22.54 ± 0.05

3.1

M51I

Buried

54.1 ± 0.5

130 ± 20

6.8 ± 0.4

8.92 ± 0.02

1.3

L166V

Buried

ND

< 10

ND

ND

ND

D170A

Active site

64 ± 2

ND

ND

ND

ND

Wild type

-

60 ± 1

522 ± 302

8.2 ± 0.2

37.8 ± 0.2

5.1

ND = not detected
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Kinetics

Figure 4.2 Reaction rates vs substrate concentration for α-GAL mutants
E398K (a) and M51I (b) Michaelis-Menten plots relating the reaction rate to the
substrate pNP-α-gal substrate concentration; (insert) absorbace of para-nitrophenolate
measured at 400 nm collected over time at various pNP-α-gal substrate concentrations:
50 mM, red; 37.5 mM, orange; 25, brown; 12.5 mM, light orange; 6.25 mM, yellow;
3.12 mM, light green; 1.56 mM, green; 0.78 mM, light blue; 0.39 mM, blue; 0.20 mM,
purple; 0.10 mM, pink.
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Figure 4.3 Apparent melting temperature of expressed α-GAL mutants at pH 6.5
as measured by CD at 222 nm
Comparison of the apparent melting temperature of expressed α-GAL mutants E398K
(), M51I (), D170A () to wild type () protein. E398K and wild type α-GAL
have similar stability, D170A is slightly more stable but comparable to the stability of
wild-type enzyme while M51I is less stable.
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We predict that E398K α-GAL should behave like the wild type enzyme because
it is a conservative substitution of an exposed residue. As expected, E398K α-GAL has a
comparable Tm as wild type (58°C vs 60°C, Figure 4.3) as measured by CD, and the two
enzymes have similar enzymatic parameters. However, this mutation causes the severe
phenotype of Fabry disease. It is unknown why the conservative substitution E398K
causes Fabry disease, because the mutation is unlikely to disrupt the three-dimensional
structure of the α-GAL mutant protein. Although the purified protein behaves much like
the wild type, they have very different phenotypes in patients.
The M51I mutant α-GAL affects a buried residue near an active site residue,
W47. Unlike E398K, M51I α-GAL is likely to have a disrupted three-dimensional
structure of the protein near the active site, thus affecting the enzyme activity. Compared
to wild type α-GAL and the E398K mutant, this mutant has one third the specific activity
and comparably reduced catalytic parameters. The decrease in activity of M51I could be
explained by either disruption of the active site of the enzyme or by a fraction of inactive
protein combined with active protein. We have observed that some purified M51I protein
stored in phosphate buffer eventually precipitates over months at 4°C. In contrast, wild
type α-GAL and other mutants stored comparably remain stable and active over the same
time period. Thermal melts of M51I monitored by CD show a lower denaturation
temperature than wild type, showing that the mutant is a less stable protein and more
susceptible to unfolding. The Michaelis constant (KM), the substrate turnover (kcat) and
the specificity constant (kcat/KM) of M51I were also measured, and plot of MichaelisMenten hyperbola for E398K and M51I are shown in Figure 4.2. Even though the
Michaelis constant is unperturbed and similar to wild type, the substrate turnover and
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specificity constant are lower, suggesting an enzyme that is less efficient at converting
bound substrate into product (see Table 4.1). M51I is not completely catalytically dead
(like the D170A mutant is) but is less stable and less active enzyme than the wild type
and E398K mutant.
The α-GAL mutant L166V is a replacement in another buried residue, however
unlike M51I, the expression level of this mutant is very low (<0.1 mg/mL), and no
mutant protein could be purified from the supernatant, thus characterization of the L166V
mutant was not possible. The low expression of this mutant suggests that it does not fold
efficiently, leading to the loss of enzyme activity in Fabry disease patients.

4.3.2. Protection from protease digestion monitored by pulse proteolysis
After characterization of the purified mutants as fully (E398K) or partially (M51I)
active, the response of these two mutants to the pharmacological chaperones DGJ and
galactose therapy was investigated. The pulse proteolysis assay we developed for wild
type α-GAL to assess the proper conformation of the protein is easily adapted to measure
the “foldedness” of the mutant enzymes. We examined the effect of increasing
concentrations of DGJ and galactose on the susceptibility of wild type and mutant α-GAL
proteins to protease digestion. Analogous to the wild type experiments, the α-GAL
mutants E3898K and M51I, were subjected to denaturing conditions that allow digestion
by protease. The resistance of the mutants to proteolytic digestion was measured by the
fraction of α-GAL mutant remaining, and the experiment was repeated in the presence of
pharmacological chaperone.
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Figure 4.4 Pulse proteolysis experiment of α-GAL mutants
Effects of DGJ and galactose on α-GAL mutant stability through resistance to
protease. (a) and (b): Thermolysin digestion (pH 6.5) of 1.2 µM E398K mutant in
8M urea with DGJ and Gal respectively; (c) and (d): Thermolysin digestion (pH 6.5)
of 1.2 µM M51I mutant in 8M urea with DGJ and Gal respectively.
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For the E398K mutant, 50% protection is estimated around 500 nM DGJ and 3.0
mM galactose, comparable to the concentrations seen for wild type α-GAL at 400 nM
DGJ and 3.0 mM galactose (Figure 4.4a and b). This shows that critical concentration
range at which we start to see significant protection between DGJ is once again
approximately 105-fold less than for galactose.
On the other hand, 50% protection from proteolytic digestion of M51I mutant is
observed at a higher concentration DGJ and galactose (600 nM and 50 mM respectively,
Figure 4.4c and d). Depending on the type of mutation and how the mutation affects the
3D structure of the protein, different pharmacological chaperone concentrations are
required to resist proteolytic digestion. Mutations that affect the active site like M51I and
D170A change their ability to bind pharmacological chaperone. At higher concentrations
of pharmacological chaperone, when the pharmacological chaperone is fully bound to the
mutant, the enhanced stability can be seen.

4.3.3. In vivo assay of the effect of different chaperones to the expression of L166V
We next examined the in vivo effects of pharmacological chaperones on
expression and activity of mutant α-GAL. To study the in vivo effect of pharmacological
chaperones on the expression of α-GAL, the low expressing L166V mutant was used. We
tested in vivo known pharmacological chaperones such as DGJ (a competitive inhibitor),
galactose (the catalytic product); glucose (a monosaccharide excluded from the active
site), and other known non-specific chemical chaperones and osmolytes (including
DMSO, proline, ficoll and dextran) (Perlmutter 2002; Ignatova and Gierasch 2006). DGJ
and galactose are active site specific chaperones while glucose, DMSO, proline, ficoll
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a.

b.

c.
d.

Figure 4.5 Pharmacological chaperones for L166V mutant
(a) Western blot of the supernatant of Tn5 insect cells transfected with L166V DNA;
lanes 3 and 4 shows the increase in L166V expression upon addition of DGJ; lane 5
shows the decrease in L166V expression after diluting out DGJ during just one
passage. (b) Western blot of L166V with different chaperones, and are the
corresponding activity of the supernatant L166V mutant using X-α-gal (c) and pNPα-gal (d) chromogenic substrates.
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and dextran affect protein stability through non-specific interactions with α-GAL. The
low basal expression level of L166V improves upon addition of DGJ to the media (Figure
4.5) as seen by the increased western blot band intensity. However when we take cells
with high L166V expression in the presence of DGJ and passage them in media without
DGJ, the expression level return to basal level (Figure 4.5). This result indicates that the
increase in L166V expression is correlated with the addition of DGJ to the media. In the
same way, addition of 100 mM galactose to the media does not affect the L166V
expression level. Non-specific chemical chaperones like glucose, DMSO, proline, ficoll,
and dextran did not affect the level of expression of L166V in our culture. Overall, the
western blots demonstrate that DGJ rescues the expression of L166V mutant in insect
cells, while galactose and other chemical chaperones do not.
We then tested the correlation between expression of L166V mutant α-GAL and
activity using two approaches. First, enzyme activity of the insect cell supernatant was
detected using a dot blot assay, where the enzyme was bound to a nitrocellulose
membrane, and activity was measured using the X-α-galactose substrate (after removal of
the small molecule chaperone). In parallel, the dialyzed supernatant was assayed for
enzymatic activity via quantification of pNP-α-galactose cleavage. Figure 4.5 illustrates
the strict correlation between western band intensity and activity of L166V. Following
incubation with DGJ, the increase in L166V expression in insect cells was matched by
the increase in activity using the X-α-galactose and pNP-α-galactose substrates. This
shows that DGJ rescues expression and activity of L166V in vivo as well as in vitro.
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4.4. Discussion
Pharmacological chaperones are proposed to bind to the active site of the mutant
enzyme to facilitate the proper folding of the protein. The mechanism of pharmacological
chaperoning of the small molecule DGJ has been explored for the first time, by
measuring the stability of the wild type α-GAL upon binding to the pharmacological
chaperone (Chapter 3). DGJ effectively stabilizes the wild type protein, allowing it to
escape ERAD and traffic to the lysosome. Using the assays developed to monitor the
stability of wild type protein, we applied the same assays to known Fabry disease-causing
mutations. Three mutants (representing different genotypes of the severe form of Fabry
disease) show very different results in biochemical assays for the stability of the protein.
These amino acid substitutions represent the three categories of missense mutations
mentioned in Chapter 1 that cause the deficiency of the protein. First, E398K is a stable
and active enzyme when over expressed in insect cells. It has a comparable apparent
melting temperature to wild-type enzyme, indicating this enzyme is as stable as wild
type. The specific activity and kinetics of this mutant also suggest a well-formed active
site. Although it is known that this amino acid substitution causes Fabry disease, E398K
has biochemical properties (including Tm and protease resistance) very similar to the
wild-type enzyme. Second, M51I is slightly less stable than wild type, with an apparent
melting temperature of about 5°C lower. The specific activity and catalytic parameters of
M51I suggest a less active enzyme. The response of the M51I mutant to increasing DGJ
concentration is different from wild type, requiring about twice as much DGJ and about
10-fold more galactose to achieve 50% protection from digestion. M51I is a destabilized
mutant, requiring a higher concentration of pharmacological chaperone to stabilize the
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structure. Once bound to the active site of M51I, DGJ acts as a pharmacological
chaperone and stabilizes the mutant protein. In both E398K and M51I there is a
significant difference in the concentrations of DGJ and galactose required to show a
chaperoning effect, suggesting that the N5-D170 ionic interaction described in the
previous chapter is relevant in the mutants also. Third, the L166V mutant is a very
unstable protein that expresses at a very low level. With this mutant, the pharmacological
chaperone effect of galactose is not detectable, and only the tight binding
pharmacological chaperone DGJ is capable of improving protein expression.
Additionally, non-specific chaperones like glucose, DMSO, ficoll, and dextran show no
chaperoning effect on the destabilized L166V mutant α-GAL.
Pharmacological chaperone therapy was originally proposed only for patients
with a mutation that causes a mild form of Fabry disease (Asano, Ishii et al. 2000; Fan
2003). The subset of mutations that cause a mild form of Fabry disease is very limited,
making up less than 1% of the total number of mutations found in Fabry disease patients.
A small number of female carriers who present a mild form of Fabry disease might also
be candidates for pharmacological chaperone therapy. However, a number of recent in
vivo and in vitro experiments (including those in this chapter) on the effect of DGJ on
mutant α-GAL proteins show many of the mutants have a dose-dependent response to
DGJ (Spada, Pagliardini et al. 2006; Ishii, Chang et al. 2007; Shimatori 2007; Shin 2007;
Shin 2008; Benjamin 2009). Overall approximately 112 mutants have been assayed for
their response to DGJ, but about 60% of the reported Fabry disease-causing mutations
have not been measured for their response to DGJ. Additionally, new Fabry diseasecausing mutations are reported regularly.
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We developed a set of rules for predicting the response of all Fabry-disease
causing mutations to DGJ. Examining the considerable experimental data available in the
literature in light of the detailed structural knowledge of α-GAL, the set of rules (listed in
Table 4.2) will predict whether a particular mutant α-GAL will respond to DGJ
chaperoning. The response of a mutant protein to DGJ depends upon 1) the kind of amino
acid substitution; 2) the location of the mutation; and 3) the amount of structure disrupted
by the mutation. Table 4.2 lists the mutations or types of mutations that we predict will
respond favorably to DGJ, leading to an increase in α-GAL activity upon addition of
DGJ. Mutations that respond favorably to the pharmacological chaperone are not
restricted to either the N- or C-terminal domains. We predict that pharmacological
chaperone therapy will be effective on a large fraction of Fabry disease patients.
Similarly we have also predicted which mutations will be unlikely to respond to
pharmacological chaperone. Most of these mutations are in to the N-terminal domain
except for some mutations that fall under the h, i and j category mentioned in Table 4.2.
Figure 4.6 a-d; g-j show some mutations predicted to be responsive and non-responsive to
DGJ respectively and a few exceptions to the rules. Figure 4.7a and b plots the 109
residues where in vivo and in vitro experimental data shows to be responsive (blue) and
non-responsive (red) to DGJ respectively. Figure 4.7c and f maps the mutations that are
predicted to be responsive and non-responsive to DGJ. We have divided the predictions
into those with high confidence and those with lower confidence, based upon how strictly
they adhere to the rules in Table 4.2. The lower confidence predictions are based on
sequence alignment as well as the rules in Table 4.2. A complete inventory of the Fabry
disease-causing mutations, their location, and the predicted DGJ response is listed in
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Table 4.2 Predictive rules on the response of FD mutations to DGJ
Responsive to DGJ
a.

any conservative mutations i.e. in general polar to polar mutations and
non-polar to non-polar mutation– Figure 4.6 a1 and a2

b.

any residues mutated to Gly (X  Gly) – Figure 4.6 b

c.

Pro mutated to any residue (Pro  X) – Figure 4.6 c

d.

residues that are exposed with surface with side chain accessible area greater
than 2Å– Figure 4.6 d

Non-responsive to DGJ
e.

any of the 13 active site residues that are critical to substrate binding

f.

either of the two catalytic residue responsible for the cleavage of the
glycosidic bond

g.

any residues around the active site that interact and stabilize the 15 active site
residues – Figure 4.6 g

h.

all Cys involved in disulfide bond - Figure 4.6 h

i.

any residues that is mutated to Pro except residues that are exposed or
located at the loop (X  Pro/exposed and loop) – Figure 4.6 i1 and i2

j.

all Gly residue that is mutated to any residue except Val and Ala provided
there is space for the additional side chain (Gly  X/A and V) –
Figure 4.6 j1 and j2
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A. Responsive to DGJ

Figure 4.6A Responsive mutants to DGJ therapy
Responsive mutants: a1 and a2 shows conserved amino acid substitution; b and c shows
any amino acid mutated to glycine and proline respectively; and d shows a mutations
that is exposed to the solvent.
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B. Non-responsive to DGJ

Figure 4.6B Non-responsive mutants to DGJ therapy
Non-responsive mutants: g shows a mutation near the active site, a residue that makes
contact with an active site residue, also shown in sphere is the galactose bound at the
active site; h shows a cysteine mutation that is involved in a disulfide bonding; i1 and
12 shows two different leucine mutated to proline where one is buried (1) and the other
one is expose (2) and the two mutations has different response. The buried one (1) is
categorized as non-reponsive however when the mutation to proline is located at the
exposed region, it is considered exception to the rule and is a responsive mutation to
DGJ; j1 and j2 shows the same buried glycine residue mutated to either a bigger residue
arginine which is non-responsive, however if the mutation is to a small residue like
alanine, this becomes a responsive mutation to DGJ.
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a.

b.

c.

d.

e.

f.

Figure 4.7 Map of mutants that respond and not respond to DGJ therapy
(a) and (b) Experimental data of mutants that are responsive (blue) and nonresponsive (red) to DGJ respectively; (c) and (d) Mutants predicted to be responsive
(purple) and non-responsive (magenta) to DGJ using the rules formulated above; (e)
and (f) Mutants predicted to be responsive (cyan) and non-responsive (orange) to DGJ
using structural analysis.
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Table 4.4. Combining both high and low confidence predictions as well as known
experimental data, this make up around 60% of all the single point missense mutations
reported to cause Fabry disease could be stabilized by DGJ. For the aprroximately 166
missense Fabry-disease causing mutations with no experimental information about DGJ
chaperoning, we have predicted the response of these mutants to DGJ chaperoning. With
the prediction of which mutations in α-GAL are likely to respond to DGJ treatment, it
will be easier to direct pharmacological chaperone therapy for Fabry disease patients
depending on their individual DNA sequence. Additionally, the rules we have developed
can be applied to newly discovered mutations in α-GAL in yet unidentified Fabry disease
patients.
In this chapter it has been established that: a) like the wild type α-GAL, mutant αGAL is stabilized by DGJ; b) like the wild-type enzyme as well, there is a difference in
the concentration of DGJ and galactose to see chaperoning effect; c) different mutants
have different dose responses to DGJ and galactose; and d) tight binding to the active site
make for effective chaperoning of mutant α-GAL. Both wild type and mutant α-GAL
enzymes are capable of pharmacological chaperoning by DGJ. Using the existing
experimental results on the response of α-GAL mutants to DGJ, we developed a list of
rules to predict the DGJ response of all known Fabry disease mutants. Our research
shows that a large number of mutant α-GAL molecules are likely to respond to DGJ
treatment. The database will aid in the clinical management of patients with Fabry
disease.
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4.5. Methods
4.5.1. Determination of assessable surface area (ASA) of amino acid side chain
The ASA of each amino acid side chain in human α-galactosidase A (PDB code:
3HG5) was calculated using AREAIMOL from CCP4i program package.

4.5.2. Multiple sequence alignment and structural alignment
The α-GAL multiple sequence alignment (MSA) was made from a PSI-BLAST
(Altschul, Madden et al. 1997) query for sequences similar to human α-galactosidase A
(E < 0.005). ClustalW was used to align the sequences (Thompson 1994). Four αgalactosidase structures (1UAS, rice; 3A5V, Mortierella vinacea; 1T0O, Trichoderma
reesei; 1SZN, Hypocerea jecorina) deposited at the protein databank (RCSB Protein Data
Bank) were structurally aligned in PyMOL (DeLano 2008). The structural alignments
superimpose with RMS deviation between 0.7 – 1 Å.

4.5.3. Mutant protein expression and purification
The α-galactosidase A mutants were obtained from site directed mutagenesis of
wild type human α-galactosidase A gene (GLA) in pIB/V5-His-TOPO vector
®

(Invitrogen), pIB/V5-His-TOPO-α-GAL. α-GAL mutations were incorporated into the
pIB/V5-His-TOPO-α-GAL construct with PhusionTM site-directed mutagensis kit
(Finnzymes) according to the manufacturer’s specifications. Table 4.3 lists the primers
(synthesized by IDT Inc., Coralville IA) used to generate the mutations. Mutations were
confirmed by sequencing the isolated and purified DNA (Genewiz Inc., USA).
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Table 4.3 Table of primers of α-GAL mutants
1. E398K
2. M51I
3. L166V

F: 5’-[PO4]GGAAGCTAGGGTTCTATAAATGGACTTCAAGG-3’
R: 5’-[PO4]TTTTCACAGGGAGGAGCTGTGTGATGAAG-3’
F: 5’-[PO4]CTGGGAGCGCTTCATCTGCAACCTTG-3’
R: 5’-[PO4]TGCAGCCAGCCCATGGTAGGCGTC-3’
F: 5’-[PO4]CTGGGGAGTAGATGTGCTAAAATTTGATGG-3’
R: 5’-[PO4]TCAGCAAAGGTCTGGGCATCAATGTC-3’

* bold letters highlights the mutation
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Mutant DNA was transfected into Tn5 cells using Hilymax (Dojindo Labs)
transfection solution. Transfection was performed following the manufacturer’s
specifications. α-GAL mutant M51I and E398K expression and Ni–affinity tag
purification is as described at Chapter 3. E398K mutants were further purified using the
Source TM 15S column (GE Healthcare, Cat#: 17-0944-10). Ni fractions containing the
protein were pooled and buffer exchanged to 20 mM citrate buffer, pH 5.0. α-GAL
mutant protein was eluted with 20 mM citrate buffer, 1.0 M NaCl, pH 5.0 and was stored
at ~1.0 mg/mL.

4.5.4. α-GAL mutant activity assay and kinetics
The specific activity and kinetic parameters of α-GAL mutants were assayed by
monitoring the hydrolysis of para-nitrophenyl-α-galactopyranoside (pNP-α-gal; Sigma
Aldrich, St. Loius Mo, N0877) at 400 nm. All assays were carried out at 37°C. The
specific activity of purified α-GAL mutants E398K and M51I were initiated by the
addition of 0.05 mg/mL enzyme to 5 mM pNP-α-gal substrate in 100 mM
citrate/phosphate buffer pH 4.5. After incubation for 10 min, the reaction was quenched
by the addition of 250 µL of borate buffer, pH 9.8. Absorbance at 400 nm was measured
using a microplate reader at room temperature. All α-GAL samples were corrected by
subtracting the blank and the final absorbance readings were multiplied by the dilution
factor.
The kinetic parameters of the enzymatic reaction were determined by monitoring
the amount of product cleaved by the α-GAL mutant enzyme over time at varying
substrate concentrations. The reaction mixture containing 10 µL of α-GAL mutant (0.01
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mg/mL) and 140 µL of increasing concentration of substrate (0-50mM pNP-α-gal) was
incubated at 37°C. Aliquots were taken every minute for 10-15 minutes and quenched by
adding 10 µL of the reaction mixture to 290 µL of borate buffer, pH 9.8. The amount of
para-nitrophenolate cleaved at each substrate concentration was plotted against time
yielding initial velocities (V0) for each substrate concentration. Vmax and Km values were
calculated as described in Equation 3.1.

4.5.5. Tm measurement (CD) of α-GAL mutants
CD wavelength scan and thermal melts were carried out on a Jasco J715
spectropolarimeter equipped with a PTC-348WI temperature controller. The CD signal at
222 nm of each α-GAL mutant (1.2 µM in 10 mM phospate buffer pH 6.5) was
monitored at a temperature speed of 1°C/min from 25-90°C as previously described in
Chapter 3.

4.5.6. Western blot analysis of α-GAL mutant expression in vivo
Tn5 insect stable cell line transfected with pIB/V5-His-TOPO-α-GAL-L166V
mutant DNA were selected in 100 µg/mL blastocidin. After two weeks of selection, the
cells are grown in fresh SFx media or SFx media with DGJ (10 µM and 100 µM; Toronto
Research Chemicals Inc., D236500), galactose (10 mM and 100 mM; Sigma Aldrich, ST.
Louis MO; G5388), D-glucose (100 mM; Fisher Scientific, Rochester, NY; 50-99-7), Lproline (100 mM; Sigma Aldrich, ST. Louis MO; P0380), DMSO (10%; Sigma Aldrich,
ST. Louis MO), ficoll (5 mg/mL; Sigma Aldrich, ST. Louis MO; F9378) or dextran
(5mg/mL; Fluka; 313-90). Secreted mutant protein was separated on 10% SDS
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polyacrylamide gels by mixing supernatant samples with 6x SDS loading buffer with βmercaptoethanol and boiling for 10 minutes. SDS samples were transferred to a
nitrocellulose membrane (Millipore). The membrane is incubated with a polyclonal rabbit
anti-His primary antibody (Genscipt) and detected with alkaline phosphatase labeled antirabbit secondary IgG (Rockland, 611-1502). α-GAL protein runs between 43 and 56 kDa.

4.5.7. In vivo activity analysis of α-GAL mutant expression
In parallel, activity of the supernatant with the different chaperones of the low
expressing L166V mutant was monitored using pNP-α-gal substrate and supernatant
incubated for 5-6 hours. The reaction was quenched by the addition of 250 µL of borate
buffer, pH 9.8 and the absorbance is detected at 400 nm. Relative activity was calculated
from the equation below:
Relative Activity = (A400nm sample – A400nm blank) x df x VT
ε x t x Vsample

(4.1)

where, df is the dilution factor, VT is the total assay volume in milliliters, ξ is the
milimolar extinction coefficient of p-nitrophenolate at 400 nm (18 mM-1cm-1), t is the
total time of the assay in minutes, and Vsample is the volume of enzyme
sample/supernatant in milliliters.
The chromogenic substrate 5-bromo-4-chloro-3-indoyl-D-α-galactosidase (X-αgal; LabScientific, Inc., 740-90-6) was used to detect small amounts of α-GAL activity
present in the supernatant using the activity dot blot assay set-up. A stock solution of Xα-gal dissolved in N,N-dimethyly formamide (DMF, Fisher Scientific, D131-1) solvent
was diluted in 40 mM sodium acetate. The supernatant containing the protein was passed
through the nitrocellulose through gravity flow. The nitrocellulose was then incubated
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with X-α-gal at 37°C overnight. In the X-α-gal assay, blue color indicates the presence of
α-GAL activity

4.5.8. Pulse proteolysis of α-GAL mutant
Pulse proteolysis with thermolysin was performed as previously described in
Chapter 3 (Park and Marqusee 2005). Thermolysin (0.13 mg/mL from Bacillus
thermoproteolyticus; Sigma T7902) in 20 mM Tris•HCl buffer (pH 8.3) containing 10
mM CaCl2, and 50 mM NaCl was used to digest α-GAL mutant (0.02-0.05 mg/mL) at
37°C. To monitor the stability of α-GAL mutants in the absence or presence of DGJ and
galactose at pH 6.5, 10-fold of the protein was first incubated with or without DGJ (or
galactose) in 10 mM phosphate buffer (pH 6.5) for 2-4 hours. The mutant-small molecule
solution was then diluted in 10 mM phosphate-8M urea solution to 1x concentration and
incubated at 20°C overnight. The digestion was initiated by the addition of approximately
0.13 mg/mL thermolysin to the 15 µL solution reaction. After 5 min, the reaction was
quenched by the addition of 50 mM EDTA (pH 8.0) to a final concentration of 12.5 mM.
After quenching, samples were mixed with 6x SDS loading buffer with βmercaptoethanol , boiled immediately for 10 min to avoid further digestion. Samples
were separated on a 10% SDS/PAGE gel and stained in GelCode Blue (Pierce 24592).
The amount of undigested protein in the presence of DGJ or galactose at pH 6.5 is a
measure of the effect to the proper conformation of the protein when the small molecule
binds to α-GAL. The data was processed as described in Chapter 3.
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Table 4.4 Fabry disease mutations

Wild type
protein
sequence

Fabry
disease
mut’n

Side
chain
accessible
surface
area (Å2)

Mut’n
category

1

M

I
T
R

Other

14
16
19
20

L
L
L
A

P
P
P
(P)

Other
Other
Other
Other

31
32
34

A
L
N

V
P
S

5.7
1.5

Other
Other
Buried

35

G

R

8.3

Exposed

40

P

S
L

0.0

Buried

I
V
T

0.6
0.8

41
42

43

T
M

Response to DGJ:
Responsive (Res) versus Nonresponsive (NR)
Prediction
Expt’l
High
Low
data*
confidence confidence

Buried
Buried

L
G
D
0.0
Buried
*Table 4.4 is continued onto the next page

Reason

Res
Res

exposed

Res

Pro  X in a loop

Res

Res
Res
Res
Res
NR

108

Small SC
Conserved mutation
Gly  X

Reference
(Blanch, Meaney et al. 1996)
(Eng, Ashley et al. 1997)
(Shabbeer, Yasuda et al.
2002)
(Tse, Chan et al. 2003)
(Garzuly, Marodi et al. 2005)
(Teragaki 2004)
(Nakao, Takenaka et al.
1995)
(Eng, Ashley et al. 1997)
(Madsen, Hasholt et al. 1995)
(Eng, Resnick-Silverman et
al. 1993)
(Davies, Christomanou et al.
1994)
(Koide, Ishiura et al. 1990)
(Ashton-Prolla, Tong et al.
2000)
(Benjamin 2009)
(Davies, Eng et al. 1996)
(Shabbeer, Yasuda et al.
2002)
(Rosenthal, Lien et al. 2004)
(Iga 2001)

R

NR

Gly  X

V

Res

Gly  V/A

NR
NR
NR

Active site (AS)
Active site (AS)
Contact with AS residues

Res
Res

exposed
X  Pro/exposed and loop

Res

X  Gly, exposed

NR
NR

Disulfide bond
Disulfide bond

NR

Disulfide bond

NR
NR

Disulfide bond
Disulfide bond

44

W

X

0.0

Other

46

H

0.0

Buried

47

W

2.6

Active

48
49

E
R

R
Y
L
G
K
L

0.0
2.0

Other
Exposed

S
P
C
G

NR
NR

Res

Res

50

F

C

0.7

Buried

NR

51

M

K

10.1

Active

Res

I

Res

52

C

S
R
X

12.0

Other

55
56

D
C

V
G

15.2
13.2

Exposed
Exposed

F
Y
*Table 4.4 is continued onto the next page

Res
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(Germain, Shabbeer et al.
2002)
(Shabbeer, Yasuda et al.
2002)
(Sakuraba, Oshima et al.
1990)
(Eng, Ashley et al. 1997)
(Blaydon, Hill et al. 2001)
(Cooper 2000)
(Blaydon, Hill et al. 2001)
(Rodriquez-Mari 2003)
(Davies, Christomanou et al.
1994)
(Davies, Eng et al. 1996)
(Blaydon, Hill et al. 2001)
(Benjamin 2009)
(Germain, Shabbeer et al.
2002)
(Shabbeer, Yasuda et al.
2002)
(Ashley, Shabbeer et al.
2001)
(Spada, Pagliardini et al.
2006)
(Eng, Niehaus et al. 1994)
(Blanch, Meaney et al. 1996)
(Topaloglu, Ashley et al.
1999)
(Benjamin 2009)
(Eng, Resnick-Silverman et
al. 1993)
(Eng, Niehaus et al. 1994)
(Davies, Eng et al. 1996)

X
59
63
65

E
C
S

K
Y
T

7.6
0.7
3.5

Other
Other
Exposed

Res

66

E

Q

3.3

Exposed

Res/
NR

NR
Res

K
G

68

L

Double
mut’n
R112C
F

72

M

V

Disulfide bond
Conserved mutation,
exposed

(Ishii, Sakuraba et al. 1992)
Res
Res

Conserved mutation
X  Gly

(Schafer, Baron et al. 2005)
(Spada, Pagliardini et al.
2006)
(Shimatori 2007)

Res

Conserved mutation

(Shabbeer, Yasuda et al.
2002)
(Okumiya, Kawamura et al.
1998)
(Slee, van Boven et al. 2000)
(Germain, Shabbeer et al.
2002)
(Spada, Pagliardini et al.
2006)
(Shimatori 2007)
(Guffon, Froissart et al.
1998)
(Takata, Okumiya et al.
1997)
(Eng, Smith et al. 1994)
(Rodriquez-Mari 2003)
(Madsen, Hasholt et al. 1995)
(Eng, Ashley et al. 1997)

NR
0.2

Buried

0.0

Buried

R
I

Res
NR

Near R301, clash
Conserved mutation

Res

WS
Gly  X
Conserved mutation,
WC

Res

73

A

V

0.0

Buried

Res

76
78

M
S

T
X

Buried
Other

Res

21.7

79

E

X

13.2

Other

81

W

0.1

85
86

G
Y

X
S
D
C

Other
Buried
Exposed
Other

7.3
0.0

(Shabbeer, Robinson et al.
2005)
(Eng, Niehaus et al. 1994)
(Schafer, Baron et al. 2005)
(Chen 1998)

NR
Res

X
*Table 4.4 is continued onto the next page

(Lee, Kim et al. 2000)
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88
89

Y
L

91
92

I
D

93

D

94

C

95

W

97

A

99
100

Q
R

103

E

107
112

Q
R

113

F

118

R

D
R
P
(T)
H
Y
N

3.8
0.0

Exposed
Buried

0.0
0.0

Buried
Active

G
N

0.0

Active

0.0

Other

V
Y
S
S

Partially exposed

NR

X  Pro

NR

Active site

NR
NR

Active site
Active site

NR

Disulfide bond

Res
NR
NR

NR

0.0

Buried

4.7

Other
Exposed

X
K
T
Q

27.0
2.5

Other
Other

18.9

Exposed

X
C
(H)
S

12.9
2.2

Other
p. Exposed

(L)
S
C

0.0

Buried

13.3

Exposed

X
V
P

Res/ NR
NR

NR
Res

WS

Res
Res

Conserved mutation
X  Pro/ exposed and
loop

Res
NR
Res

Conserved mutations,
exposed

Res
Res
Res
Res
Res

*Table 4.4 is continued onto the next page

111

Conserved mutations

(Cooper 2000)
R(Eng, Niehaus et al. 1994)
(Eng, Ashley et al. 1997)
(Eng, Ashley et al. 1997)
(Davies, Eng et al. 1996)
(Eng, Ashley et al. 1997)
(Ashley, Shabbeer et al.
2001)
(Davies, Eng et al. 1996)
(Shabbeer, Robinson et al.
2005)
(Shimatori 2007)
(Eng, Ashley et al. 1997)
(Blaydon, Hill et al. 2001)
(Ashton-Prolla, Tong et al.
2000)
(Rodriquez-Mari 2003)
(Eng, Ashley et al. 1997)
(Kimura 2002)
(Eng, Niehaus et al. 1994)
(Eng, Niehaus et al. 1994)
(Eng, Ashley et al. 1997)
(Schafer, Baron et al. 2005)
(Davies, Eng et al. 1996)
(Ishii, Sakuraba et al. 1992)
(Eng, Smith et al. 1994)
(Shabbeer, Robinson et al.
2005)
(Eng, Ashley et al. 1997)
(Blaydon, Hill et al. 2001)
(Spada, Pagliardini et al.
2006)

119
120
121
128
129

Q
L
A
G
L

X
P
P
E
P

17.6
0.5
0.1
8.2
0.0

Other
Buried
Buried
Exposed
Buried

131
132

L
G

P
R

0.0
0.0

Buried
Buried

134

Y

S
X

0.0

135

A

V

136

D

138

G

141

T

142

C

NR
NR

Double mutation A121T
X  Pro

NR

X  Pro

Active

NR

Active site (AS)

0.1

Buried

Res

Conserved mutations

H

0.0

Buried

R
E
I

0.0

Buried

0.0

Active

Y
R

3.9

Active

NR

NR
NR

NR

Interact with AS

NR

Gly  X

NR

Active site (AS)

NR

Active site (AS)

NR

Active site (AS)

NR

Gly  X, near AS

NR

NR

X

143

A

144
146
147
148

G
P
G
S

W
P
T
V
(S)
R
R
N

5.2

Exposed

7.9
3.0
1.3
0.0

Other
Other
Buried
Buried

NR
Res
Res
Res
NR
Res

*Table 4.4 is continued onto the next page
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(Davies, Eng et al. 1996)
(Benjamin 2009)
(Lorenz, Hauser et al. 2003)
(Blanch, Meaney et al. 1996)
(Whybra, Kampmann et al.
2001)
(Eng, Smith et al. 1994)
(Shabbeer, Yasuda et al.
2002)
(Eng, Ashley et al. 1997)
(Ashton-Prolla, Tong et al.
2000)
(Shabbeer, Robinson et al.
2005)
(Ashley, Shabbeer et al.
2001)
(Eng, Ashley et al. 1997)
(Germain 2002)
(Shabbeer, Yasuda et al.
2002)
(Okumiya, Ishii et al. 1995)
(Topaloglu, Ashley et al.
1999)
(Topaloglu, Ashley et al.
1999)
(Schafer, Baron et al. 2005)
(Eng, Smith et al. 1994)
(Eng, Ashley et al. 1997)
(Eng, Smith et al. 1994)
(Ploos van Amstel 1994)
(Schafer, Baron et al. 2005)
(Eng, Ashley et al. 1997)
(Ashton-Prolla, Tong et al.
2000)

151

Y

X

10.8

Other

152

Y

X

1.7

Other

155

D

H

0.0

Buried

156

A

T
V
X
R

0.0

Buried

157
162

Q
W

15.0
4.2

Exposed
p. Exposed

G
D

X
V
V

1.0
2.1

Other
p. Exposed

166
167

L
L

V
P

1.0
0.1

Buried
Buried

168

K

R

1.9

Active

169
170

F
D

0.0
0.0

Buried
Active

Res ??

171

G

S
V
H
D

0.0

Buried

NR

Same size as Val

11.7

Active

F

Res

Partially exposed

Res
Res/NR

Gly  Val
Partially exposed

Res
NR

X  Pro, contact with AS

NR

Active site
Res

R
Y
R

Res

NR

163
165

C

Clash with HB

Res

C

172

NR

FS

NR

Active site (AS)

NR

Gly  X

NR

Active site (AS)

NR

Active site (AS)

Res??

*Table 4.4 is continued onto the next page
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(Shabbeer, Robinson et al.
2005)
(Shabbeer, Yasuda et al.
2002)
(Dobrovolny, Dvorakova et
al. 2005)
(Eng, Smith et al. 1994)
(Okumiya, Ishii et al. 1995)
(Eng, Smith et al. 1994)
(Eng, Resnick-Silverman et
al. 1993)
(Germain, Biasotto et al.
1996)
(Rosenberg 2000)
(Eng, Ashley et al. 1997)
(Davies, Christomanou et al.
1994)
(Okumiya, Ishii et al. 1995)
(Morrone, Cavicchi et al.
2003)
(Shabbeer, Yasuda et al.
2002)
(Cooper 2000)
(Eng, Ashley et al. 1997)
(Rodriquez-Mari 2003)
(Shabbeer, Robinson et al.
2005)
(Dobrovolny, Dvorakova et
al. 2005)
(Eng, Smith et al. 1994)
(Ashton-Prolla, Tong et al.
2000)
(Ashley, Shabbeer et al.
2001)

G

NR

177

L

W
X

12.0

Other

183

G

D

0.3

Buried

S

NR

Active site (AS)

Conserved mutations

Res
NR

187

M

V

0.0

Buried

Res

191

L

P
Q

1.3

Buried

NR

194
199

T
V

I
M

0.4
0.3

Buried
Buried

Res

X  Pro
No space for side chain
(SC)
Accommodate SC
Conserved mutations

201

S

F

2.4

p. Exposed

NR

Interact with AS

202

C

0.0

Other

NR

Disulfide bond

204

W

W
Y
X

0.1

Other

205

P

T
R

0.0

Buried

Res

Pro  X

Y

L
S

215

N

C
(S)

216

Y

D

207

NR
Res

NR

5.5

Res
Res

Active

Res

12.0

Exposed

Res
Res

1.1

Buried

Res

*Table 4.4 is continued onto the next page
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Accommodate SC,
partially exposed,

(Yasuda, Shabbeer et al.
2003)
(Schafer, Baron et al. 2005)
(Shabbeer, Robinson et al.
2005)
(Topaloglu, Ashley et al.
1999)
(Shabbeer, Yasuda et al.
2002)
(Ashton-Prolla, Tong et al.
2000)
(Cooper 2000)
(Ashley, Shabbeer et al.
2001)
(Schafer, Baron et al. 2005)
(Shabbeer, Yasuda et al.
2002)
(Shabbeer, Robinson et al.
2005)
(Ploos van Amstel 1994)
(Eng, Ashley et al. 1997)
(Ashton-Prolla, Tong et al.
2000)
(Blanch, Meaney et al. 1996)
(Shabbeer, Yasuda et al.
2002)
(Schafer, Baron et al. 2005)
(Shabbeer, Yasuda et al.
2002)
(Benjamin 2009)
(Davies, Winchester et al.
1993)
(Eng, Ashley et al. 1997)

220
221

R
Q

X
X

7.0
17.1

Other
Other

222
223

Y
C

X
G
R

4.7
0.0

Other
Other

Y
224

N

D

0.0

H
W

R
X

R

C
Q

NR

Disulfide bond
Res

Accommodate SC,
maintain H bonding
Conserved mutation

Res

WC

Res
0.0
0.0

Other
Other

NR

Buried

NR

0.2

Active

NR

R

227

Disulfide bond
Disulfide bond

Other

S
225
226

NR
NR

X
230

A

T

45.4

Active

231

D

N

9.2

Active

234

D

Y

0.1

Other

NR
NR
NR

E
235

S

C

Res
2.7

p. Exposed

Active site (AS)

Res

F
Res
*Table 4.4 is continued onto the next page
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Clash to other residues
Conserved mutation

(Meaney, Blanch et al. 1994)
(Shabbeer, Yasuda et al.
2002)
(Yang, Lai et al. 2003)
(Germain and Poenaru 1999)
(Shabbeer, Yasuda et al.
2002)
(Shabbeer, Yasuda et al.
2002)
(Guffon, Froissart et al.
1998)
(Ashton-Prolla, Tong et al.
2000)
(Politei, Pagano et al. 2005)
(Davies, Christomanou et al.
1994)
(Ashton-Prolla, Tong et al.
2000)
(Rodriquez-Mari 2003)
(Eng, Resnick-Silverman et
al. 1993)
(Davies, Winchester et al.
1993)
(Ashton-Prolla, Tong et al.
2000)
(Redonnet-Vernhet, Ploos
van Amstel et al. 1996)
(Shabbeer, Yasuda et al.
2002)
(Shabbeer, Robinson et al.
2005)
(Topaloglu, Ashley et al.
1999)
(Shimatori 2007)

236

W

C
L

1.6

Other

Res

WC
Conserved mutation

NR

buried

Res

X

239

I

R
T

0.0

Buried

NR

242

I

N

0.3

Buried

NR

Near AS

243

L

F

0.0

Buried

Res

Conserved mutation

244

D

N
H

12.4

Exposed

Res
Res/ NR

245

W

X

3.6

Other

247

S

P

2.8

p. Exposed

C
250

Q

X

27.3

Other

257
258

A
G

0.0
1.5

Buried
Buried

259

P

P
R
V
L

10.5

Exposed

G
G
W

A
D
C

NR

X  Pro

Res

Conserved mutation

NR
NR

X  Pro
Gly  X

Res

Pro  X

Res

R
260
261
262

Exposed but could clash
with domain 2 HB

Res
0.0
0.0
0.0

Buried
Buried
Buried

Res
NR
Res/NR

*Table 4.4 is continued onto the next page
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W  C but packs against
P259

(Davies, Eng et al. 1996)
(Topaloglu, Ashley et al.
1999)
(Germain, Shabbeer et al.
2002)
(Benjamin 2009)
(Kotanko, Kramar et al.
2004)
(Takata, Okumiya et al.
1997)
(Germain, Shabbeer et al.
2002)
(Eng, Smith et al. 1994)
(Topaloglu, Ashley et al.
1999)
(Germain, Shabbeer et al.
2002)
(Ashley, Shabbeer et al.
2001)
(Germain, Shabbeer et al.
2002)
(Ashley, Shabbeer et al.
2001)
(Cooper 2000)
(Blaydon, Hill et al. 2001)
(Shimatori 2007)
(Topaloglu, Ashley et al.
1999)
(Ashley, Shabbeer et al.
2001)
(Okumiya, Ishii et al. 1995)
(Shin 2008)
(Schafer, Baron et al. 2005)

263
264

N
D

S
V

1.3
2.2

Buried
Active

Y

Res
NR
NR

265

P

R

1.8

Buried

266

D

L
V

0.8

Active

Active site (AS)

N
E

NR
NR

Active site (AS)
Active site (AS)
Active site (AS)

0.3

Active

NR

268
269

L
V

S
A

0.0
0.0

Buried
Buried

Res

270
271

I
G

T
C

0.0
3.3

Buried
p. Exposed

272
276

N
S

V
K
N
G

0.0
0.9

Other
Other

X

6.6

Q

280

Pro  X but near AS

NR

I

279

Res/NR

H

M

W

Pro  X but near AS

NR

267

277

Res/NR

Res

Accommodate SC
Conserved mutation

Res

Accommodate SC

NR
NR
NR
Res

Conserved mutation

Res
Other

(E)
0.2
Other
Res
H
R
Q
H
5.0
Exposed
*Table 4.4 is continued onto the next page

Res
NR
Res
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Stacks against W232
Clash with W232
Exposed

(Benjamin 2009)
(Eng, Resnick-Silverman et
al. 1993)
(Shabbeer, Robinson et al.
2005)
(Germain, Biasotto et al.
1996)
(Schafer, Baron et al. 2005)
(Eng, Resnick-Silverman et
al. 1993)
(Ashton-Prolla, Tong et al.
2000)
(Lee, Kim et al. 2000)
(Germain, Shabbeer et al.
2002)
(Topaloglu, Ashley et al.
1999)
(Schafer, Baron et al. 2005)
(Davies, Winchester et al.
1993)
(Schafer, Baron et al. 2005)
(Shabbeer, Yasuda et al.
2002)
(Benjamin 2009)
(Eng, Niehaus et al. 1994)
(Schafer, Baron et al. 2005)
(Shabbeer, Robinson et al.
2005)
(Topaloglu, Ashley et al.
1999)
(Ishii, Sakuraba et al. 1992)
(Blaydon, Hill et al. 2001)
(Rodriquez-Mari 2003)
(Blaydon, Hill et al. 2001)

K
282

T

N

0.0

Other

284
285

M
A

A
T
P

0.3
0.0

Buried
Buried

287

W

X

0.0

Other

A

D

0.9

NR

Accommodate SC
X  Pro

Res

X  Gly

Buried

NR

Clash with other AA at
hydrophobic core

Res

I

F

0.0

Buried

293

P

S
A

0.0

Buried

294
295
296

L
F
M

X
C
(V)
(I)

0.4
0.0

Other
Buried
Buried

297

S

F

0.0

Buried

C
K

Conserved mutation

Res/
NR

289

N

Res

Res

Buried

P

298

Exposed

Res

G
C
288

Res

Res
Pro  X
Pro  X

Res
Res

Res
Res
Res
NR
Res

0.0

Buried

Conserved mutation
NR

*Table 4.4 is continued onto the next page
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No room for F

Clash with other residues
at the hydrophobic core

(Dobrovolny, Dvorakova et
al. 2005)
(Ashley, Shabbeer et al.
2001)
(Shimatori 2007)
(Blanch, Meaney et al. 1996)
(Shabbeer, Robinson et al.
2005)
(Davies, Winchester et al.
1993)
(Davies, Eng et al. 1996)
(Ashton-Prolla, Tong et al.
2000)
(Eng, Smith et al. 1994)
(Shabbeer, Yasuda et al.
2002)
(Topaloglu, Ashley et al.
1999)
(Cooper 2000)
(Shabbeer, Yasuda et al.
2002)
(Blaydon, Hill et al. 2001)
(Shin 2008)
(von Scheidt W. 1991)
(Nakao, Takenaka et al.
1995)
(Eng, Resnick-Silverman et
al. 1993)
(Germain, Shabbeer et al.
2002)
(Blanch, Meaney et al. 1996)

H

300

301

L

R

S
H
F
P
(Q)

NR

0.0

4.1

Buried

p. Exposed

I

G
N

308
310
312
313

K
L
Q
D

N
F
R
Y

316
317

V
I

320

N

X  Pro at loop

Res
1.7

Buried

Res
Res

7.3

Exposed
Buried
Exposed
p. Buried

E
T

0.1
2.4

Buried
Buried

Res

N
K

0.2

Other

0.2

Y
I
E

Res

Res
Res

X
P

303

Res
Res
Res

Clash with other residues
at the hydrophobic core
Conserved mutation
Conserved mutation
Conserved mutation

Res

X  Gly
Accommodate SC, loop

Conserved mutation

Res
NR

Res
Res
Res/ NR

Accommodate SC
Accommodate SC
Accommodate SC but
clash with other SC

Res
Res

321

Q

7.0

Other

325

X
G
D
0.4
Buried
Res
*Table 4.4 is continued onto the next page

Res
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Accommodate SC
Conserved mutation

(Davies, Eng et al. 1996)
(Eng, Ashley et al. 1997)
(Schafer, Baron et al. 2005)
(Shabbeer, Robinson et al.
2005)
(Benjamin 2009)
(Sakuraba, Oshima et al.
1990)
(Eng, Smith et al. 1994)
(Ashley, Shabbeer et al.
2001)
G(Lai 2001)
(Shabbeer, Yasuda et al.
2002)
(Shimatori 2007)
(Calado 2004)
(Shimatori 2007)
(Eng, Resnick-Silverman et
al. 1993)
(Schafer, Baron et al. 2005)
(Shabbeer, Yasuda et al.
2002)
(Schafer, Baron et al. 2005)
(Okumiya, Ishii et al. 1995)
(Ashton-Prolla, Tong et al.
2000)
(Schafer, Baron et al. 2005)
(Topaloglu, Ashley et al.
1999)
(Schafer, Baron et al. 2005)
(Schafer, Baron et al. 2005)

327

Q

K

0.3

Other

328

G

E
R
A

0.2

Buried

Res/ NR

Q

X

3.8

Other

333
338

Q
E

X
K

18.2
1.0

Other
Other

0.1

Other

Res

Gly  V

NR
Res

V
330

Res

Accommodate SC but
loses HB with N363
Conserved mutation

NR

Breaks HB network,
domain interface

Buried

NR

Other

Res
Res

Clash with hydrophobic
core, domain interface
C terminal domain,
accommodate mutation
Conserved mutation

X  Pro
X  Pro, exposed

X
340

W

X
R

341

E

K

0.1

D
342

R

X

0.0

Other

344
345
349

L
S
W

Q
P
P
X

1.3
16.5
2.2

Buried
Exposed
Other

NR
Res

350
352

A
A

P
D

0.0
0.0

Buried
Buried

NR

Res

NR

*Table 4.4 is continued onto the next page
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X  Pro
Domain interface, no space

(Davies, Winchester et al.
1993)
(Schafer, Baron et al. 2005)
(Ishii, Sakuraba et al. 1992)
(Eng, Resnick-Silverman et
al. 1993)
(Shabbeer, Robinson et al.
2005)
(Dobrovolny, Dvorakova et
al. 2005)
(Lorenz, Hauser et al. 2003)
(Shabbeer, Robinson et al.
2005)
(Shabbeer, Robinson et al.
2005)
(Eng, Resnick-Silverman et
al. 1993)
(Davies, Eng et al. 1996)
(Beyer, Karpova et al. 1999)
(Shabbeer, Yasuda et al.
2002)
(Davies, Winchester et al.
1993)
(Ploos van Amstel 1994)
(Schafer, Baron et al. 2005)
(Schafer, Baron et al. 2005)
(Ashley, Shabbeer et al.
2001)
(Schafer, Baron et al. 2005)
(Morrone, Cavicchi et al.
2003)

355

N

K

0.1

Other

356

R

W

5.0

p. Exposed

357
358

Q
E

X
K
G

8.3
4.6

Other
Exposed

Res

Near loop, accommodate
SC

Res/
NR
Res
Res

X  Gly

360

G

A
S

0.4

Other

Res
Res

Gly  X, loop, exposed

361

G

R

3.7

Exposed

Res

Gly  X, exposed

362

P

L

12.1

Exposed

Res

Pro  X

363

R

H
C

5.3

Exposed

365

Y

X

3.9

Other

373

G

0.0

Buried

377
378

A
C

S
D
D
Y

0.1
0.0

Buried
Other

382

C

0.0

Other

384

I

W
Y
N

0.0

Buried

385

T

P

6.6

Exposed

386
396

Q
F

X
X

0.3
13.7

Other
Other

Res
Res

NR
NR
Res
NR
NR
NR
Res
Res

*Table 4.4 is continued onto the next page
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Accommodate SC, loop
Disulfide bond
Disulfide bond
Disulfide bond
Accommodate SC
X  Pro, exposed

(Germain, Shabbeer et al.
2002)
(Bernstein, Bishop et al.
1989)
(Miyazaki, Kajita et al. 1998)
(Miyazaki, Kajita et al. 1998)
(Germain, Shabbeer et al.
2002)
(Shabbeer 2006)
(Dobrovolny, Dvorakova et
al. 2005)
(Germain, Shabbeer et al.
2002)
(Shabbeer, Yasuda et al.
2002)
(Cooper 2000)
(Shabbeer, Yasuda et al.
2002)
(Miyamura, Araki et al.
1996)
(Okumiya, Ishii et al. 1995)
(Germain 2001)
(Blaydon, Hill et al. 2001)
(Topaloglu, Ashley et al.
1999)
(Galanos 2002)
(Rodriquez-Mari 2003)
(Shabbeer, Yasuda et al.
2002)
(Shabbeer, Yasuda et al.
2002)
(Eng, Ashley et al. 1997)
(Shabbeer, Yasuda et al.
2002)

398

E

X

21.5

K
399
401

W
S

X
X

403
407
409

L
I
P

S
K
T
A
S

410

Other
Exposed

10.5
10.3

Other
Other

0.1
0.0

Buried
Buried
Buried

Res

Exposed

Res
Res

NR

Clash onto β sheet
Pro  X

Res

Pro  X

Res

T

K

0.0

Buried

411

G

(A)
P
D

0.1

Buried

414
415

L
L

S
P

0.0
0.0

Buried
Buried

NR

Buried

Res

Clash onto domain 1 α
helix
Accommodate SC

NR
Gly  X

NR
Res

Accommodate SC

NR

* References of the Experimental data: Benjamins (2009); Shin (2008); Shimotori (2007); Ishii (2007); Shin (2007); Spada (2006
p. Exposed = partially exposed
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(Eng, Resnick-Silverman et
al. 1993)
(Shabbeer, Yasuda et al.
2002)
(Eng, Ashley et al. 1997)
(Shabbeer, Yasuda et al.
2002)
(Shimatori 2007)
(Rodriquez-Mari 2003)
(Blaydon, Hill et al. 2001)
A(Blaydon, Hill et al. 2001)
(Germain, Shabbeer et al.
2002)
(Ashley, Shabbeer et al.
2001)
(Yang, Lai et al. 2003)
(Shimatori 2007)
(Guffon, Froissart et al.
1998)
(Rodriquez-Mari 2003)
(Serebrinsky, Pascucelli et al.
2006)

CHAPTER 5

INTERCONVERSION OF LIGAND SPECIFICITY OF α-GALACTOSIDASE A
This chapter is part of a paper in preparation written in collaboration with Ivan Tomasic
and Scott C Garman. (Tomasic, I., Metcalf, M., Guce, A. I., Clark, N., Garman, S.G.,
2010)
5.1. Introduction
Human α-GAL and α-NAGAL are two closely related lysosomal enzymes first
thought to be isozymes of α-GAL because α-NAGAL is able to cleave α-glycosylated
substrates (Crawhall and Banfalvi 1972; Remeo, D'Urso et al. 1975; Bishop, Dean et al.
1980; Desnick 2001). Differences in electrophoretic migration and isoelectric focusing
led to the separation of the two enzymes (Bishop, Dean et al. 1980). Both enzymes form
a N-terminal (β/α)8 barrel and a C-terminal β sandwich fold (Garman, Hannick et al.
2002; Garman and Garboczi 2004). The two enzymes show 46% amino acid sequence
identity, and structurally are very similar, with a RMS deviation of 1.5 Å (for 660 αC)
when the dimmers are superimposed. Both enzymes also belong to the family 27 and clan
D of glycoside hydrolases (Vocadlo and Davies 2008). Although it has been shown that
both enzymes have similar structural features, they have completely different
immunogenic properties, where polyclonal antibodies raised against each enzyme do not
cross-react (Beutler and Kuhl 1972; Schram, Hamers et al. 1977).
The purified enzymes show differences in substrate specificity. α-GAL cleaves
terminal α-linked galactosides while α-NAGAL hydrolyzes the cleavage of terminal α-N-
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acetylgalactosaminides (α-GalNAc, see Figure 5.1) (Garman, Hannick et al. 2002;
Garman and Garboczi 2004; Clark and Garman 2009). The difference in the specificity of
the two enzymes is derives from amino acid differences in the active site. Thirteen out of
the 15 residues at the catalytic center are highly conserved between the homologues
enzyme, but two are not (Figure 5.2). Therefore substrate specificity between the two
enzymes appears to be solely dictated by the two non-conserved amino acids found at the
“recognition loop”. Both α-GAL and α-NAGAL select and bind substrate using the same
H-bonding and hydrophobic contacts as described in Chapter 1.3.1 but distinguish αgalactose and α-GalNAc using the two residues at the recognition loop. α-GAL
recognizes a smaller hydroxyl group at the C2 position of the sugar ring using E203 and
L206 at the recognition loop. However, α-NAGAL uses smaller side chains, S188 and
A191, to distinguish a larger N-acetyl group moiety at the same position (Garman,
Hannick et al. 2002; Garman and Garboczi 2004). Since α-NAGAL utilizes smaller
amino acid residues at the recognition loop, this enzyme does not exclusively bind αGalNAc, but can bind α-galactose as well. α-NAGAL has α-GAL activity, with the
ability to bind and cleave terminal α-galactose; however the reverse is not observed
(Schram, Hamers et al. 1977). α-GAL cannot accommodate the bigger α-GalNAc in the
active site therefore no α-NAGAL activity is detectable in α-GAL. In the lysosome, a
small part of α-GAL activity can be attributed to α-NAGAL (Beutler and Kuhl 1972).
However in Fabry disease patients where α-GAL enzyme is deficient, the α-GAL activity
contained within α-NAGAL is not sufficient to prevent disease development.
Although the ligand specificity of α-GAL and α-NAGAL has been established by
the crystal structures of the enzymes, the conversion of the specificity of α-GAL to α-
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a.

b.

Figure 5.1 Catalytic reaction of α-GAL and α-NAGAL
The reaction catalyzed by α-GAL (a) and α-NAGAL (b). α-GAL hydrolyzes the α1-R
linkage of a substrate containing a terminal α-galactose and α-NAGAL hydrolyzes the
α1-R linkage of a substrate containing a terminal α-N-acetylgalactosamine. For both
enzymes, the substrate and the product are α anomers.
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L206,
A191
E203,
S188

Figure 5.2 Superimposition of the active sites of α-GAL and α-NAGAL
α-GAL and α-NAGAL are two homologous lysosomal enzymes that have a similar fold.
A close up of the active site of α-GAL (green) and α-NAGAL (blue) with galactose
bound superimposed to each other with an rmsd of 0.25 Å for the 15 active site residues.
13 out of the 15 residues are conserved except two residues at the “recognition loop”
that discriminates a hydroxyl or N-acetyl at the C2 position. The two residues that are
not conserved are E203, S206 (α-GAL) that recognizes a hydroxyl group (OH) at C2 of
a galactose and S188, A191 (α-NAGAL) that allows the binding of a bulkier N-acetyl
group at the C2 position of the GalNAc.
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NAGAL has never been shown. Based upon the crystal structures of each enzyme, we
predicted that mutagenesis of two residues would be enough to convert the α-GAL
enzyme into an α-NAGAL enzyme. We used rational design approaches to interconvert
the specificity of α-GAL and α-NAGAL.
The therapeutic relevance of an engineered enzyme with a wild type backbone
(such as α-GAL and α-NAGAL) but with an altered enzyme activity could be useful for
an alternative enzyme for enzyme replacement therapy. Clinical studies have shown that
large percentage of the patients receiving recombinant enzyme as a therapy develop
immune response and neutralize the injected foreign enzyme. This poses a problem
because now patients need a higher dose of enzyme as well as additional medication for
the immune response. By engineering the active site of the protein that is not foreign to
the patients enable us to circumvent this problem. In particular, comprehension of the
nature of ligand specificity of α-GAL and α-NAGAL could open doors for clinical
applications for lysosomal storage diseases, particularly Fabry disease and Schindler
disease, caused by deficiency of α-GAL and α-NAGAL respectively.

5.2. Experimental Strategy
In this study, we examine the role of the recognition loop to the substrate
specificity, enzyme activity, function and structure of the α-GAL enyzme. Here, the
active site of human α-galactosidase A was engineered to resemble the α-NAGAL active
site. Specific activity and kinetic parameters of the engineered α-GAL were interrogated
to assess the switch in activity of α-GAL. We provide evidence of the conversion of αGAL activity and specificity into that of α-NAGAL. We call the engineered α-GAL
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enzyme with α-NAGAL activity “α-GALSA”, indicating the two amino acids introduced
into the human α-GAL sequence. We changed E203 and L206 in the recognition loop at
the active site of α-GAL enzyme to serine and alanine, to mimic α-NAGAL recognition
loop. To compare and confirm the role of the recognition loop residues in distinguishing
substrate, our laboratory has also engineered α-NAGAL active site to resemble the αGAL active site. Similarly, specific activity and kinetic parameters of the engineered αNAGAL were also determined to confirm the switch in activity of α-NAGAL. We call
the engineered α-NAGAL enzyme with α-AGL activity “α-NAGALEL”, indicating S188
and A191 in the recognition loop at the active site of α-NAGAL enzyme to glutamic acid
and leucine. Furthermore, we have determined the crystal structures of α-GALSA with αgalactose and α-N-acetylgalacosamine bound at the active site, revealing the molecular
basis for ligand specificity and activity of α-GAL and other enzymes in family 27.

5.3. Results
5.3.1. α-NAGAL activity of α-GAL enzyme
The inherent activity of α-GAL towards its synthetic substrate (pNP-α-galactose)
and the α-NAGAL synthetic substrate (pNP-α-GalNAc) was measured to establish the
baseline of the activity and specificity of the enzyme. In comparison, the activity of αGALSA was also measured using pNP-α-galactose and pNP-α-GalNAc substrate. Wild
type α-GAL shows activity towards pNP-α-gal substrate (as expected) and very little
cleavage is detected of the pNP-α-GalNAc substrate. Wild type α-GAL shows a strong
preference for pNP-α-gal only. Engineered α-GALSA, on the other hand, binds both
substrates, and shows activity towards both substrates as well. Although α-GALSA is not
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Table 5.1 Specific activity and kinetic parameters of wild type enzymes and α-GALSA
and α-NAGALEL
Enzyme

Substrate

wt α-GAL
wt α-GAL
α-GALSA
α-GALSA
wt α-NAGAL
wt α-NAGAL
α-NAGALEL
α-NAGALEL

pNP-α-Gal
pNP-α-GalNAc
pNP-α-Gal
pNP-α-GalNAc
pNP-α-Gal
pNP-α-GalNAc
pNP-α-Gal
pNP-α-GalNAc

ND = not detected

Spe. Act.
(U/mg)

Km
(mM)

kcat
(s-1)

kcat/Km
(s-1/mM)

330.07 ± 0.02
ND
3.5 ± 0.0
145.4 ± 0.0
20.90 ± 0.03
287.04 ± 0.03

6.88 ± 0.07
ND
49 ± 7
21.0 ± 0.8
28 ± 5
0.68 ± 0.01
7.58 ± 0.07
ND

37.8 ± 0.2
ND
1.2 ± 0.1
21.5 ± 0.7
10.7 ± 0.9
15.09 ± 0.06
13.71 ± 0.08
ND

5.49 ± 0.03
ND
0.02 ± 0.00
1.02 ± 0.03
0.39 ± 0.03
22.34 ± 0.08
1.81 ± 0.01
ND

ND
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as efficient as either wild type enzymes, the engineered enzyme gained α-NAGAL
activity that was not indigenous to α-GAL. The kinetic parameters KM, kcat, and kcat/KM
of α-GALSA are not as optimal as the wild type enzyme α-NAGAL, but α-GALSA has
nearly the same enzymatic activity as α-NAGAL against alpha-linked Nacetylgalactosamine substrate (see Table 5.2, gained activity and specificity in red).
Compared to wild type α-GAL, α-GALSA has much improved α-NAGAL activity. αGALSA has now greater specificity (kcat/KM) for α-NAGAL substrate, turns over pNP-αGalNAc substrate about 20-fold faster than pNP-α-Gal, and binds both substrates a higher
concentration (KM) than the wild type enzymes. Since the engineered enzyme is mostly
α-GAL in amino acid sequence, we hypothesize it will have similar biochemical
parameters as α-GAL. The apparent melting temperature (Tm) measured for the α-GALSA
is around 57°C, showing comparable stability to wild type α-GAL (60°C).
Similarly, our laboratory has also shown a parallel experiment where a α-NAGAL
activity and specificity is altered by mutating the α-NAGAL recognition loop residues to
S188E, A191L. Engineered α-NAGALEL has completely lost its specificity towards its
substrate (pNP-α-GalNAc) and now has exclusive activity and specificity towards pNPα-gal (see Table 5.1). It is known that wild type α-NAGAL has both α-NAGAL activity
and residual α-GAL activity. α-NAGALEL on the other hand completely and exclusively
exhibits α-GAL properties. Again the engineered enzyme is not as efficient enzyme
compared to wild type α-GAL, however it has adopted α-GAL activity and characteristics
not seen with wild type α-NAGAL enzyme.
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5.3.2. Immunogenicity of α-GAL, α-NAGAL and α-GALSA enzymes
To assess the immunogenic properties of these enzymes we used western blots to
demonstrate that the engineered proteins have retained their inherent antigenic
characteristics. Since only two residues in the active site of both the engineered enzymes
where changed, it is expected that the antibodies raised against the wild type enzyme
would recognize the mutant enzymes α-GALSA and α-NAGALEL. To verify the
specificity of the antibodies, wild-type enzymes were used as controls. The SDS gel with
all the enzymes (wild type the α-GAL, α-NAGAL; engineered enzymes α-GALSA and αNAGALEL) shows that α-GALSA has a similar electrophoretic mobility as the wild-type
enzyme counterpart; likewise α-NAGALEL also behaves like the wild-type enzyme (see
Figure 5.3a). The SDS gel also demonstrates a uniform amount of enzyme loaded for the
succeeding western blot experiment. Next, immunoblots using either monoclonal anti-αGAL or polyclonal anti-α-NAGAL as primary antibodies were performed for all the
enzymes. The western blots show that there is no cross reactivity between the two
antibodies used. The anti-α-GAL antibody only reacted with the α-GAL and α-GALSA
enzymes, and the anti-α-NAGAL antibody only reacted with the α-NAGAL and αNAGALEL enzymes (see Figure 5.3b). More importantly the western blot has
demonstrated that both the engineered enzymes α-GALSA and α-NAGALEL retained their
respective wild type antibody epitope.

5.3.3. α-GALSA crystal structure
The structures of the engineered α-GAL with glycerol, α-galactose and α-Nacetylgalactosamine bound at the active site were solved using x-ray crystallography (see
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a.

b.

Figure 5.3 SDS and western blots of wild type and engineered enzymes
(a) SDS gel of the four enzyme (wild type α-GAL and α-GALSA; wild type α-NAGAL
and α-NAGALEL) shows difference in electrophoretic mobility, both engineered
protein α-GALSA and α-NAGALEL display the same property as the wild type enzyme;
(b) Western blot of the same four enzyme as in (a) shows no cross reactivity between
the monoclonal anti-α-GAL or polyclonal anti-α-NAGAL. Anti-α-GAL recognizes
only the wild type α-GAL and α-GALSA which suggest that the engineered enzyme
with α-NAGAL active retained its α-GAL backbone, likewise the engineered αNAGALEL though exclusively turns over α-GAL substrate retained its α-NAGAL
immunogenicity.
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Table 5.2 and Figure 5.4 a, b, c). The structures give a view of the small
molecule/product and its interaction with the residues at the active site. α-GALSA
superimposed to the 2.0 Å wild type α-GAL structure with galactose bound at the active
site shows the α-GAL substrate galactose and the active site residues are
indistinguishable with the exception of the two mutated residues (E203S; L206A) at the
recognition loop (see Figure 5.5a) (Guce 2009). Similarly, α-GALSA bound to α-Nacetylgalactosamine superimposes on the 1.9 Å wild type α-NAGAL structure, showing
that the active sites superimpose well, with a root mean square deviation of 0.25 Å for 15
amino acid residues (see Figure 5.5b) (Clark and Garman 2009; Guce 2009).
This is the first structure of α-GAL enzyme with α-N-acetylgalactosamine bound
at the active site, made possible by the extra space introduced by the smaller Ser and Ala
residues. The residues at the catalytic center of α-GALSA with both α-Nacetylgalactosamine and galactose soak show that the important contacts to small
molecule are maintained as described in Chapter 1. As shown in the crystal structure
with α-N-acetylgalactosamine, mutating E203 and L206 to smaller side chains opens up a
cavity in the active site for the N-acetyl group at C2 of the sugar ring. The engineered
enzyme can now accommodate, bind and turnover alpha-linked N-acetylgalactosamine
substrate. Modeling α-GalNAc in the active site of wild type α-GAL counterpart shows
steric clashes between the α-GalNAc substrate because E203 and L206 occupy the same
space as the bulkier N-acetyl group.
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5.4. Discussion
Wild type α-GAL and α-NAGAL were used as a starting point to change the
specificity of the enzyme to that of the homologous enzyme. We used the structures of
two related enzymes as the starting point for the protein engineering exercise, then we
verified our design by determining the x-ray structures of α-GALSA with different
substrate soaks. The structures reveal that the entire basis for substrate specificity for αGAL and α-NAGAL enzymes is contained in the two residues in the recognition loop. By
switching the two critical residues at the recognition loop, the specificity of the α-GAL
enzyme was changed to that of α-NAGAL similarly α-NAGAL to α-GAL.
The E203 and L206 of α-GAL discriminate between the terminal α-galactose
versus α-N-acetylgalactosamine substrates. By mutating E203S and L206A, the activity
of α-GALSA behaves more like α-NAGAL enzyme than like the α-GAL enzyme from
which we started. The activity assay, kinetics experiments, and structure all support the
rationally designed α-GALSA protein to alter specificity and switch activity to behave like
α-NAGAL. This experiment shows a simple case of protein design, where changing two
residues in the active site of an enzyme leads to new enzymatic function. This approach
might be extended to engineering a number of distinct enzymatic activities into a
common scaffold, which could be a valuable tool for alternative enzyme replacement
therapy for lysosomal storage diseases or among homologous disease-causing protein.
ERT is the principal treatment for most lysosomal storage disease and has been
shown to be effective in reducing accumulation of substrate and thereby slowing of
disease progression (Eng, Banikazemi et al. 2001; Eng, Guffon et al. 2001; Germain
2002; Schoenmakere 2003; Wilcox, Banikazemi et al. 2004). However, ERT involves the
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Table 5.2 Crystallographic statistics of α-GALSA
Soak :
PDB code:
Protein
Expression system
Space group
Cell lengths, Å
Cell angles, °
X-ray data
X-ray source
Wavelength, Å
Resolution (last shell)
Observations
Unique observations
(last shell)
Completeness, %
(last shell)
Multiplicity (last shell)
Rsym (last shell)
I/σI (last shell)
Refinement
Rwork/Rfree, %
No. of atoms
Protein
Carbohydrates
Water
Others
Ave. B, Å2

Glycerol

α-Galactose

α-N-acetylgalactosamine*

Tn5
P212121
59.57, 106.92, 181.51

Tn5
P212121
59.50, 105.85, 181.85

Tn5
C2221
89.15, 139.41, 182.94

BNL X6A

BNL X6A

BNL X6A

45.27 - 2.85 (2.90 - 2.85)
136,330
27,897
(1334)
99.3
(99.9)
4.9 (4.9)
0.177 (0.616)
9.1 (2.2)

49.63 – 3.04 (3.23 – 3.11)
172,299
23,638
(2297)
100.0
(100.0)
7.3 (7.4)
0.271 (0.859)
7.6 (2.5)

47.35 – 2.81 (2.90 – 2.80)
211,219
28,304
(2809)
100.0
(100.0)
7.5 (7.5)
0.217 (0.812)
11.0 (2.8)

22.6/26.7
6658
6320
170
132
36
22.8

21.4/24.4
6557
6303
218
36
0
28.4

21.2/26.2
6551
783
16
49
2
33.3

* Table 5.2 is continued onto the next page
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Ramachandran Plot
Favored (%)
Allow (%)
Generous (%)
Forbidden (%)
RMS deviations
Bonds (Å)
Angles (°)
* refinement in progress

89.5
9.6
0.7
0.1

89.9
9.3
0.4
0.3

0.0089
1.214

0.0119
1.1413
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84.1
13.8
1.5
0.6

a.

b.

c.

α-GALSA
+ α-GalNAc

α-GALSA
+ α-Gal

α-GALSA
+ Glycerol

Figure 5.4 α-GALSA active site with small molecule soaks
(a), (b), and (c) shows electron density of the ligand at the α-GALSA active site.
The electron density corresponds to a σA-weighted 2Fo-Fc omit map calculated in
SFCHECK contoured at 1.5 σ. The substitution of a smaller side chains at the
active site produced a gap that could now fit a bulkier N-acetyl group at the C2
position.
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a.
α-GAL + α-galactose
α-GALSA + α-galactose

b.
α-NAGAL + α-GalNAc
α-GALSA + α-GalNAc

Figure 5.5 Superimposition of the active site of α-GAL, α-NAGAL and
α-GALSA
(a) α-GAL and α-GALSA with α-galactose bound at the active site, active site
residues are indistinguishable except of the two residues at the recognition loop
(E203S; L206A); (b) α-NAGAL and α-GALSA active sites with α-Nacetylgalactosamine superimposes with an rmsd of 0.23 Å.
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introduction of a recombinant protein into the bloodstream of patients. Since many Fabry
disease patients make no functional α-GAL protein, injection of recombinant enzyme can
lead to severe immune complications. Independent clinical studies report a large
percentage (56-88%) of Fabry disease patients develops IgG antibodies when infused
with recombinant α-GAL (Eng, Guffon et al. 2001; Linthorst, Hollak et al. 2004;
Schiffmann, Ries et al. 2006; Vedder, Breunig et al. 2008). The immune response in
these patients could cause enzyme replacement therapy to be less effective due to
neutralizing effect of the antibodies (Garman, Munroe et al. 2004; Wang, Lozier et al.
2008).
Here we have shown that the mutation of the two residues at the recognition loop
of α-GAL protein converts the activity of α-GAL into α-NAGAL. The reverse
experiment is also true, because others in the lab have engineered α-NAGAL into αGAL. Using our understanding of α-GAL ligand specificity, α-NAGAL (which Fabry
disease patients make normally) was engineered to function as α-GAL. The α-NAGAL
recognition loop was engineered to produce a protein that cleaves terminal α-galactose.
Since Fabry disease patients have normal levels of α-NAGAL, we predict the engineered
protein will not be treated as foreign by the immune system of Fabry patients. The
interconverted enzymes might be a promising avenue for enzyme replacement therapy for
Fabry disease and other lysosomal storage disease.
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5.5. Methods
5.5.1. α-GALSA expression and purification
The α-galactosidase A mutant α-GALSA was generated from site directed
mutagenesis of wild type human α-galactosidase A gene (GLA) in pIB/V5-His-TOPO

®

vector (Invitrogen), pIB/V5-His-TOPO-α-GAL. α-GAL mutation was incorporated into
the pIB/V5-His-TOPO-α-gal construct with PhusionTM site-directed mutagensis kit
(Finnzymes) according to the manufacturer’s specifications. Forward (5ʹ′-PO4-G TAC
TCC TGT TCG TGG CCT GCT TAT ATG TGG CCC-3ʹ′, mutations in bold), and
reverse primers (5ʹ′-PO4-CAC AAT GCT TCT GCC AGT CCT ATT CAG GGC3ʹ′), were used to introduce the mutations into the GLA gene (IDT Inc., Coralville IA).
The mutation was confirmed by sequencing the isolated and purified DNA (Genewiz
Inc., USA).
Mutant DNA was transfected into Tn5 cells as previously described in Chapter 2.
α-GALSA protein secreted to the supernatant was purified using Ni affinity tag and anion
exchange chromatography as described in Chapters 2 and 4.

5.5.2. α-GALSA activity assay and kinetics
The specific activity and kinetic parameters of α-GALSA and α-NAGALEL were
assayed by monitoring the hydrolysis of para-nitrophenyl-α-galactopyranoside (pNP-αgal; Sigma Aldrich, St. Loius Mo, N0877) and para-nitrophenyl 2-Acetamido-2-deoxy-α
-D-galactopyranoside (pNP-α-GalNAc; Toronto Research Chemicals Inc., Canada) at
400 nm. The specific activity of purified α-GALSA and α-NAGALEL was measured by the
addition of 0.012 mg/mL enzyme to 5 mM pNP-α-gal substrate or pNP-α-GalNAc in 100
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mM citrate/phosphate buffer pH 4.5. After incubation for 10 min, the reaction was
quenched by the addition of 250 µL of borate buffer, pH 9.8. Absorbance at 400 nm was
measured using a microplate reader at room temperature. Activities were measured by
subtracting the blank and adjusting for the dilution factor.
The kinetic parameters of the enzymatic reaction were determined by monitoring
the amount of product cleaved by the α-GAL and α-NAGAL mutant enzymes over time
at varying substrate concentrations. The reaction mixture containing 10 µL of α-GALSA
and α-NAGALEL mutant (0.01 mg/mL) and 140 µL of increasing concentration of
substrate (0-50 mM pNP-α-gal; 0-10 mM pNP-α-GalNAc) was incubated at 37°C. The
reaction was quenched by adding 10 µL of the reaction mixture to 290 µL of borate
buffer, pH 9.8 every minute for 10-15 minutes. The amount of para-nitrophenolate
cleaved at each substrate concentration was plotted against time yielding initial velocities
(V0) for each substrate concentration. Vmax and Km values were calculated as described
in Equation 3.1. All stock pNP-α-GalNAc and pNP-α-gal solutions were dissolved in
citrate buffer (100mM citric acid, 100mM NaH2PO4, pH 4.5), and all enzyme solutions
diluted in 100mM citric acid, 100mM NaH2PO4, 0.1% BSA, pH 4.5. All kinetic
experiments were performed in triplicate and verified by two separate experimenters.

5.5.3. Tm measurement (CD) of α-GALSA
CD wavelength scan and thermal melts were carried out on a Jasco J715
spectropolarimeter equipped with a PTC-348WI temperature controller. The CD signal at
222 nm of α-GALSA and α-NAGALEL mutant (1.2-5 µM in 10 mM phospate buffer, pH
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6.5) were monitored at increasing temperature at a temperature speed of 1°C/min from
25-90°C as previously described in Chapter 3.

5.5.4. Western blot analysis of α-GALSA and α-NAGALEL mutant
Purified enzyme (wild type α-GAL and α-NAGAL; and mutant enzymes αGALSA and α-NAGALEL) were separated on 10% SDS polyacrylamide gels by mixing
supernatant samples with 6x SDS loading buffer with β-mercaptoethanol and boiling for
10 minutes. The four samples were run in triplicate. One SDS gel was stained with
codeBlue (Pierce) to visualize protein loaded to the gel. The other two SDS gels were
transferred to a nitrocellulose membrane (Millipore). The first membrane was incubated
with a monoclonal chicken anti-α-GAL primary antibody (Genetel Labs, OA0005,
1:2000 dilution) and detected with alkaline phosphatase (AP) labeled anti-chicken
secondary IgG (Genetel Labs, RCYAP, 1:5000 dilution). The second membrane was
incubated with a polyclonal rabbit anti-α-NAGAL primary antibody (1:100000 dilution)
and detected with AP labeled anti-rabbit secondary IgG (Rockland, 611-1502, 1:5000
dilution). All four enzymes run between 43 and 56 kDa.

5.5.5. Crystallography
All crystals were grown using the hanging drop vapor diffusion method at 20°C
incubator. Crystals that grew in the space group P212121 were optimized using
microseeding to increase crystal size.
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5.5.5.1. Crystal conditions
Glycerol and galactose soak: Small crystals were obtained from 1:1 mixture of
reservoir solution (8% (w/v) PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 22 mM
magnesium acetate) with a 7.0 mg/mL protein solution (10 mM sodium phosphate buffer,
pH 6.5). The crystals were crushed and used to seed a pre-equilibrated 1:1 mixture of
reservoir solution and stock protein solution. Crystals appeared in the seeded solution
after two weeks. Crystals were transferred and harvested to a similar solution with 20%
glycerol (glycerol bound structure) or with 20% glycerol and 200 mM galactose
(galactose bound structure). Both crystals grew in the P212121 space group.
α-N-acetylgalactosamine soak: Crystals grown in space group C2221 were grown
using a reservoir solution (12.0% PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 22 mM
magnesium acetate). A single crystal was transferred into a harvest solution (15.0% PEG
8k, 100 mM sodium cacodylate pH 6.5, 0.022 M magnesium acetate, and 200 mM α-Nacetylgalactosamine). The crystal was flash cooled in liquid nitrogen in harvest solution
supplemented with 20% glycerol as a cryoprotectant.

5.5.5.2. Data collection and refinement
Several crystals were screened in-house using a RU-H3R rotating anode generator
(Rigaku). Crystals that diffracted to around 4 – 3.5 Å were transported to the
Brookhaven National Laboratory Synchrotron Light Source where data sets were
collected at the X6A beamline. X-ray images were processed using HKL2000 software
package. Rigid body refinement was used to generate solutions for α-GALSA with
glycerol and galactose soaked. The α-GALSA structure with α-GalNAc soak was phased

143

by molecular replacement in the CCP4 program AMoRe using the 1.9 Å D170A α-GAL
mutant structure (PBD code 3HG3) (Guce 2009).
For all structures: Atomic models were built into electron density using the
program O, and refinement and water placement were done using REFMAC (Jones, Zou
et al. 1991). Coordinates were superimposed using LSQMAN, molecular docking studies
were performed in O and in PyMol (Jones, Zou et al. 1991; Kleywegt 1997; DeLano
2008). Figures were made in MolScript, pymol and POVScript+ (Kraulis, Fenn) (DeLano
2008).
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CHAPTER 6

FUTURE DIRECTION

The mechanistic studies done on α-GAL described in Chapter 2 represent the first
complete crystallographic evidence of the catalytic mechanism of a retaining enzyme and
of glycoside hydrolase family 27 enzymes. This structural study also includes two novel
structures for both family 27 enzymes and α-GAL enzyme; one is a substrate bound (1.9
Å) and the other is the covalent intermediate (2.3 Å), respectively. Enzymes belonging to
family 27 of the glycoside hydrolase have conserved active site residues therefore the
catalytic mechanism determined in this study is most likely identical for the entire family.
In addition, the high-resolution structure α-GAL solved with covalent intermediate bound
in the active site revealed two new conformation of the sugar; (1) a skew boat
conformation that mimics the covalent intermediate, and (2) the half chair conformation
transition state-like inhibitors. This opens the door for a new class of potent inhibitors
that could be pharmacological chaperone candidates for α-GAL and other alpha-retaining
enzymes. Designed novel mechanism-based inhibitors would selectively bind to the
active site of the target protein and could be screened for its chaperoning effect. In
addition these new small molecule inhibitors would belong to a different chemical patent
space. Potent inhibitors of family 27 or retaining glycosidase have immense clinical
relevance as well. As an example, a disease called “ gastric dumping syndrome” causing
uncontrolled or delayed bowel movement is a result of an excess of insulin secretion after
a sharp increase in blood glucose level (Harju and Nordback 1987; Hasegawa, Yoneda et
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al. 1998). Known inhibitors of α-glucosidase (EC 3.2.1.20, a family 27 as well as a
retaining enzyme) such as acarbose are available drug for the treatment of non-insulindependent diabetes mellitus (NIDDM) (Hermans, Kroos et al. 1991; Bischoff 1994;
Spengler 1995). Interestingly, acarbose is also a type 2 diabetes drugs that prevents the
breakdown and release of glucose from the polysaccharide substrate in the stomach thus
regulating the blood glucose level in patients (Josse 1995; Campbell, White et al. 1996;
Martin and Montgomery 1996). Acarbose in particular is a polysaccharide drug that
resembles a transition state structure (Yoon and Robyt 2002). Retaining enzymes like the
one described above will have a similar catalytic mechanism where new class of
inhibitors could be designed based on to the novel mechanism-based inhibitors described
here. The assays optimized to assess the chaperoning effect of a new chaperone molecule
as described in Chapter 3 and 4 could be used to screen for chaperoning-activity.
Substrate reduction therapy is also a treatment option for other lysosomal storage disease
where potent inhibitors could be used. Industrial applications also include modulating
leaf development in plants and seed germination in legumes. Additionally, discovery of
the second sugar-binding site away from the active site is a potential site to bind a small
pharmacological chaperone molecule without competitively inhibiting the enzyme
function. These structures provide new insights for drug design efforts on
pharmacological chaperones or tight inhibitors of α-GAL and homologous enzymes.
The molecular mechanism of the chaperoning effect of DGJ elucidated through
biophysical techniques and structural studies described in Chapter 3 enabled us to
understand the biochemistry behind pharmacological chaperones as well as the basic
concept for the potency of DGJ as a chaperone. The biochemical experiments mentioned
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in this study is the first biophysical evidence of pharmacological chaperone, specifically
DGJ, stabilizing α-GAL enzymes at physiologically relevant pH conditions. The studies
done with α-GAL described in this thesis will act as a model system to understanding
pharmacological chaperones for other lysosomal storage diseases. The mechanistic
insights from the experiments developed for wild type α-GAL also provide valuable
information on the basic design of pharmacological chaperones for other enzymes.
Pioneering work on the effect in the stability of α-GAL in the presence of DGJ led to a
new model for pharmacological chaperone therapy and other avenues of research such as
stability-activity correlation and trafficking experiments. As a follow up experiment to
the stability-activity correlation of wild type α-GAL, monitoring enzyme activity as a
function of temperature is being proposed. To investigate further the observed
chaperoning effect of DGJ at sub-stoichiometric concentrations, chimera protein with two
different active sites is being considered. We propose an obligate dimer of α-GAL with
two different active sites, one that will accommodate its natural substrate and the other
that will bind α-GalNAc, as discussed in Chapter 5. This will enable us to interrogate the
effect of DGJ on the other half of the dimer using the assays developed in Chapter 3. By
filling the α-GALSA active site with a bigger inhibitor, we could measure the chaperoning
effect and inhibition of the single monomer.
Experiments described in Chapter 4 have validated the effect of DGJ to known αGAL mutants. The guidelines that we have developed in Chapter 4 to predict the
response of Fabry disease-causing mutations to DGJ is a useful clinical tool to estimate
patient response. We are now in the position to test these predictions using the
biochemical experiments developed and described in Chapters 3 and 4. Expressing
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mutants that are described in Chapter 4 and testing them to see the chaperoning effect of
DGJ. This would further confirm the effect of DGJ to these mutants as well as test the
validity of the rules/guidelines described in Chapter 4. This will lead to a better, cheaper
and safer treatment and management option for Fabry disease patients other than enzyme
replacement therapy.
Finally the engineering studies in α-GAL have established the role of the two
recognition loop residues for ligand specificity. The rational design of the active site
residues have proven the possibility of designing homologous recombinant enzymes for
replacement therapy to prevent adverse immune response from patients. Altering the
active site of an enzyme indigenous to the host designed to function similar to the
deficient enzyme in any of the lysosomal storage disease and/or disease requiring enzyme
replacement. In this way the immune system would recognize the engineered enzyme
similar to α-GALSA as “self” at the same time step up to the role of cleaving the
accumulated substrate. This has a great impact in the design of recombinant enzymes for
enzyme replacement therapy to increase efficiency of the treatment and reduce adverse
immunogenicity side effects. As a follow up to the engineered α-GALSA enzyme to probe
the role of the two residues in the recognition loop, the other residues at the active site
could also be rationally mutated to interrogate its function and effect to enzyme activity,
stability and catalysis.

148

APPENDIX A

THE STRUCTURE OF HUMAN α-GALACTOSIDASE A AND IMPLICATIONS
FOR FABRY DISEASE (BOOK CHAPTER SECTION)
This is a section of a book chapter on inherited diseases particularly the lysosomal
storage disorder, Fabry disease. (Abigail I. Guce and Scott C. Garman), in press.
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7.1 Overview of the structure
The three-dimensional structure of human α-galactosidase A was determined by
x-ray crystallography in 2004 (1), revealing the locations of the atoms in the
glycoprotein. The crystal structure showed a homodimeric molecule with each monomer
containing two domains. The N-terminal domain is a classic (β/α)8 barrel, and the Cterminal domain contains eight antiparallel β strands packed into a β sandwich (Figure
7.1). Residues 32-328 comprise the N-terminal domain, and residues 329-421 fold into
the C-terminal antiparallel β domain. The C-terminal residues 421-429 are disordered in
most crystal structures, and the 31-residue signal sequence is removed during the folding
of the protein in the endoplasmic reticulum. The lozenge-shaped dimer has overall
dimensions of approximately 75 x 75 x 50Å.
The N-terminal domain contains the active site, which is located at the C-terminal
end of β strands β1-β7, near the center of the β barrel. The active site appears as a small
depression on the surface of the molecule. The function of the C-terminal domain is
unclear, but it is conserved in all members of the family, including α-galactosidases from
rice and from Trichoderma reesei (2, 3). The interface between the N- and C-terminal
domains of human α-galactosidase A is extensive, burying 2500Å2 of surface area,
including many hydrophobic interactions. The dimer interface is also extensive, with
2200Å2 of buried surface area.
Three N-linked carbohydrates are found on the surface of the molecule, away
from the location of the active site and away from the dimer interface. The carbohydrate
residues attach to aspartic acid residues N139, N192, and N215 and extend from the
surface of the molecule. N-linked carbohydrates are critical for the correct folding and
trafficking of the molecule in the cell (4-6). The N-linked carbohydrates are highly
heterogeneous in composition, as judged from the distribution of carbohydrates on the
recombinant glycoproteins used in enzyme replacement therapies (7). The N139 site
contains complex carbohydrate with two to four branches and from zero to four sialic
acid residues per chain. The N192 and N215 carbohydrates are mixtures of complex,
hybrid, and oligomannose glycoforms, each with variable amounts of phosphorylation
and sialylation (7). Assuming independence of the three N-linked glycosylation sites, the
recombinant enzymes used in enzyme replacement therapies represent approximately 500
and 1300 different glycoforms.
The dimer has a pronounced negative charge, with 22 more acidic residues than
basic residues in the polypeptide sequence. This results in a dimer with a highly negative
electrostatic potential surface at neutral pH (Figure 7.2). With the large excess of acidic
residues over basic residues, the α-galactosidase A protein has a pronounced negative
charge at neutral pH and little overall charge at lysosomal pH. The calculated isoelectric
point of the mature polypeptide is 5.2, and because of the negative charges on the
carbohydrate, the glycoprotein migrates at approximately pH 4.5 on an isoelectric
focusing gel (7).
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7.2 Active site and ligand binding
The correct function of α-galactosidase A requires the enzyme to discriminate
between α-galactosides and the many other saccharides in the lysosome. The enzyme
manages this by folding into a three dimensional fold that gathers 15 residues into an
active site configuration specific for α-galactosides (Figure 7.3). The active site is formed
from the side chain residues of W47, D92, D93, Y134, C142, K168, D170, C172, E203,
L206, Y207, R227, D231, D266, and M267. C142 and C172 make a disulfide bond. The
two active sites in the dimer are separated by approximately 50Å.
A number of crystal structures of human α-galactosidase A have now been
determined, revealing details of ligand binding interactions (1, 8). The cocrystal
structures of human α-galactosidase A with the catalytic product α-galactose bound
reveal that the enzyme makes contacts to each functional group on the ligand (Figure
7.3). When galactose monosaccharide (an equilibrium mixture of α and β anomers) is
soaked into crystals of human α-galactosidase A, only the α anomer appears in the active
site. In contrast, the rice and Trichoderma reesei α-galactosidase active sites are able to
accommodate both the α and β anomers of galactose (2, 3). In human α-galactosidase A,
Y207 (one of three active site residues not conserved in the rice and Trichoderma reesei
α-galactosidase sequences) sterically occludes binding of β-galactose.
The chemical chaperone 1-deoxygalactonojirimycin (DGJ) was originally
modeled into the binding site of human α-galactosidase A (9); later a crystal structure of
the complex was determined (8). DGJ, an iminosugar analog of galactose, has identical
binding interactions to the protein as galactose does. Thus the chemical chaperone acts as
a competitive inhibitor of the α-galactosidase A enzyme. The binding of DGJ helps
stabilize the folded conformation of wild type and mutant α-galactosidase A
glycoproteins, allowing for more efficient delivery of the enzyme to the lysosome.

7.3 Catalytic mechanism
The α-galactosidase A enzyme uses a double displacement reaction mechanism
(10), where two consecutive nucleophilic attacks on the anomeric carbon of the substrate
lead to breakage of the glycosidic linkage with overall retention of the anomer in the
product. This double displacement mechanism requires two carboxylates, one acting as a
nucleophile and one acting as an acid and then a base over the course of the reaction
mechanism. In human α-galactosidase A, the catalytic nucleophile is D170 and the
catalytic acid/base is D231. The double displacement reaction mechanism can be broken
down into discrete steps (Figure 7.4). First, the D170 nucleophile attacks C1 of the
substrate, breaking the glycosidic linkage (with the donation of a proton by D231). This
results in a covalent glycosyl-enzyme intermediate, and the free portion of the cleaved
product diffuses away. Second, D231, acting as a base, deprotonates a water molecule,
which attacks C1 of the glycosyl-enzyme intermediate, breaking the bond between the
protein and the sugar and generating α-galactose as the catalytic product. Finally, the αgalactose product diffuses out of the active site, regenerating the empty enzyme for
another catalytic cycle.
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7.4 Fabry disease mutations
Fabry disease phenotypes fall into three general classifications, depending on the
degree of residual enzymatic activity. The classical or severe phenotype leads to
dysfunction in multiple organ systems (including the skin, eyes, heart, kidneys), while
two other milder phenotypes (which typically show some residual enzymatic activity)
have symptoms restricted to the heart and kidney respectively. The structure of the
human α-galactosidase A glycoprotein allows for some degree of personalized medicine
in Fabry disease, where a patient’s treatment might be chosen in light of the individual’s
α-galactosidase A gene sequence. Using the database of mutations identified in Fabry
patients, it may be possible to predict the course and severity of the disease depending on
the specific mutation in the α-galactosidase A gene sequence.
There	
   have	
   been	
   a	
   large	
   number	
   of	
   mutations	
   identified	
   in	
   Fabry	
   disease	
  
patients.	
   The	
   database	
   of	
   point	
   and	
   stop	
   mutations	
   in	
   Fabry	
   disease	
   patients	
  
contains	
   257	
   point	
   mutations	
   and	
   43	
   stop	
   mutations.	
   The	
   effect	
   of	
   the	
   mutations	
   on	
  
the	
  α-‐galactosidase	
  A	
  glycoprotein	
  is	
  summarized	
  in	
  Table	
  7.1.	
  The	
  full	
  database	
  of	
  
mutations	
   is	
   considerably	
   larger,	
   because	
   it	
   includes	
   insertions	
   and	
   deletions	
   that	
  
lead	
   to	
   frame	
   shifts,	
   mutations	
   that	
   lead	
   to	
   splice	
   defects,	
   and	
   mutations	
   in	
   the	
  
promoter	
  region	
  of	
  the	
  gene,	
  but	
  in	
  this	
  chapter,	
  we	
  address	
  only	
  the	
  mutations	
  that	
  
affect	
  the	
  structure	
  of	
  the	
  protein.	
  	
  
The	
  mutations	
  in	
  α-‐galactosidase	
  A	
  that	
  perturb	
  the	
  structure	
  of	
  the	
  protein	
  
can	
   be	
   grouped	
   into	
   three	
   broad	
   categories.	
   First,	
   there	
   are	
   mutations	
   that	
  
compromise	
  the	
  active	
  site	
  of	
  the	
  enzyme,	
  leading	
  to	
  loss	
  of	
  enzyme	
  activity.	
  Second,	
  
perturbations	
   in	
   the	
   hydrophobic	
   core	
   of	
   the	
   protein	
   lead	
   to	
   folding	
   defects	
   in	
   the	
  
enzyme.	
   This	
   class	
   comprises	
   the	
   largest	
   group	
   of	
   mutations	
   in	
   Fabry	
   disease,	
  
indicating	
   that	
   Fabry	
   disease	
   is	
   usually	
   a	
   protein	
   folding	
   disease.	
   The	
   rest	
   of	
   the	
  
mutations	
  are	
  grouped	
  into	
  a	
  third	
  category,	
  which	
  includes	
  mutations	
  that	
  lead	
  to	
  
broken	
   disulfide	
   bonds,	
   loss	
   of	
   N-‐linked	
   glycosylation	
   sites,	
   mutations	
   with	
   no	
  
obvious	
  explanation,	
  and	
  others.	
  Figure	
  7.5	
  maps	
  the	
  mutations	
  onto	
  the	
  structure,	
  
showing	
  that	
  most	
  of	
  the	
  molecular	
  defects	
  that	
  lead	
  to	
  Fabry	
  disease	
  fall	
  far	
  from	
  
the	
   active	
   site	
   of	
   the	
   enzyme.	
   Over	
   half	
   of	
   the	
   residues	
   in	
   the	
   mature	
   protein	
   are	
  
found	
  mutated	
  in	
  the	
  database	
  of	
  Fabry	
  disease	
  patients.	
  	
  
Fabry disease can serve as model for the entire family of lysosomal storage
disorders because of the wealth of informational available at the genetic, clinical, and
structural levels. The extensive database of mutations identified in Fabry disease patients,
combined with the three-dimensional structure of the glycoprotein, leads to a unique
molecular understanding of the disease. Additionally, the family of lysosomal storage
diseases have many similar traits, so better understanding of the molecular defects in
Fabry disease will lead to better understanding of the entire family. Finally, the threedimensional structure of α-galactosidase A shows that Fabry disease is typically a disease
of protein folding, so it can serve as a model for other protein folding diseases, including
Alzheimer’s and Parkinson’s diseases.
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7.6 Table

Table 1: α-Galactosidase A protein mutants in Fabry disease

Wild type
protein
sequence
1

M

14
16
19
20
31
32
34
35
40

L
L
L
A
A
L
N
G
P

42

M

43

G

44
46

W
H

47

W

48
49

E
R

50
51

F
M

52

C

56

C

59
63
65
66

E
C
S
E

68
72

L
M

73
78
79
81

A
S
E
W

Fabry
disease
sequence:
severe /
(variant)
I
T
R
P
P
P
(P)
V
P
S
R
S
L
V
T
L
D
R
V
X
R
Y
L
G
K
L
S
P
G
C
K
I
S
R
X
G
F
Y
X
K
Y
T
Q
K
G
F
V
R
I
V
X
X
X
S

Importance in α-galactosidase A

Side chain
accessible
surface
area (Å2)

Mutation
category

AUG start

Other

in signal sequence
in signal sequence
in signal sequence
in signal sequence
in signal sequence
signal sequence cleavage site
H-bond to N224
G phi/psi, R collides with N192 carbohydrate

5.7
1.5
8.3
0.0

Other
Other
Other
Other
Other
Other
Buried
Other
Buried

no room for beta branch

0.8

Buried

no room for side chain

0.0

Buried

stop
next to W47 in the active site

0.0
0.0

Other
Buried

active site residue

2.6

Active

H-bond to main chain E48 and N272
located on dimer interface

0.0
2.0

Other
Buried

buried in hydrophobic pocket
contacts to active site W47 and dimer interface

0.7
10.1

Buried
Active

disulfide required near the active site

12.0

Other

stop
disulfide bond

13.2

Other

stop
ion pairs across dimer interface to H406
disulfide bond
near disulfide bond
partially buried in ion pair

7.6
0.7
3.5
3.3

Other
Other
Buried
Buried

buried in hydrophobic pocket
totally buried

0.2
0.0

Buried
Buried

totally buried
stop
stop
stop
buried in hydrophobic pocket

0.0
21.7
13.2
0.1

Buried
Other
Other
Other
Buried
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Reference
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(12)
(18)
(19)
(20)
(21)
(22)
(23)
(13)
(24)
(25)
(26)
(13)
(27)
(12)
(28)
(29)
(28)
(30)
(20)
(23)
(28)
(26)
(13)
(31)
(32)
(33)
(11)
(34)
(19)
(33)
(23)
(35)
(33)
(36)
(37)
(38)
(36)
(32)
(13)
(39)
(40)
(26)
(32)
(41)
(42)
(43)
(30)

85
86

G
Y

88
89

Y
L

91
92

I
D

93

D

94

C

95

W

97

A

99
100

Q
R

103
107
112

E
Q
R

113

F

118
119
121
128
129
131
132
134

R
Q
A
G
L
L
G
Y

135
136
138

A
D
G

141
142

T
C

143

A

144
146
147
148

G
P
G
S

151
152
155
156

Y
Y
D
A

157
162

Q
W

163
165
166
167

G
D
L
L

D
C
X
D
R
P
(T)
H
Y
N
G
N
Y
S
S
X
V
P
X
K
T
Q
X
C
(H)
S
(L)
S
C
X
P
E
P
P
R
S
X
V
H
R
E
I
Y
R
X
W
P
T
V
(S)
R
R
N
X
X
H
T
V
X
R
C
X
V
V
V
P

restricted phi/psi in turn
H-bond to main chain L311
stop
buried in hydrophobic pocket, initiates β2
buried in hydrophobic pocket

7.3
0.0

Other
Other

3.8
0.0

Buried
Buried

buried in hydrophobic pocket
active site residue

0.0
0.0

Buried
Active

active site residue

0.0

Active

disulfide bond

0.0

Other

buried in hydrophobic pocket
stop
mostly buried in turns, no room for larger side
chain
stop
ion pairs to D155, stacked on Y151

0.0
4.7

Buried
Other
Buried

27.0
2.5

Other
Other

totally exposed
stop
mostly buried, guanidium group in ion pair

18.9
12.9
2.2

Other
Other

completely buried in packed hydrophobic core

0.0

Buried

totally exposed
stop
buried, little room for large side chain
restricted phi/psi in turn
Buried, located between α4 and β4
completely buried
no room for side chain
active site residue
stop
buried in a hydrophobic pocket
buried
buried, no room for side chain

13.3
17.6
0.1
8.2
0.0
0.0
0.0
0.0

Other
Buried
Other
Buried
Buried
Buried
Active

0.1
0.0
0.0

Buried
Buried
Buried

H-bond with D93
active site residue, disulfide bond

0.0
3.9

Active
Active

larger side chain disrupts C52-C94 disulfide

5.2

Other

in turn, G restricted phi/psi
partially buried in hydrophobic pocket
able to accommodate a small side chain
H-bond to D155, little room for large side chain

7.9
3.0
1.3
0.0

Other
Other
Buried

stop
stop
H-bond to Y100
buried, no room for larger side chain

10.8
1.7
0.0
0.0

Other
Other
Buried
Buried

stop
mostly buried in hydrophobic pocket

15.0
4.2

Exposed
Buried

stop
in turn, restricted phi/psi
buried ion pair to H125
buried, little room for branch at beta carbon
buried in hydrophobic pocket

1.0
2.1
1.0
0.1

Other
Buried
Buried
Buried

stop
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(18)
(12)
(44)
(29)
(43)
(12)
(12)
(23)
(12)
(31)
(23)
(35)
(12)
(28)
(22)
(30)
(12)
(45)
(43)
(43)
(12)
(36)
(23)
(38)
(43)
(35)
(12)
(28)
(32)
(23)
(46)
(11)
(47)
(43)
(13)
(12)
(22)
(35)
(31)
(12)
(26)
(13)
(48)
(34)
(34)
(36)
(43)
(12)
(43)
(49)
(36)
(12)
(22)
(35)
(13)
(50)
(43)
(48)
(43)
(19)
(51)
(52)
(12)
(20)
(48)
(53)

168
169
170

K
F
D

171

G

172

C

177
183

L
G

187
191

M
L

194
199
201
202

T
V
S
C

204
205

W
P

207
215
216
220
221
222
223

Y
N
Y
R
Q
Y
C

224

N

225
226

H
W

227

R

230
231
234

A
D
D

235
236

S
W

239
242
243
244

I
I
L
D

245
247

W
S

222555000
222555777
222555888
222555999

Q
Q
Q
A
A
A
G
G
G
PPP

222666000
222666111

G
G
G
G
G
G

R
S
V
H
D
R
Y
R
F
G
W
X
D
S
V
P
Q
I
M
F
W
Y
X
T
R
L
S
(S)
D
X
X
X
G
R
Y
D
S
R
X
R
C
Q
X
T
N
Y
E
C
C
L
X
T
N
F
N
H
X
P
C
X
P
R
L
R
A
D

active site residue
buried in hydrophobic pocket
active site mutation, nucleophile

1.9
0.0
0.0

Active
Buried
Active

no room for larger side chain

0.0

Buried

active site residue, disulfide bond

11.7

Active

stop
buried, no room for side chain

12.0
0.3

Other
Buried

totally buried, no room for branched beta carbon
buried in hydrophobic pocket

0.0
1.3

Buried
Buried

little room for longer side chain
buried, little room for longer side chain
buried, no room for larger side chain
disulfide bond

0.4
0.3
2.4
0.0

Buried
Buried
Buried
Other

stop
buried hydrophobic residue

0.1
0.0

Other
Buried

active site residue, H-bond to D170
mutation disrupts N-linked glycosylation
buried hydrophobic residue
stop
stop
stop
disulfide bond

5.5
12.0
1.1
7.0
17.1
4.7
0.0

Active
Other
Buried
Other
Other
Other
Other

buried H-bonding network to N34

0.0

Other

buried H-bonding to T41, S201, and H225
stop
buried in hydrophobic pocket

0.0
0.0

Other
Other
Buried

active site residue
stop
affects critical D231 in active site
active site residue
H-bond network to main chain D234, F273 and
G274
initiates α6 helix
H-bond to E358

0.2

Active

45.4
9.2
0.1

Active
Active
Other

2.7
1.6

Buried
Other

Stop
buried in hydrophobic pocket
buried in hydrophobic pocket
buried in hydrophobic pocket, no room for F
ion pair to R356

0.0
0.3
0.0
12.4

Buried
Buried
Buried
Other

stop
H-bond to Q330, no room for P

3.6
2.8

Other
Buried

stop
no room for P
buried, restricted phi/psi in turn
P259 and G260 form beta turn

27.3
0.0
1.5
10.5

Other
Buried
Buried
Other

buried in turn, restricted phi/psi
buried in turn, no room for side chain

0.0
0.0

Buried
Buried

160

(13)
(29)
(12)
(30)
(35)
(50)
(43)
(22)
(31)
(54)
(36)
(35)
(34)
(13)
(22)
(29)
(31)
(36)
(13)
(35)
(49)
(12)
(22)
(11)
(13)
(36)
(13)
(55)
(12)
(56)
(13)
(57)
(58)
(13)
(13)
(41)
(22)
(59)
(20)
(22)
(30)
(19)
(55)
(22)
(60)
(13)
(35)
(34)
(23)
(34)
(26)
(61)
(42)
(26)
(43)
(34)
(26)
(31)
(26)
(31)
(29)
(28)
(34)
(31)
(48)
(42)

222666222
222666333
222666444

W
W
W
N
N
N
D
D
D

222666555

PPP

222666666

D
D
D

222666777
222666888
222666999
222777000
222777111
222777222
222777666

M
M
M
L
L
L
V
V
V
III
G
G
G
N
N
N
SSS

222777777
222777999

W
W
W
Q
Q
Q

222888000

Q
Q
Q

222888222
222888444
222888555
222888777

T
T
T
M
M
M
A
A
A
W
W
W

222888888

A
A
A

222888999
222999333

III
PPP

222999444
222999666

L
L
L
M
M
M

222999777

SSS

222999888

N
N
N

333000000

L
L
L

333000111

R
R
R

333000333
333111000
313
316
317

III
L
L
L
D
V
I

320

N

321

Q

325
327

G
Q

328

G

C
S
V
Y
R
L
V
H
N
E
I
S
A
T
C
K
N
G
X
(E)
H
R
H
K
N
T
P
X
G
C
D
P
F
S
A
X
(V)
(I)
F
C
K
H
S
H
F
(Q)
X
P
G
N
F
Y
E
T
N
K
Y
I
E
X
D
K
E
R
A
V

buried in a hydrophobic pocket, stack with P259
buried H-bonding network to W226 and N228
near active site residue

0.0
1.3
2.2

Buried
Buried
Active

buried, little room for longer side chain

1.8

Buried

near active site residue

0.8

Active

buried, little room for branch at beta carbon
buried hydrophobic residue
completely buried
buried hydrophobic residue
in turn, restricted phi/psi, no room for C side chain
H-bond to E48, no room for K side chain
H-bond to Q279 on dimer axis

0.3
0.0
0.0
0.0
3.3
0.0
0.9

Buried
Buried
Buried
Buried
Other
Other
Other

stop
H-bond to main chain G274 on dimer axis

6.6
0.2

Other
Other

little room for larger side chain

5.0

Other

H-bond to main chain N278
buried in hydrophobic pocket
buried in hydrophobic pocket
stop
buried hydrophobic residue

0.0
0.3
0.0
0.0

Other
Buried
Buried
Other
Buried

buried in hydrophobic pocket on helix 7

0.9

Buried

no room for F side chain
Buried

0.0
0.0

Buried
Buried

stop
completely buried in a hydrophobic pocket

0.4
0.0

Other
Buried

No room for F side chain

0.0

Buried

H-bond to active site W47 and to I270 main chain

0.0

Active

no room for aromatic side chain

0.0

Buried

partially buried, ion pair to D299
stop

4.1

Other

partially buried in hydrophobic pocket
domain interface
domain interface, little room for Y side chain
domain interface helix
buried in a hydrophobic pocket

1.7
0.2
7.3
0.1
2.4

Buried
Buried
Buried
Buried
Buried

H-bond to Q321 and main chain W287

0.2

Other

H-bond network to N320 and T39
stop
no room for D side chain
H-bond to N263

7.0

Other

0.4
0.3

Buried
Other

No room for side chain

0.2

Buried

161

(36)
(12)
(19)
(35)
(51)
(36)
(19)
(22)
(44)
(26)
(34)
(36)
(55)
(36)
(13)
(33)
(36)
(35)
(34)
(38)
(28)
(30)
(28)
(50)
(31)
(11)
(35)
(55)
(23)
(22)
(43)
(13)
(34)
(29)
(13)
(28)
(62)
(17)
(19)
(26)
(11)
(23)
(12)
(36)
(35)
(27)
(43)
(31)
(63)
(13)
(64)
(19)
(36)
(13)
(36)
(48)
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Figure 7.1: Overview of the α-galactosidase A dimer
The α-galactosidase A polypeptide trace is shown with a rainbow from blue at the Nterminus to red at the C-terminus. This color scheme is repeated in Table 1. N-linked
carbohydrates are shown as bonds, and the galactose ligand is shown as spheres, marking
the active site in the first domain.
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Figure 7.2: The electrostatic surface of α-Galactosidase A
The α-galactosidase A dimer surface is shown colored by electrostatics as calculated by
the program CCP4mg. The dimer is colored by electrostatic potential, from -10 kBT/e
(red) to +10 kBT/e (blue), with the galactose ligand colored green and the N-linked
carbohydrates yellow. The overall dimer is markedly negatively charged, consistent with
a molecule that is most stable in the low pH of the lysosome.
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Figure 7.3: The α-galactosidase A active site and binding interactions
Top: The α-galactosidase A active site is shown with a galactose ligand (green) bound.
The surface indicates the complementary shapes of the protein and the ligand in the
active site. The residues in active site are labeled, and interactions between the protein
and the ligand are shown as dashed lines.
Bottom: The interactions between the protein and the α-galactose ligand are detailed. Red
dashed lines represent hydrogen bonds, and blue dashed lines represent van der Waals
interactions. Note that the protein makes contacts to every functional group on the
protein.
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Figure 7.4: The α-galactosidase A catalytic mechanism
α-Galactosidase A uses a double displacement reaction mechanism, where the substrate
undergoes two successive nucleophilic attacks on the same chiral carbon. First, D170
makes a nucleophilic attack on C1 of the substrate, breaking the glycosidic linkage and
generating a covalent intermediate. Second, a water molecule (deprotonated by D231)
makes a nucleophilic attack on the same carbon, breaking the covalent bond between the
enzyme and ligand and generating the product of the reaction, α-galactose. When the
product diffuses from the active site, the enzyme is ready for another cycle of catalysis.
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Figure 7.5: Fabry disease mutations and the α-galactosidase A protein
The α-galactosidase A dimer is shown as in ribbon form. Residues affected in the severe
form of Fabry disease are colored blue, and those affected in the variant phenotypes of
Fabry disease are colored yellow. Overall, more than half of the residues in the protein
have been implicated in Fabry disease. The residues affected in the variant phenotypes
tend to be more exposed than those found in the severe phenotype.
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THE CATALYTIC MECHANISM OF HUMAN α-GALACTOSIDASE
Guce, A.I., Clark, N.E., Salgado, E.N., Ivanen, D.R., Kulminskaya, A.A., Brumer 3rd , H.,
and Garman, S.C. 2010. J. Biol. Chem: 285: 3625-3632.
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The enzyme !-galactosidase (!-GAL, also known as !-GAL
A; E.C. 3.2.1.22) is responsible for the breakdown of !-galactosides in the lysosome. Defects in human !-GAL lead to the development of Fabry disease, a lysosomal storage disorder characterized by the buildup of !-galactosylated substrates in the
tissues. !-GAL is an active target of clinical research: there are
currently two treatment options for Fabry disease, recombinant
enzyme replacement therapy (approved in the United States in
2003) and pharmacological chaperone therapy (currently in
clinical trials). Previously, we have reported the structure of
human !-GAL, which revealed the overall structure of the
enzyme and established the locations of hundreds of mutations
that lead to the development of Fabry disease. Here, we describe
the catalytic mechanism of the enzyme derived from x-ray crystal structures of each of the four stages of the double displacement reaction mechanism. Use of a difluoro-!-galactopyranoside allowed trapping of a covalent intermediate. The ensemble
of structures reveals distortion of the ligand into a 1S3 skew (or
twist) boat conformation in the middle of the reaction cycle. The
high resolution structures of each step in the catalytic cycle will
allow for improved drug design efforts on !-GAL and other glycoside hydrolase family 27 enzymes by developing ligands that
specifically target different states of the catalytic cycle. Additionally, the structures revealed a second ligand-binding site
suitable for targeting by novel pharmacological chaperones.

The degradation of macromolecules, including glycopeptides and glycolipids, occurs in the lysosome via catabolic
enzymes. For example, glycosidases cleave the oligosaccharides from glycoproteins and glycolipids into smaller components used by the cell. One such lysosomal enzyme is !-galactosidase (!-GAL,3 also known as !-GAL A; E.C. 3.2.1.22),
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which catalyzes the removal of a terminal !-galactose residue
from polysaccharides, glycolipids, and glycopeptides (1). !GAL also has the ability to convert human blood group B to
blood group O (2, 3). The reaction catalyzed by !-GAL is shown
in Fig. 1A.
Defects in human !-GAL lead to Fabry disease, an X-linked
inherited disorder affecting 1 in every 40,000 males characterized by chronic pain, vascular degeneration, cardiac abnormalities, and other symptoms (1). The disease displays distinct phenotypes correlated with the amount of residual enzymatic
activity: a severe form affecting multiple organ systems including the eyes, liver, kidney, and heart; and a milder phenotype
with symptoms restricted to cardiac and/or renal abnormalities. The severe phenotype generally results from a complete
loss of enzymatic activity in affected individuals, whereas
patients with milder phenotypes typically show some residual
enzyme activity. The data base of independent Fabry disease
mutations now numbers in the hundreds, from thousands of
patients. Most Fabry disease patients have a single point mutation in their GLA gene coding for !-GAL, and over 400 missense and nonsense mutations have been identified in different
patients (4). Fabry disease is a lysosomal storage disorder, a
family of over 40 diseases characterized by the accumulation of
a substrate in the absence of a functional lysosomal enzyme.
The family includes inherited diseases such as Tay-Sachs, Sandhoff, and Gaucher diseases.
Lysosomal storage diseases are active subjects of clinical
research. In Gaucher disease (a defect in the lysosomal enzyme "-glucosidase), enzyme replacement therapy in pediatric patients successfully treats disease and is currently in use in
over 3500 patients from 55 countries (5). Gaucher disease was
the first lysosomal storage disease approved for treatment with
recombinant enzyme replacement therapy in 1994 (6), and
Fabry disease became the second in 2003 (7, 8). Because recombinant enzymes typically will not cross the blood-brain barrier,
enzyme replacement therapy is unsuitable for patients with
lysosomal storage disorders that manifest neurological symptoms (9), and pharmacological chaperone therapy has been
proposed instead. Fabry disease was the first lysosomal storage
disease to show the potential efficacy of pharmacological chaperone therapy, with two small molecule compounds, 1-deoxygalactonojirimycin (DGJ) (10, 11) and galactose (12), proposed
as pharmacological chaperones in Fabry patients.
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Human !-Galactosidase Catalytic Mechanism

EXPERIMENTAL PROCEDURES
Molecular Biology

FIGURE 1. !-GAL reaction and trapping stages for crystallographic analysis. A, double displacement reaction mechanism in human !-GAL. Asp-170
acts as the nucleophile, and Asp-231 acts as an acid and then a base over the
course of the reaction cycle. B, structures of the different stages in the catalytic cycle. Empty enzyme (blue) required a cryoprotectant sterically excluded
from the active site. The substrate-bound structure (green) resulted from
deletion of the active site nucleophile, followed by addition of a disaccharide
substrate. The covalent intermediate (yellow) used a difluoro-substituted galactoside to slow the second stage of the reaction. The product-bound structure (red) resulted from product inhibition of the enzyme. The color scheme is
maintained throughout.

!-GAL is an !-retaining enzyme, where both substrate and
product have anomeric carbons with ! configurations. The
mechanism of !-retaining glycosidases was originally proposed
by Koshland to be a double displacement reaction mechanism,
where two consecutive nucleophilic attacks on the anomeric
carbon lead to overall retention of the anomeric configuration
(13, 14). This reaction mechanism requires two carboxylates,
one acting as nucleophile and one acting as an acid/base (15).
The mechanism is proposed to go through oxocarbenium ionlike transition states at two stages in the cycle. In glycoside
hydrolases, addition of electronegative fluorine atoms to the 2
or 5 position of the hexoside slows the reaction, allowing for
trapping of a covalent intermediate (16). This strategy, combined with mutation of the acid/base carboxylate, helped clarify
the mechanism of lysozyme (17) after many years of study. In
glycoside hydrolase family 27 (GH27), which includes human
!-GAL and 395 other sequences (18), fluorinated substrates
have been used to map the catalytic nucleophile by mass spectrometry (19, 20). The identical catalytic mechanism is conserved across glycoside hydrolase clan D (21), which includes
1927 sequences in families 27, 31, and 36 (18).
Previously, we reported structures of human !-GAL at 3.25
and 3.45 Å resolution (22). Additionally, others have recently
determined three structures of partially deglycosylated human
!-GAL at resolutions of 2.2–3.0 Å (23). Taken as a group, the
five structures showed no significant changes in the protein
upon binding of ligands including galactose or the pharmaco-

Human !-GAL was expressed in Trichoplusia ni (Tn5) insect
cells. The wild-type GLA gene was subcloned by PCR from a
pOTB7 vector (OpenBiosystems) using Phusion DNA Polymerase (Finnzymes) with forward (5!-ACA ATG CAG CTG
AGG AAC CCA GAA CTA CAT-3!) and reverse (5!-TTA ATG
ATG ATG ATG ATG ATG AAG TAA GTC TTT TAA TGA
CAT-3!) primers. The purified PCR product was incubated at
72 °C for 15 min with Taq polymerase (New England Biolabs) to
add single 3!-deoxyadenosine overhangs for subsequent TOPO
TA cloning into a pIB/V5-His-TOPO vector (Invitrogen). The
resulting pIB/V5-His-TOPO-!-GAL construct contains the
wild-type !-GAL sequence (including the N-terminal signal
sequence) and a C-terminal His6 tag.
The D170A mutant was generated from the above wild-type
construct by site-directed mutagenesis using forward (5![PO4]CTG CTA AAA TTT GCT GGT TGT TAC TGT GAC
AG-3!, mutation in bold) and reverse (5!-[PO4]ATC TAC TCC
CCA GTC AGC AAA GGT CTG-3!) PCR primers and confirmed by sequencing.
Cell Transfection
Approximately 2.0 " 106 adherent Tn5 cells were transfected with a 2-ml mixture containing SFX-Insect medium
(Hyclone), 1.8 "g of plasmid DNA, and Hilymax (Dojindo
Labs). After 3 days, 100 "g/ml blasticidin in fresh SFX was
added to select for stable transfectants, and supernatants were
tested for protein expression. Stable adherent cells were resuspended in SFX medium for larger scale suspension cultures.
Protein Expression and Purification
Stable cells expressing D170A !-GAL mutant protein were
grown to 5– 6 " 106 cell/ml for 3 days. The supernatant was
concentrated and buffer exchanged with nickel binding buffer
(50 mM Na3PO4, 500 mM NaCl, and 20 mM imidazole, pH 7.0)
using a Prep/Scale tangential flow filtration cartridge (Millipore). Retentate was loaded onto a Ni2#-Sepharose 6 Fast Flow
column (GE Healthcare) and eluted with a gradient of 0 –50%
elution buffer (50 mM Na3PO4, 500 mM NaCl, and 1 M imidazole, pH 7.0). Fractions containing pure !-GAL, as determined
by SDS-PAGE analysis, were pooled, concentrated to 2.0 mg/ml
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logical chaperone DGJ. We used a combination of genetic engineering, microseeding techniques, and synthetic substrates to
improve the resolution of the crystals to 1.9 Å and to interrogate the catalytic mechanism of the enzyme. Here we report a
series of four new structures of the human !-GAL glycoprotein
representing each stage in the catalytic cycle (Fig. 1B). The
covalent intermediate stage shows a novel conformation of the
ligand in the active site, a distorted skew boat conformation of
the sugar. The structures reveal conformational changes in the
ligand over the course of the reaction cycle, suggesting novel
mechanism-based inhibitors. Additionally, the structures
reveal a second sugar-binding site distal from the active site,
which is ideal for targeting by a new class of pharmacological
chaperones.

Supplemental Material can be found at:
http://www.jbc.org/content/suppl/2009/12/17/M109.060145.DC1.html

Human !-Galactosidase Catalytic Mechanism
using a 10-kDa molecular mass cutoff spin concentrator (Sartorius), and stored in 10 mM Na3PO4 buffer, pH 6.5.
Kinetic Assays

Sugars and Sugar Analogues
TNP-2,2-di-F-!-Gal was prepared as described (14, 19).
Thioethyl-!-galactose was prepared from 2,3,4,6-tetraacetylthioethyl-!-D-galactose (Toronto Research Chemicals) by treatment with HCl for 1 h and neutralization with NaOH. Mass
spectrometry confirmed that the hydrolysis of the four acetyls
had run to completion. Galactose, lactose, and melibiose were
obtained from Sigma.
Crystallization and X-ray Data Collection
Empty, Intermediate, and Product—Crystals were grown as
described in Ref. 22, except that microseeding techniques
increased the size of the crystals from 100 to 400 "m in the
longest dimension, leading to much improved diffraction. Seed
crystals were grown in 25% PEG 4000, 200 mM (NH4)2SO4, and
100 mM NaCH3COO, pH 4.6 mixed 1:1 with 9 mg/ml !-GAL
stock. The crystals were crushed, diluted 1:100,000, and added
to a 1:1:1 mixture of crystallization buffer, protein stock, and
water. Crystals appeared in the seeded solution after a few days.
Crystals were harvested into buffer containing 30% PEG 4000,
200 mM (NH4)2SO4, and 100 mM NaCH3COO. Crystals were
then transferred to similar solutions supplemented with ligand:
15% !-lactose (empty structure), 20 mM TNP-2,2-di-F-!-Gal
(covalent intermediate), or 5% D-(")-galactose (productbound). For the covalent intermediate structure, salt concentrations were reduced to 100 mM (NH4)2SO4 and 50 mM
NaCH3COO, and 15% N-acetylglucosamine was used as a cryoprotectant. Five crystals were transferred into the TNP-2,2-diF-!-Gal solution; all but one shattered immediately after transfer. Ice rings limited the quality of the galactose-soaked crystal
diffraction data. After flash-cooling the crystals, diffraction
data were collected on a RU-H3R generator (Rigaku) and processed with HKL2000 (24). The P3221 crystals diffract anisotropically, with #1.9 Å resolution limits along the c axis and #2.8
Å diffraction limits in perpendicular directions; we limited the
overall resolution to 2.3 Å based upon I/#I criteria. The isotropic integration of the anisotropic diffraction data resulted in
poor merging statistics. The structures were phased by Fourier
synthesis using the 3.25 Å human !-GAL coordinates (PDB
code 1R46) (22).
Substrate—The crystals of Asp-170 !-GAL mutant were
obtained by hanging-drop vapor diffusion at 20 °C. Crystals
were obtained from a 1:1 mixture of reservoir solution

RESULTS
Overall Description of the Structures
Human !-GAL is a homodimer where each monomer has
two domains, an N-terminal ($/!)8 barrel containing the active
site and a C-terminal antiparallel $ domain. The homodimer
contains two active sites separated by 43 Å. Previous reports
have suggested cooperativity between the two active sites (with
a Hill coefficient of 1.9) (32), but the three-dimensional structures show no evidence for cooperativity within the dimer:
there are no substantial differences between the two monomers
in the asymmetric unit (root mean square deviation of 0.4 – 0.5
Å for 390 C! atoms), or among the four steps in the catalytic
cycle.
Stages in the Catalytic Cycle
We determined four crystal structures representing each
stage in the catalytic cycle of human !-GAL: the empty enzyme
at 2.3 Å, the substrate-bound enzyme at 1.9 Å, the covalent
intermediate at 2.3 Å, and the product-soaked enzyme at 2.3 Å.
Overall the four structures give a snapshot of the catalytic
mechanism of the enzyme at each stage. Crystallographic statistics are shown in Table 1. Omit map electron density of the
active site contents and interaction maps of the active sites
show that most protein:ligand interactions are conserved during the cycle (Fig. 2). Details of each stage in the cycle follow
below.
Empty Active Site—Determining the structure of the empty
enzyme was not straightforward. Using 20% glycerol or ethylene glycol as a cryoprotectant resulted in an active site containing bound cryoprotectant. The use of larger cryoprotectants
(glucose and lactose) that are sterically occluded from the active
site allowed for determination of the structure of the empty
enzyme.
The empty enzyme shows a collection of water molecules
that approximate the locations of the atoms in the galactose
ligand (Fig. 2A). Three waters reflect the positions of oxygens
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!-GAL hydrolysis of the synthetic substrate para-nitrophenyl-!-galactose (pNP-!-Gal) (Toronto Research Chemicals) at
37 °C was monitored by absorbance at 400 nm and an extinction coefficient of 18.1 mM!1 cm!1. 1 "g of enzyme in 100 mM
citrate/phosphate buffer pH 4.5 was added to 8 substrate concentrations of pNP-!-Gal from 0.1 to 50 mM. Every minute for
10 min, sample absorbance was measured after adding 200 mM
Na3BO3 buffer, pH 9.8. Statistics were calculated from triplicate
measurements. Km, Vmax, and kcat were calculated in KaleidaGraph from a weighted fit of Michaelis-Menten hyperbola.

(12% PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 22 mM
Mg(CH3COO)2) and 2.0 mg/ml protein in 10 mM Na3PO4, pH
6.5. Prior to freezing and data collection, crystals were transferred stepwise into reservoir solution with 100 mM melibiose
(Sigma), and then into a cryoprotectant solution (40% PEG 8K,
0.1 M sodium cacodylate pH 6.5, 22 mM Mg(CH3COO)2, 20%
ethylene glycol, and 100 mM melibiose). Crystals were flashcooled in liquid nitrogen, and x-ray data were collected at 100 K
at beamline X25 at the Brookhaven National Laboratory. X-ray
images were processed using HKL2000 (24) in space group
P212121 and phased by molecular replacement in AMoRe (25)
using the coordinates of the galactose-soaked crystal.
For all structures, atomic models were built using the program O (26), with refinement in REFMAC5 (25). Ramachandran plots were computed using PROCHECK (27). Coordinates
were superimposed using LSQMAN (28), and accessible surface areas were calculated in AREAIMOL (25). Molecular docking studies were performed in O (26) and in Pymol (29). Figures
were made in MolScript (30) and POVScript" (31). Coordinates and structure factors are deposited in the Protein Data
Bank under accession codes 3HG2, 3HG3, 3HG4, and 3HG5.
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TABLE 1
Crystallographic statistics
Active site:

Substrate

Intermediate

Product

Protein
Protein sequence
Space group
Cell lengths, Å
Cell angles, °

3HG2

3HG3

3HG4

3HG5

Wild type
P3221
90.8, 90.8, 217.2
90, 90, 120

D170A
P212121
59.5, 106.1, 181.7
90, 90, 90

Wild type
P3221
90.2, 90.2, 216.6
90, 90, 120

Wild type
P3221
90.8, 90.8, 217.2
90, 90, 120

X-ray data
X-ray source
Wavelength, Å
Resolution (last shell)
Observations
Unique observations
Completeness, % (last shell)
Multiplicity (last shell)
Rsym (last shell)a
I/#I (last shell)

Cu anode
1.54
50-2.3 (2.38-2.3)
637,404
45,612
97.2 (95.4)
14.0 (14.2)
0.115 (0.818)
25.5 (3.5)

BNL X25
1.0085
50-1.90 (1.97-1.9)
1,248,391
90,308
98.6 (88.4)
13.8 (9.9)
0.088 (0.755)
30.2 (3.1)

Cu anode
1.54
50-2.3 (2.38-2.3)
739,029
46,337
99.7 (100.0)
15.9 (16.0)
0.112 (0.944)
28.3 (3.4)

Cu anode
1.54
50-2.3 (2.38-2.3)
398,547
47,076
99.9 (100.0)
8.5 (8.4)
0.099 (0.989)
21.4 (2.3)

17.6/20.2
6767
6255
156
329
27
36.4

16.5/19.7
7539
6377
216
893
53
23.1

16.5/22.1
7251
6262
276
682
31
49.8

19.1/22.7
6694
6255
167
236
36
43.4

Refinement
Rwork/Rfree,b %
No. of atoms
Protein
Carbohydrate
Water
Other
Average B, Å2
Ramachandran Plotc
Favored (%)
Allowed (%)
Generous (%)
Forbidden (%)

a
b
c

RMS deviations
Bonds (Å)
Angles (°)

90.7
8.4
0.6
0.3

th

92.1
7.0
0.9
0.0

0.008
1.128

0.006
1.058

90.0
9.4
0.4
0.1
0.008
1.159

90.5
8.4
0.7
0.3
0.008
1.175

Rsym $ %h%i!Ih,i " #Ih&!/%h%i!Ih,i!, where Ih,i is the i intensity measurement of reflection h and #Ih& is the average intensity of that reflection.
Rwork, Rfree $ %h!FP " FC!/%h!FP!, where FC is the calculated and FP is the observed structure factor amplitude of reflection h for the working or free set, respectively.
Ramachandran statistics are calculated in PROCHECK.

O2 (0.92 Å away), O3 (0.27 Å), and O6 (0.21 Å) of the galactose,
and two waters reflect the positions of carbons C1 (0.51 Å away)
and C4 (1.1 Å) of the galactose.
Substrate-bound—To determine the structure of the substrate-bound crystal, we initially soaked a non-hydrolyzable
substrate analogue into the active site. In two different experiments, 25 mM thioethyl-!-D-galactose was added to the crystals; however the active site was unoccupied in each of those
experiments (data not shown). We modeled the thioethyl-!-Dgalactose structure based upon the thiomethyl-!-D-galactosyl
component of the antibiotic clindamycin (33), and the thioethyl
group had steric clashes with the protein residues in their normal location.
We then turned to engineering the protein to capture substrate-bound !-GAL. We made a mutant protein D170A, lacking the active site nucleophile, in insect cells. We performed
kinetic studies of wild-type and D170A mutant enzymes using
the synthetic substrate para-nitrophenyl-!-D-galactoside. The
wild-type enzyme had a Km of 8.3 ! 0.5 mM and a kcat of 63.5 !
0.1 s"1, (comparable to the two recombinant !-GALs used in
enzyme replacement therapy, Ref. 34) whereas the mutant
enzyme had no detectable activity (kcat # 0.1 s"1). We grew
crystals of the D170A mutant protein and soaked 100 mM melibiose (D-Gal-!1– 6-D-Glc) into the crystals. The electron density reveals that the melibiose substrate binds to the active site
(Fig. 2B) with the glucose portion of the substrate extending out
of the active site of the enzyme. The galactoside portion of the
melibiose substrate is in standard 4C1 chair conformation. As

expected for an enzyme with exquisite specificity for the terminal !-galactoside but little specificity beyond the glycosidic
linkage, the enzyme makes specific interactions with each functional group on the galactoside portion of the melibiose, but few
interactions with the glucoside portion of the disaccharide.
Interactions between the galactoside of melibiose and the protein are summarized in Fig. 2B.
Covalent Intermediate—To trap a covalent intermediate, we
used the synthetic substrate TNP-2,2-di-F-!-Gal (14, 19). The
fluoro substituents attached to the 2 position of the galactopyranose ring destabilize the two oxocarbenium ion-like transition states in the catalytic mechanism, but the excellent leaving
group TNP allows the first nucleophilic attack to proceed. The
second nucleophilic attack by a deprotonated water molecule is slowed considerably, allowing us to trap the intermediate (Fig. 3A). Cryogenic temperatures increased the lifetime
of the covalent complex, allowing collection of complete x-ray
data. Although fluoro sugars have been used in mass spectrometry experiments to identify the catalytic nucleophile of !-GAL
from Phanerochaete chrysosporium (19) and Coffea arabica
(20), this is the first three-dimensional structure of a covalent
complex in the family. The trapped fluoro intermediate is likely
to be identical in conformation to the natural intermediate, by
extension from studies on Drosophila melanogaster !-mannosidase II, where three covalent intermediates show the same
conformation independent of fluorine substitution (35).
The electron density for the covalent intermediate shows
clear connectivity between C1 of the ligand and O"2 of the
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FIGURE 2. Ligand density and interactions. A–D, first and second columns show side and top views of the electron density for the ligand in the four different
structures. The third column shows the interactions around the ligand in the active site, where red lines represent hydrogen bonds and blue lines represent van
der Waals interactions. Empty (A), substrate-bound (B), covalent intermediate (C), and product-bound structures (D) are shown, respectively. The electron
density corresponds to a #A-weighted 2Fo-Fc total omit map calculated in SFCHECK (25), contoured at 1.5# in A and 2.0# in B–D, with a cover radius drawn
around residues and/or waters in the active site.

catalytic nucleophile Asp-170 (Fig. 2C). The covalent intermediate is in a 1S3 skew (or twist) boat conformation. The conformation of the covalent intermediate is distorted from the
favored chair conformation of the sugar ring. The ligand is held

in this distorted conformation at one end by the covalent bond
between C1 of the ligand and O!2 of Asp-170 and at the other
end of the ligand by van der Waals interactions between Trp-47
and the 4-, 5-, and 6 carbons on the " face of the sugar (Fig. 3B).
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A Second Ligand-binding Site in
Human !-GAL
In our crystal soaks, we have discovered a second ligand-binding
site on the surface of the "-GAL
molecule, at the interface between
the two domains of the monomer.
FIGURE 3. Covalent intermediate and ligand deformation. A, reaction mechanism for the TNP-2,2-di-F-"-Gal In three of the four structures
substrate. The first step of the reaction remains fast because of the good leaving group, but the second step slows,
allowing for trapping of the covalent intermediate species. B–D, close-up views of the substrate-bound, covalent presented here, a monosaccharide
intermediate, and product-bound ligands. The catalytic nucleophile Asp-170, the catalytic acid/base Asp-231, and packs on the surface of Tyr-329
the conserved Trp-47 are labeled. The ligand conformation changes from4C1 to 1S3 to 4C1 geometry over the course and forms hydrogen bonds with
of the reaction. The modeled transition states in 4H3 half-chair conformations are shown in the insets.
Asp-255 and Lys-374. (In the fourth
structure, the D170A melibiose
soak, the disaccharide is sterically excluded from the second
binding site, and a PEG molecule is found there.)
The second ligand-binding site prefers the ! anomer of
galactose (Fig. 4). When D-galactose (approximately a 70:30
mixture of ! and " anomers) is added to the crystals, the primary binding site (the active site) binds only the " anomer, and
the secondary binding site binds only the ! anomer. The secondary binding site binds ligand when the crystals are soaked
with 15% lactose (empty active site), 100 mM melibiose (substrate bound in active site), or 20% galactose (product in active
site). Additionally, when 20% glucose is added to the crystals,
glucose binds in the second binding site (data not shown). The
second binding site uses the plane of Tyr-329 to pack against
the ! face of the monosaccharide, a common protein/carbohydrate interaction (38). Electron density in the second site is
likely a result of fortuitous binding in the presence of high concentrations of sugars used as cryoprotectants. The second binding site is comparable in size to the active site: there are 154 Å2
FIGURE 4. The second ligand-binding site in human !-GAL. The second of protein surface area buried when !-galactose binds to the
ligand-binding site is centered on Tyr-329, at the interface between domain 1
2
and domain 2 of the structure. A surface drawn around all the atoms reveals a protein at the second site, larger than the 107 Å of protein
pocket that is selective for !-galactose. The electron density from the galac- surface buried when "-galactose binds in the active site.
tose-soaked crystal shows a #A-weighted 2Fo-Fc total omit map calculated in
SFCHECK, contoured at 1.1# with a cover radius drawn around the ligand.
Residues Glu-251, Asp-255, Tyr-329, and Lys-374 are shown.

Product-bound—We determined the structure of the
product-bound crystal by soaking in the catalytic product
galactose. Although galactose solution contained a 70:30

DISCUSSION
In this report, we describe four structures of human "-GAL
with improved resolution, allowing us to examine the catalytic
mechanism of the enzyme in detail. The structures here represent the first member of GH27 with crystallographic evidence
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mixture of ! and " anomers of
galactose, the active site selects for
the " anomer only (Fig. 2D). This
selectivity is unique to the animal
kingdom enzymes in GH27, as differences in the active site residues
in the rice and Trichoderma reesei
"-GAL structures accommodate
both " and ! anomers of galactose
in the active site (36, 37). The
galactose in the product soak is
in a standard 4C1 conformation.
After the second nucleophilic attack
on the anomeric carbon, the ligand
reverts to a low energy conformation
from its distorted state in the covalent
intermediate structure.
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torting the substrate into 1S3 geometry, and the subsequent covalent intermediate adopts the low energy 4C1 conformation (42, 43).
This is the exact inverse of the !-GAL and !-glucosidase mechanisms (41), where the substrate has the 4C1 conformation and the
covalent intermediate has 1S3 geometry. On the Stoddart map of
pyranose ring interconversions (44), "-glucosidase and !-galactosidase travel the same path between 4C1 and 1S3 conformations,
but in opposite directions, reminiscent of the !- and "- retaining
mannosidases, which traverse a path between 1S5 and OS2 conformations in opposite directions (35).
Mechanism-based Inhibitors—Galactose and DGJ have
shown promise as pharmacological chaperones for treatment
of Fabry disease, but they are the catalytic product and a product analogue respectively. With pharmacological chaperones
for Fabry disease, in vitro inhibition correlates with intracellular !-GAL activity enhancement (10), so tighter binding compounds could be promising candidates for pharmacological
chaperone therapy. Imino sugars such as DGJ are generally not
good mimics of transition state geometry (45), but transition
state or covalent intermediate mimics might now be developed
from the human !-GAL structures reported here.
The carbohydrate conformations found in the !-GAL catalytic cycle suggest two new classes of inhibitors for human
!-GAL (and, by extension, the entire GH27 family). The first
class of inhibitors are analogues of the 1S3 skew boat covalent
intermediate. Whereas there are currently no inhibitors of
!-GAL with this configuration, other glycosidases have potent
inhibitors that mimic the covalent intermediate, such as the
Golgi !-mannosidase inhibitor mannostatin (46).
The second class of novel inhibitors suggested by our !-GAL
mechanistic studies are transition state analogues. We modeled
the conformation of the sugar ring during the two transition
states of the catalytic mechanism as 4H3 (half-chair) conformations (Fig. 3, insets). Thus, a new class of inhibitors for !-GAL
(and other related family 27 glycosidases) might adopt a 4H3
half-chair (or the closely related 4E envelope) conformation of
the ring. Transition state mimics have not been developed for
!-GAL, however, transition state analogues have been developed as selective inhibitors of mannosidases and other glycosidases (45, 47, 48).
The active site residues of GH27 members are highly conserved, so we predict that the two classes of mechanism-based
inhibitors above would be effective for all GH27 members and
potentially for the entire 1927 glycosidases in clan D. Given the
huge variety of catabolic and anabolic processes that use glycosidases (e.g. digestion, lysosomal degradation, ER-associated
degradation, and biosynthesis), potent inhibitors of glycosidases are valuable commercial and research products (49).
Inhibitors of clan D glycosidases would have broad applications, including, for example, modulating leaf development in
plants (50), seed germination in legumes (51), and substrate
reduction therapy in galactosemia (52).
In summary, we have discovered a second ligand-binding site
on human !-GAL that is suitable for binding by a novel pharmacological chaperone. Second, the structures described
herein open the door to designing a new family of mechanismbased inhibitors for the entire family and clan of glycosidases.
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for each step in the reaction mechanism. Given the strict conservation in the binding site residues within the GH27 family
and the conserved mechanism across clan D (14), the mechanistic studies presented here extend to the entire clan of over
1900 protein sequences. To demonstrate the mechanism, we
modeled the entire catalytic cycle of the enzyme, including the
conformational changes of the ligand over the course of the
reaction (supplemental Movie S1).
Pharmacological Chaperones—The discovery of a second
ligand-binding site on the !-GAL molecule leads to another
approach for pharmacological chaperoning for the treatment of
Fabry disease. Pharmacological chaperones bind to the folded conformation of a protein and help to stabilize it. The current generation of pharmacological chaperones for the treatment of Fabry
disease, including galactose and DGJ, are substrate and product
analogues that bind to the active site of the folded glycoprotein.
Because they bind to the active site, they act as competitive inhibitors as well as chaperones; thus they must depart from the active
site before the enzyme can hydrolyze substrate. An alternative
approach, as noted by the Petsko group (23), might capitalize upon
a pharmacological chaperone-binding site distal to the !-GAL
active site, which would stabilize the molecule without competitively inhibiting the enzyme. Here we report such a site. The second binding site has distinct substrate specificity from the active
site: when we soaked in a mixture of both the ! and the " anomers
of galactose, the ! anomer bound specifically at the active site and
the " anomer bound specifically at the second ligand-binding site.
Thus, we predict that a new class of pharmacological chaperones
can be directed to bind to the second ligand-binding site.
Ligand Geometry in Retaining Glycosidases—The conformational pathways of !-retaining enzymes represent something of
a paradox. For the pathways with known structures of covalent
intermediates, some (including GH29, GH31, GH38, and now
GH27) show distorted sugars in the covalent intermediate, but
others (such as GH13 and GH77) show distorted sugars in the
noncovalent substrate complex. For example, human !-Nacetylgalactosaminidase (GH27) has a strained 1S3 intermediate (39), Thermotoga maritima !-L-fucosidase (GH29) has a
strained 3S1 intermediate (40), Escherichia coli !-glucosidase
YicI (GH31) has a strained 1S3 intermediate (41), and Drosophila melanogaster Golgi !-mannosidase II (GH38) has a strained
1
S5 intermediate (35). However, the !-amylase family enzymes
Bacillus circulans cyclodextrin glucanotransferase (GH13) and
Thermus thermophilus amylomaltase (GH77) have covalent
intermediates in the low energy 4C1 conformation, but distort
the sugars in the noncovalent Michaelis complexes (42, 43).
The results presented here clarify the mechanisms of retaining
!-glycosidases. When coupled with the other glycosidases with
detailed structural information, some general rules emerge. First,
retaining enzymes need to align thesyn lone pair of the nucleophile
to attack the accessible side of the anomeric carbon opposite the
leaving group. In the !-retaining enzymes !-galactosidase, !-fucosidase, !-glucosidase, and !-mannosidase, little distortion in the
substrate is required to achieve the in-line attack of the nucleophile
(35, 40, 41). Second, the same sugar conformations can be used
very differently in glycosidase reaction mechanisms. For example,
in "-retaining glucosidases (and other "-retaining enzymes),
access to in-line attack of the anomeric carbon is achieved by dis-
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Role of Conserved Tyrosine Residues in NiSOD Catalysis: A Case of Convergent
Evolution†
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ABSTRACT:

Superoxide dismutases rely on protein structural elements to adjust the redox potential of the
metallocenter to an optimum value near 300 mV (vs NHE), to provide a source of protons for catalysis,
and to control the access of anions to the active site. These aspects of the catalytic mechanism are examined
herein for recombinant preparations of the nickel-dependent SOD (NiSOD) from Streptomyces coelicolor
and for a series of mutants that affect a key tyrosine residue, Tyr9 (Y9F-, Y62F-, Y9F/Y62F-, and D3ANiSOD). Structural aspects of the nickel sites are examined by a combination of EPR and X-ray absorption
spectroscopies, and by single-crystal X-ray diffraction at ∼1.9 Å resolution in the case of Y9F- and D3ANiSODs. The functional effects of the mutations are examined by kinetic studies employing pulse radiolytic
generation of O2- and by redox titrations. These studies reveal that although the structure of the nickel
center in NiSOD is unique, the ligand environment is designed to optimize the redox potential at 290 mV
and results in the oxidation of 50% of the nickel centers in the oxidized hexamer. Kinetic investigations
show that all of the mutant proteins have considerable activity. In the case of Y9F-NiSOD, the enzyme
exhibits saturation behavior that is not observed in wild-type (WT) NiSOD and suggests that release of
peroxide is inhibited. The crystal structure of Y9F-NiSOD reveals an anion binding site that is occupied
by either Cl- or Br- and is located close to but not within bonding distance of the nickel center. The
structure of D3A-NiSOD reveals that in addition to affecting the interaction between subunits, this mutation
repositions Tyr9 and leads to altered chemistry with peroxide. Comparisons with Mn(SOD) and Fe(SOD)
reveal that although different strategies for adjusting the redox potential and supply of protons are employed,
NiSOD has evolved a similar strategy for controlling the access of anions to the active site.

Superoxide dismutases (SODs)1 are enzymes that catalyze
the conversion of superoxide to molecular oxygen and
hydrogen peroxide (eqs 4-3) and are thus part of cellular
†
This work was supported by National Science Foundation Grants
MCB-0321482 and CHE-0809188 to M.J.M. S.C.G. acknowledges the
University of Massachusetts and the Charles H. Hood Foundation for
support. The U.S. Department of Energy, Division of Materials Sciences
and Division of Chemical Sciences, supported XAS and X-ray
diffraction data collection at the National Synchrotron Light Source
(NSLS) at Brookhaven National Laboratory. The National Institutes
of Health supports beamlines X3B and X6A at NSLS. Pulse radiolysis
studies were funded under Contract DE-AC02-98CH10886 with the
U.S. Department of Energy.
* To whom correspondence should be addressed. Phone: (413) 5454876. Fax: (413) 545-4490. E-mail: mmaroney@chemistry.umass.edu.
‡
Department of Chemistry, University of Massachusetts.
§
Brookhaven National Laboratory.
|
Department of Biochemistry and Molecular Biology, University
of Massachusetts.
1
Abbreviations: SOD, superoxide dismutase; XAS, X-ray absorption
spectroscopy; EPR, electron paramagnetic resonance; NHE, normal
hydrogen electrode; ROS, reactive oxygen species; PDTC, bis[pyridine2,6-bis(thiocarboxylate)]nickel(III); EXAFS, extended X-ray absorption
spectroscopy; XANES, X-ray absorption near edge structure; ICP-OES,
inductively coupled plasma optical emission spectroscopy; ESI-MS,
electrospray ionization mass spectrometry; DSC, differential scanning
calorimetry; Amp, ampicillin; Cam, chloramphenicol; OD, optical
density; FPLC, fast protein liquid chromatography; IPTG, isopropyl
β-D-1-thiogalactopyranoside; PDB, Protein Data Bank; PCR, polymerase chain reaction.

defenses against damage due to reactive oxygen species
(ROS) (1-4).
(n)

M

M(n+1) + O2•- f M(n) + O2 (1)
+ 2H+ + O2•- f M(n+1) + H2O2 (2)
2O2•- + 2H+ f O2 + H2O2 (3)

SODs utilize one-electron redox-active metal centers to carry
out catalysis. There are four known SODs categorized by
the metal present: (1) Cu/Zn, (2) Mn, (3) Fe, and (4) Ni.
These four SODs fall into three protein classes based on
amino acid sequence homology, with Fe and Mn in the same
class. In addition to having no sequence homology with other
SODs (5), NiSOD has other notable differences. Nickel is
the only metal found in a SOD where the aquated ion does
not react with O2- (1), presumably because the redox
potential of Ni(OH2)62+/3+ (>2 V) (6) lies outside of the
potentials for oxidation and reduction of O2-. In SODs, the
protein component serves at least three important functions
with regard to catalysis: to adjust the redox potential of the
metallocenter (7-10), to provide a source of protons (11, 12),
and to control the access of anions to the active site (13-16).
In NiSOD, the mechanism by which the protein tunes the
redox potential of nickel is also distinct from those of other
SODs in that it is the only metal center that employs cysteine
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to a role for Tyr9 in the mechanism for regulating anion
access that has many features in common with other SODs,
particularly MnSOD. Thus, NiSOD represents a fascinating
case of molecular convergent evolution.
EXPERIMENTAL PROCEDURES

FIGURE 1: Active site from one monomer of the homohexameric
NiSOD from S. coelicolor, showing the first nine residues and Tyr62
(17). The nickel is shown in the five-coordinate pyramidal oxidized
His-on form. PDB entry 1T6U. The image was generated with
PyMOL (75).

thiolate ligands (17-21), which at first glance would seem
to be incompatible with a catalytic center that produces
oxygen and peroxide (22-24).
Crystal structures of NiSOD reveal a five-coordinate
pyramidal site that is associated with an oxidized Ni(III)
center (Figure 1), and a four-coordinate planar site associated
with a reduced Ni(II) center (17, 21). The nickel ligands
derive from three amino acid residues: the N-terminal amino
group of His1, an amidate N-donor from Cys2, and side chain
thiolates from Cys2 and Cys6. The fifth ligand in the Ni(III)
site is provided by the imidazole side chain of His1 (Hison), which is unbound in the Ni(II) (His-off) site (17, 21).
There are four tyrosine residues in the amino acid sequence
of Streptomyces coelicolor NiSOD, two of which (Tyr9 and
Tyr62) are conserved in nearly all NiSODs (see the Supporting Information). Tyr9 is positioned near the vacant
coordination site opposite the His1 imidazole ligand in the
His-on structure (O-Ni distance of 5.47 Å) and is involved
in H-bonding with two ordered water molecules in the active
site, neither of which is a nickel ligand (O-Ni distances of
2.57 and 3.15 Å). These water molecules are also H-bonded
to amide protons from Cys6 and Asp3. The other conserved
tyrosine, Tyr62, is near Tyr9 and ∼13 Å from the nickel
center.
The SOD proteins supply protons for the production of
H2O2 and control access of anions to the active sites (7-10).
NiSOD lacks an aqua ligand that has been associated with
redox tuning and proton supply (8) in MnSOD and FeSOD,
but the thiolate ligands may serve an analogous role (25, 26).
Anion access is controlled in SODs using a combination of
size constraint (27), electrostatic steering (28-30), and, in
the cases of MnSOD (12, 31, 32) and FeSOD (15, 33), a
“gatekeeper” tyrosine and neighboring phenylalanine (27).
Herein, we probe the role of the conserved tyrosine residues
and the aspartate (Asp3) in the Ni hook domain for insights
into the NiSOD mechanism using a combination of mutagenesis to systematically perturb the tyrosine residues,
crystallographic and spectroscopic studies to assess the
structural ramifications of the mutations, and kinetics using
pulse radiolytic generation of superoxide to examine function.
The mutation of Tyr9 led to the serendipitous isolation and
the first crystallographic characterization of an anion complex
of NiSOD (Cl- and Br-). In addition to intersubunit
interactions, Asp3 also affects the position of Tyr9 in a way
that changes the function of the active site. The results point
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Molecular Biological Methods. The sodN gene from H15
(the native gene has a 14-amino acid leader sequence that is
cleaved in vivo, leaving H15 as the first amino acid after
post-translation modification) forward was cloned out of the
pET3a-SODN vector using PCR amplification with the
primers 5′-GGTATTGAGGGTCGCCACTGCGACCTGCCCTG-3′ (5′SODN15) and 5′-AGAGGAGAGTTAGAGCCCTTTGTTAGCAGCCGG-3′ (3′SODNU). The PCR product was purified from a 1% agarose gel. Treatment of the
PCR product with T4 DNA polymerase created overhangs
complementary to ligation independent cloning (LIC) vector
pET30 Xa/LIC (Novagen). The sodN gene was annealed into
the vector directly after the factor Xa recognition site (IEGR)
so that upon cleavage with factor Xa, H1 would be the
N-terminal residue. This 47-amino acid N-terminal extension
also contains a His tag used during purification to isolate
the fusion peptide (vide infra). The insert was annealed to
the vector, and NovaBlue (Novagen) competent cells were
transformed with the pET30 Xa/LIC plasmid containing the
sodN gene. The NovaBlue cells were plated on LB medium
containing 34 µg/mL kanamycin (kan) and grown overnight
at 37 °C. Plasmid mini preps (Qiagen) were performed after
single colonies were grown in 3 mL of LB kan medium
overnight. BL21(DE3) pLysS (Novagen) competent cells
were transformed with plasmid pET-30Xa/LIC-SODNH15
(pSODNH15) and were plated and grown overnight at 37
°C on LB medium containing kan and 30 µg/mL chloramphenicol (cam). Single colonies were grown overnight in 3
mL cultures (LB kan/cam) and diluted 1:100 in 100 mL of
fresh medium. Cells were grown at 37 °C to an OD at 600
nm of 0.6 and induced with isopropyl β-D-thiogalactoside
(IPTG), at a final concentration of 0.8 mM. After 3 h, the
cells were harvested via centrifugation, and SDS-PAGE was
conducted on cell extract to determine expression of the
target fusion protein. Plasmids producing proteins of the appropriate molecular mass (18 kDa) were submitted to the
University of Massachusetts DNA sequencing facility to
confirm the presence of the His-tagged wild-type (WT) gene.
Single colonies of cells containing the pSODNH15 plasmid
were grown in a 10 mL culture (LB cam/kan) overnight at
37 °C with shaking and then added to 1 L of prewarmed
fresh medium. Cultures were grown to an OD at 600 nm of
0.6 and induced (0.8 mM IPTG) for 3 h. Cells were harvested
by centrifugation, resuspended in 50 mL of Ni-NTA binding
buffer [10 mM imidazole, 50 mM sodium phosphate, and
300 mM sodium chloride (pH 8.0)] with 1 mM phenylmethanesulfonyl fluoride (PMSF), and frozen at -80 °C.
Cells were thawed, and 100 µL of a DNase I solution [10
mg/mL DNase I, 10 mM magnesium chloride, 20 mM Tris
(pH 7.5), and 40% glycerol] was added and the mixture
incubated at 37 °C until the viscosity of the solution was
significantly reduced. All chromatographic purifications
employed an AKTA-FPLC system (Amersham Biosciences).
The cell lysate was then loaded onto a column (Pharmacia
HR10) containing Ni-NTA His · Bind Superflow resin
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Table 1: Mutagenic Primers for Y62F- and Y9F/Y62F-NiSOD
mutant

forward primer

reverse primer

parental DNA

Y62F-NiSOD
Y9F/Y62F-NiSOD

5′-GCTGTGGAGCGACTTCTTCAAGCCCCCGC-3′
5′-GCTGTGGAGCGACTTCTTCAAGCCCCCGC-3′

5′-GCGGGGGCTTGAAGAAGTCGCTCCACAGC-3′
5′-GCGGGGGCTTGAAGAAGTCGCTCCACAGC-3′

WT-NiSOD
Y9F-NiSOD

(Novagen). Nonspecifically or weakly bound proteins were
removed by using a step gradient of 0 to 30% elute buffer
[250 mM imidazole, 50 mM sodium phosphate, and 300 mM
sodium chloride (pH 8.0)]. Following a wash step, the fusion
protein was eluted from the column with 100% elute buffer.
The eluted protein was then dialyzed into factor Xa buffer
[5 mM calcium chloride, 50 mM Tris, and 100 mM sodium
chloride (pH 8.0)] that contained 0.25 mM PMSF to prepare
the sample for N-terminal processing.
N-Terminal processing (required to remove the leader
sequence, which contains the His tag for purification) was
accomplished by cleaving the fusion protein at the IEGR
site using factor Xa. The cleavage reaction was performed
at 4 °C until the reaction was complete, as monitored by
SDS-PAGE. Subsequently, the reaction mixture was dialyzed against 20 mM Tris-HCl (pH 8.0) to remove excess
salt. Anion exchange chromatography (Pharmacia FPLCMono Q) using a 350 mM sodium chloride gradient over 10
column volumes at a slow flow rate of 0.5 mL/min gave
pure apo-NiSOD in the first fractions off the column, as
confirmed by the molecular weights of the products obtained
from ESI-MS (Table 3) and by Edman N-terminal peptide
sequencing (Midwest Analytical, Inc., St. Louis, MO). The
oligomeric state of the protein (hexamer) was confirmed by
size-exclusion chromatography and by ESI-MS under nondenaturing conditions (Supporting Information, vide infra).
Reconstitution of the recombinant, N-terminally processed
apo-NiSOD was achieved by addition of a 3-fold excess of
dithiothreitol (DTT) for 2 h in an anaerobic chamber (Coy
Laboratory Products Inc., Grass Lakes, MI) followed by
addition of a 5-fold excess of NiCl2. The properties of the
reconstituted enzyme were virtually identical to those previously reported for native enzymes (see Results).
D3A-NiSOD. The mutation of Asp3 to Ala was made by
PCR. The PCR used the WT-NiSOD gene along with
3′SODNU and the mutagenesis primer 5′-GGTATTGAGGGTCGCCACTGCGCGCTGCCCTGCGGCG-3′. The
PCR product was gel purified (2% agarose), and the gene
was ligated into the pET30 Xa/LIC vector and then transformed, overexpressed, purified, processed, and reconstituted
with nickel chloride (NiCl2) in the same manner as WTNiSOD (vide supra).
To probe the nature of a protein-based radical signal
observed in the product of the reaction of D3A-NiSOD with
H2O2, a sample of this mutant in which all four tyrosine
residues present were substituted with d4-Tyr was prepared.
Thus, all four aromatic protons are substituted with deuterons
in each Tyr residue. To incorporate d4-Tyr into D3A-NiSOD,
Escherichia coli BL21(DE3) pLysS cells were grown in LB
broth until they reached an OD at 600 nm of 0.6. The cells
were then spun down and resuspended in M9 medium
containing glyphosate (1 g/L), Trp, His, Phe, and d4-Tyr (0.5
g/L) and grown for an additional 30 min before being
induced with 1 mL of IPTG (200 mg/mL). Cells were grown
for an additional 3 h and then harvested. d4-Tyr-D3A-NiSOD
was purified and isolated as described above for WT-NiSOD.
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Y9F-NiSOD. The Y9F point mutation was introduced in
two steps. Two fragments were created in two different PCRs
(reactions A and B) using the WT gene. Reaction A utilized
the 5′SODN15 primer and 5′-GCGGCGTGTTCGACCCTGCCCAG-3′, while reaction B used the 3′SODNU primer
alongwith5′-GGCCGTCCAGGAGAAGCTGGCCGGCAACGACGACG-3′. The PCR fragments were gel purified (2%
agarose) and then combined with the 5′SODN15 and
3′SODNU primers in a third PCR to generate the NiSOD
gene with Tyr9 mutated to a Phe. The mutated gene was
ligated into the pET30 Xa/LIC vector as described for WTNiSOD (vide supra). The transformation, overexpression,
isolation, purification, and N-terminal processing of Y9FNiSOD were performed in the same manner described for
WT-NiSOD (vide supra).
Y62F- and Y9F/Y62F-NiSOD. Both Y62F- and Y9F/Y62FNiSOD were made using the QuikChange (Stratagene)
mutagenesis kit. Table 1 shows the primers and the parental
DNA that were used in the two PCRs. DNA isolated using
the Qiagen miniprep kit was sequenced at the W. M. Keck
DNA facility (Yale University, New Haven, CT) to ensure
that the correct mutation was present. Transformation,
induction, protein purification, and N-terminal processing
were preformed as described above for WT-NiSOD. The
protein product was confirmed by the molecular weight of
the fusion protein determined using ESI-MS (Table 3, vide
infra).
Quaternary Structure and Stability. The oligomeric states
as well as the stabilities of WT and mutant NiSODs were
determined by a combination of three techniques: sizeexclusion chromatography, ESI-MS under nondenaturing
conditions, and differential scanning calorimetry (DSC). Sizeexclusion chromatography employed solutions of WTNiSOD or mutant NiSODs that were applied to a HiLoad
16/60 Superdex 200 (GE lifesciences) column. The column
was standardized with albumin (67 kDa), ovalbumin (43
kDa), chymotrypsinogen (25 kDa), and ribonuclease A (13.7
kDa). All reconstituted NiSOD samples eluted with molecular weights appropriate for homohexamers. To determine
the MW of the expression products, ESI-MS was performed
using a Bruker Esquire mass spectrometer on solutions of
denatured proteins in an aqueous ammonium acetate solution
(final concentration of 5 mM) with 3% acetic acid and 50%
MeOH. To confirm the oligomeric state of the enzyme, ESIMS was also performed on a JMS-700 MStation magnetic
sector (double focusing) mass spectrometer under “nondenaturing conditions”. To prevent oligomeric breakdown, the
orifice voltage was turned to 0 V and the skimmer voltage
was set to 120 V. A solution of 60 µM NiSOD monomer
dissolved in 10 mM ammonium acetate solution was used.
Under these conditions, WT-NiSOD exhibits peaks characteristic of the hexameric holoprotein and little else (see the
Supporting Information).
Differential scanning calorimetry thermograms were measured with a Microcal VP-DSC with 0.5 mL of sample and
reference cells. NiSOD samples were concentrated to 2-5

Structure and Function of NiSOD

Biochemistry, Vol. 48, No. 15, 2009 3357

Table 2: NiSOD Mutant Data Collection and Refinement Statistics
in house

synchrotron

Y9F (Cl) [3G4X]a

NiSOD mutant

Y9F (Cl) [3G4Z]

Y9F (Br)

D3A [3G50]

0.9184
(1.94-1.87)
59.99, 112.46, 110.96
127478
29651 (2757)
4.3 (3.2)
94.2 (89.1)
0.038 (0.732)
28.5 (1.6)

21.57-1.90 (1.97-1.90)
59.99, 112.27, 111.70
238695
29881 (2929)
8.0 (7.2)
99.9 (99.9)
0.046 (0.929)
41.6 (2.3)

Data Collection
wavelength (Å)
resolution (last shell) (Å)
cell parameters (C2221) a, b, c (Å)
no. of observations
no. of unique observations (last shell)
multiplicity (last shell)
completeness (%) (last shell)
Rsym (last shell)
I/σI (last shell)

1.5418
50-2.01 (50-2.02)
60.09, 112.57, 111.87
118668
25413 (2175)
4.7 (4.4)
99.4 (97.8)
0.054 (0.515)
28.0 (3.1)

Rwork/Rfree (%)
average B-factor (Å2)
no. of atoms
no. of waters

16.8/23.7
26.8
3213
389

20.9-1.87 (1.94-1.87)
59.87, 111.58, 111.55
211352
29628 (2765)
7.1 (5.7)
95.3 (91.0)
0.030 (0.337)
42.1 (3.0)
Refinement

a

18.3/25.4
30.7
3249
458

18.6/24.0
38.0
3058
291

PDB codes listed in [].

Table 3: Analytical Data for WT-NiSOD and Its Mutants
NiSOD
sample

ESI-MS MWa
(calcd value)

no. of
kinetics,e kcalc × 108 M-1 s-1 E1/2 (mV vs NHE)
Ni atoms
at pH 7.5 [range of O2reductive oxidative
per protein EPR as isolated [% Ni(III)]
concentrations (µM)]
titration titration Tm (°C)

quaternary
structured

WT

18171.2b (18169.6) hexamer

0.88

D3A

1.11

Y9F

13160.9c (13157.0) hexamer with
decreased stability
13183.4c (13185.0) hexamer

Y62F

18154.1b (18153.3) hexamer

0.90

b

Y9F Y62F 18137.5 (18137.2) hexamer

0.72

0.74

g ) 2.30, 2.23, 2.01;
Azz ) 24.9 G [51(2)]
g ) 2.30, 2.24, 2.01;
Azz ) 24.9 G [48(2)]
g ) 2.30, 2.23, 2.01;
Azz ) 24.9 G [53(2)]
g ) 2.30, 2.23, 2.01;
Azz ) 24.9 G [48(2)]
g ) 2.30, 2.23, 2.01;
Azz ) 24.4 G [46(2)]

7.07 (1.93-5.97)

290(4)

279(6)

84.8

2.09 (1.68-5.99)

308(3)

290(7)

73.9

3.71 (1.54-2.38)

297(5)

299(8)

86.3

6.42 (2.09-9.8])

ND

ND

82.4

2.41 (2.18-4.12)

ND

ND

74.7

a

ESI-MS measurements were conducted under denaturing conditions resulting in monomer MW values of processed NiSOD or fusion peptide.
Fusion peptide. c Processed NiSOD. d From size-exclusion chromatography and/or ESI-MS under nondenaturing conditions (see Experimenta
Procedures). e Rates determined under first-order conditions; kcalc ) kobs/[Ni], where [Ni] ) 2 µM. The value of kcalc was determined by averaging the
values over the range of O2- concentrations where there is no apparent decrease in kobs.

b

was set to 20 mW with a frequency of 9.46 GHz. To
determine the number of Ni(III) centers present in each
mutant NiSOD, spin integration was performed on each EPR
spectrum. The concentration of Ni in each sample was
determined using ICP-OES (λ ) 231.604 nm) on a PerkinElmer Optima 4300 DV instrument. The resulting EPR
spectra were then integrated twice and compared to a spin
standard with a known concentration, bis[pyridine-2,6bis(thiocarboxylate)]nickel(III) (NiPDTC) (34), to determine
the percentage of Ni centers that were in the oxidized state
(Table 3).
Redox Titrations. A modification of the procedure of Reiter
et al. was used to determine the E1/2 values of WT-NiSOD
and the various mutants (35). Solutions of NiSOD (3 mL,
100-200 µM) were prepared in 100 mM potassium phosphate buffer (pH 7.5) with 100 mM potassium chloride as a
supporting electrolyte. Samples were degassed and kept
under argon throughout the experiment. Electrochemical
potentials were monitored with an Extech Instruments True
rms digital multimeter connected to a platinum wire and a
Ag/AgCl reference electrode. Optical spectra were monitored
on a Hewlett-Packard 8452A diode array spectrophotometer
equipped with a thermostated cell holder that held all samples
at 25 °C.
Prior to the experiment, the samples were treated with
KMnO4 (3 µL aliquots of a 6 mM aqueous solution) until
the absorbance at 380 nm was at a maximum, ensuring the

Table 4: XANES Analysis of Dithionite-Reduced WT-NiSOD and
Mutant Enzymes
sample
WT
Y9F
Y62F
Y9F/Y62F
D3A

edge energy 1s f 3d peak
(eV)
area (×10-2 eV)
8340.5(2)
8339.5(2)
8339.3(2)
8340.0(2)
8342.0(2)

4.7(5)
5(2)
3.2(4)
5.8(5)
4.5(5)

geometry
planar, CN ) 4
planar, CN ) 4
planar, CN ) 4
SPY, CN ) 5
planar, CN ) 4

ref
47
this
this
this
this

work
work
work
work

µM hexamer (Y62F- and Y9F/Y62F-NiSOD) or 100-140
µM in hexamer (WT-, D3A-, Y9F-NiSOD) in buffer [50 mM
Tris-HCl (pH 8.0)], degassed under vacuum, and added via
syringe to the sample and reference cells. Spectra were
collected at 30 psi between 6 and 100 °C at a scan rate of
30 °C/h. Baseline correction and normalization were performed with the Microcal interface to the Origin graphing
program. Peak maxima were taken as melting temperatures,
Tm. The values of Tm obtained are listed in Table 3, and
thermograms are included as Supporting Information.
Electron Paramagnetic Resonance (EPR). X-Band EPR
spectra were recorded on a Bruker ELEXSYS E-500 X-band
spectrometer. Samples in polycarbonate XAS holders were
inserted into a liquid N2 finger dewar. The data were collected
over a 1000 G field centered at 3000 G. The modulation
receiver and signal-channel parameters were as follows:
modulation frequency of 100 kHz, modulation amplitude of
10 G, and time constant of 327 ms. The microwave power
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enzyme was in its most oxidized form. Reductive titrations
were performed by adding aliquots (1-5 µL) of reduced
methylviologen [6 mM, electrochemically prepared with a
Bioanalytical Systems (BAS) CV50W instrument using a
BAS bulk electrolysis cell under argon; concentration was
confirmed by measuring the absorption of the MV+ solution
at 606 nm, ε ) 13700 cm-1 M-1 (36)] via a Hamilton
gastight syringe. After complete reduction, the oxidative
titrations were performed in a similar manner by the addition
of small aliquots (1-5 µL) from a 6 mM KMnO4 stock
solution (degassed).
The data were plotted as absorbance (at 378 nm) versus
potential (converted to NHE) and fit to eq 4, which was
derived from the Nernst equation by the method of Bernhardt
et al. (37)
absorbance )

Aox × 10n(E-E◦)/59 + Ared

(4)
1 + 10n(E-E◦)/59
where Aox is the absorbance of the solution when all the
species are in the oxidized form, Ared is the absorbance of
the solution when all the species are present in the reduced
form, n is the number of electrons being transferred during
the reaction, and E° is the midpoint potential of the redox
reaction. To obtain the reported E° values for NiSOD
samples, n was fixed at 1.0 and the other three parameters
were allowed to vary.
X-ray Absorption Spectroscopy. X-ray absorption spectroscopy (XAS) data collection and analysis were performed
as previously described (38). Ni K-edge XAS data were
collected on beamline X9B at the National Synchrotron Light
Source (Brookhaven National Laboratory). Samples of frozen
protein solutions [1-3 mM, based on Ni content, in 20 mM
Tris-HCl (pH 8.0)] were placed in polycarbonate holders
inserted into aluminum blocks and held near 50 K using a
He displex cryostat. The ring conditions for data collection
were 2.8 GeV and 120-300 mA. A sagittally focusing
Si(111) double-crystal monochromator and a 13-channel Ge
fluorescence detector (Canberra) were used for data collection. X-ray absorption near-edge spectroscopy (XANES) data
was collected from -200 to 200 eV relative to the Ni edge.
The edge energy reported was taken to be the maximum of
the first derivative of the XANES spectrum. Extended X-ray
absorption fine structure (EXAFS) was collected to 9307 eV
(k ) 16 Å-1). The X-ray energy for the K-edge of Ni was
internally calibrated to 8331.6 eV using transmission data
from a Ni foil. The data shown are the average of four to
eight scans and were analyzed using EXAFS123 for XANES
data (39), and SixPack was used for EXAFS analysis (40).
Scattering parameters for EXAFS fitting were generated
using FEFF 8 (41). SixPack builds on the ifeffit engine (41, 42)
and uses iterative FEFF calculations to fit EXAFS data during
model refinement and is thus an improvement over previous
methods that employ a static set of calculated scattering
parameters. To compare different models to the same data
set, ifeffit uses three goodness of fit parameters, χ2, reduced
χ2, and the R-factor. χ2 is given by eq 5
χ2 )

Nidp N
{[Re(fi)]2 + [Im(fi)]2}
Nε2 ∑
i)1

(5)

where Nidp is the number of independent data points, Nε2 is
the number of uncertainties to minimize, Re(fi) is the real
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part of the EXAFS fitting function, and Im(fi) is the
imaginary part of the EXAFS fitting function. Reduced χ2
) χ2/(Nind - Nvarys) (where Nvarys is the the number of refining
parameters) and represents the degrees of freedom in the fit.
Ifeffit also calculates the R-factor for the fit, which is given
by eq 6 and is scaled to the magnitude of the data, making
it proportional to χ2.
N

R)

∑ {[Re(fi)]2 + [Im(fi)]2}
i)1

N

∑ {[Re(x̃datai)]2 + [Im(x̃datai)]2}

(6)

i)1

To compare different models (fits), the R-factor and
reduced χ2 parameters can be assessed to determine which
model is the best fit, in which case both parameters should
be minimized. Although the R-factor will always improve
with an increasing number of adjustable parameters, reduced
χ2 will go through a minimum and then increase, indicating
that the model is over fitting the data.
Crystallography. Crystallization experiments were performed using the hanging-drop vapor-diffusion method. All
crystals grew after 2-3 weeks at 20 °C. Crystals of Y9FNiSOD (Cl) were obtained by mixing 1 µL of the reservoir
solution [0.05 M CaCl2, 0.1 M Bis-Tris (pH 6.5 with HCl),
and 25% (v/v) PEG MME (Fluka) 550] with 1 µL of a
protein solution at 8.0 mg/mL in a buffer of 50 mM TrisHCl (pH 8.0). Prior to being frozen and data collection, the
crystals were transferred stepwise into a cryoprotectant
solution containing 40% (v/v) PEG MME (Fluka) 550, 0.05
M CaCl2, and 0.1 M Bis-Tris (pH 6.5 with HCl).
To produce crystals of Y9F-NiSOD (Br) with bromide in
place of chloride, the protein was exchanged into a buffer
solution containing 50 mM Tris-HBr (pH 8.0). Crystals of
Y9F-NiSOD (Br) were obtained by mixing 1 µL of the
reservoir solution [0.1 M Bis-Tris (pH 6.5 with HBr) and
30% (v/v) PEG MME (Fluka) 550] with 1 µL of a protein
solution at 8.0 mg/mL. Prior to being frozen and data
collection, the crystals were transferred stepwise into a
cryoprotectant solution containing 40% (v/v) PEG MME
(Fluka) 550 and 0.1 M Bis-Tris (pH 6.5 with HBr).
Crystals of D3A-NiSOD were obtained by mixing 1 µL
of the reservoir solution [0.05 M MgCl2, 0.1 M HEPES (pH
7.5), and 30% (v/v) PEG MME (Fluka) 550] with 1 µL of
a protein solution at 8.2 mg/mL in 50 mM Tris-HCl (pH
8.0). Prior to being frozen and data collection, the crystals
were transferred stepwise into a final cryoprotectant solution
containing 40% (v/v) PEG MME (Fluka) 550, 0.5 M MgCl2,
and 0.1 M Bis-Tris (pH 6.5).
Crystals were frozen in liquid nitrogen and then transferred
into a gaseous nitrogen stream at 100 K for X-ray data
collection. Data collection was performed at National
Synchrotron Light Source (NSLS) beamline X6A at the
Brookhaven National Laboratory. All data were collected at
13500 eV (0.9184 Å), which is above the Br absorption edge
energy. Each frame consisted of 0.75° rotation taken for
exposures of 5 s [for Y9F (Cl-) and Y9F (Br-)] or 15 s (for
D3A). X-ray images were integrated, indexed, and scaled
using HKL2000 (43). The diffraction data were scaled in
space group C2221, leading to a solvent content of 47% and
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three subunits in the asymmetric unit. Data collection and
refinement statistics are given in Table 2.
Molecular replacement calculations were performed in the
CCP4 program MolRep (44) using a trimeric search model
derived from the native NiSOD structure (PDB entry 1T6Q)
(1). The starting model for manual building was the native
structure with the first 10 amino acids and the solvent
molecules omitted. Rigid body refinement and positional
refinement with 3-fold noncrystallographic symmetry (NCS)
imposed were performed using the CCP4 program Refmac5
(44), and 2Fo - Fc and Fo - Fc electron density maps
showed substantial density representing the omitted parts of
the model. The entire model, including the 10 N-terminal
amino acids, was built into the electron density using the O
graphics program (45). Weighted 2Fo - Fc and Fo - Fc maps
were examined at each stage of the refinement. In later
rounds of refinement, heteroatoms, such as the Ni2+/3+, Cl-,
and Br- ions, were assigned to electron density peaks. The
experimental electron density was of very high quality except
for that of the seven N-terminal residues, where 3-fold
averaging was imposed to aid in map interpretation. The final
statistics for the model are presented in Table 2. To determine
if the electron density near the Ni in the Y9F-NiSOD
structure was Cl- or water, crystals were grown using Brinstead of Cl-. After the determination that the Cl- was
replaced with Br-, the Y9F (Br) structure was not fully
refined because the Y9F (Cl) data were of better quality.
The quality of the model was assessed with PROCHECK
(46).
Kinetics. The kinetics of superoxide dismutation was
examined using pulse radiolytic generation of superoxide and
was carried out at Brookhaven National Laboratory as
previously described (47). Samples of NiSOD (final concentration of 2 µM, based on the Ni concentration) were
placed into a 2 cm cuvette that contained phosphate buffer
(10 mM), formate (30 mM), and ethylenediaminetetraacetic
acid (EDTA, 5 µM). The sample was then pulsed from a
2.0 MeV van de Graaff accelerator, varying the pulse width
(100-2000 ns), resulting in a range of initial superoxide
concentrations (2-40 µM). The disappearance of the absorbance at 260 nm that corresponds to O2- was fit to a firstorder process (Figure 7 of the Supporting Information).
Catalytic rate constants were determined by dividing the firstorder rate by the nickel concentration, assuming all of the
nickel is bound and active in the enzyme. The rate of O2disappearance in the absence of NiSOD was measured for
the O2- concentrations and pHs used and was, in all cases,
at least 1 order of magnitude slower than the enzymatically
driven rate. The rate constants are reported on a per Ni basis
as determined by the Ni content of each sample. Nickel
content was determined by ICP-OES using the Ni wavelength
of 231.604 nm.
Reactions with H2O2. Both WT- and D3A-NiSOD in 20
mM Tris-HCl (pH 8) were treated anaerobically with a 10fold excess of H2O2 at room temperature. The peroxide
concentration was determined by titration with a standard
solution of potassium permanganate (48). After 10 min, the
peroxide was buffer exchanged using spin concentrators
(Vivaspin, 5K MW cutoff) and five 1:10 dilutions with
buffer. The resulting enzyme solutions were examined by
pulse radiolysis to determine if any activity was lost. A
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portion of each solution was set aside for MW determination
by ESI-MS to determine if oxygen incorporation had
occurred.
RESULTS
Protein Characterization. Data regarding the molecular
weight of expressed protein, the quaternary structure, the Tm,
and the Ni content following reconstitution of recombinant
proteins are summarized in Table 3. All of the recombinant
proteins had the MW expected for the amino acid substitutions involved, and all were present largely as homohexamers
following reconstitution with NiCl2. In the case of D3ANiSOD, a significant amount of monomeric protein was also
observed in the nondenaturing mass spectrum (see the
Supporting Information); however, this was not observed by
size-exclusion chromatography, indicating that the protein
is not completely stable to the ESI-MS conditions. These
results are consistent with the lower Tm value obtained from
DSC analysis (Table 3). WT and Y9F had high thermal
stabilities with Tm values of 84.8 and 86.3 °C, respectively,
whereas D3A had a lower thermal stability (Tm ) 73.9 °C),
which may be attributed to weaker interactions between
subunits in the hexamer (vide infra).
Electron Paramagnetic Resonance. EPR spectroscopy was
used to examine the redox state of the nickel center in the
resting enzymes and probe the electronic structure of the
Ni(III) site in mutant NiSODs. The EPR data show that the
Ni(III) center present in all the mutants is similar to that of
WT-NiSOD. As isolated, native NiSOD has a distinctive
rhombic EPR spectrum that arises from a five-coordinate,
low-spin, S ) 1/2 Ni(III) center, with the unpaired electron
in dz2. X-Band EPR spectra of the WT recombinant NiSOD,
tyrosine mutants (Y9F, Y62F, and Y9F/Y62F) and D3A
(Table 3) also exhibit typical rhombic Ni(III) signals with
strong N-hyperfine splittings on the gz feature (Az ) 24.9
G) arising from the apical imidazole bound to the Ni(III)
center (47, 49). The electronic structure of the Ni(III) center
was not expected to be greatly perturbed by mutations in
the second coordination sphere, and this was confirmed by
the spectra obtained (Table 3). When Tyr9 is mutated to Phe,
subtle hyperfine structure on the gy feature that is not resolved
in the spectrum of WT-NiSOD is observed (Supporting
Information).
Careful integration of the Ni(III) signal in WT-NiSOD
indicates that the EPR signal accounts for only half of the
nickel present in the samples (Table 3). All samples were
approximately 50:50 Ni(III):Ni(II). Excess potassium permanganate or hexachloroiridate was used in attempts to
oxidize the remaining Ni(II) centers in as-isolated WTNiSOD. In both cases, no additional oxidation was seen.
These results do not coincide with a previous report in which
excess ferricyanide was used to reach a maximum level of
oxidation of 72% Ni(III) in WT-NiSO (17). However, it
should be noted that both permanganate and hexachloroiridate are stronger oxidants than ferricyanide, which has a
redox potential (360 mV) that is barely above the midpoint
potential of the enzyme.
In summary, the EPR results from the nickel center are
consistent with a resting oxidized state that contains 50%
Ni(III) and 50% Ni(II), which is not significantly perturbed
by mutation of Tyr9 or Asp3.

3360

Herbst et al.

Biochemistry, Vol. 48, No. 15, 2009

Table 5: EXAFS Analysis for Dithionite-Reduced NiSOD Samples
sample
WT

a

N

2N
2S
b
WT
2N
2S
2C
2C
Y9F
2N
1S
1S
2C
Y62F
1N
1N
2S
3C
2C
D3A
3N
2S
2C
Y9F/Y62F 2N
1S
1S
2C

R (Å)
1.91(1)
2.160(4)
1.83(4)
2.16(2)
2.73(4)
2.90(5)
1.95(2)
2.23(2)
2.52(3)
3.00(4)
1.90(3)
2.2(2)
2.17(3)
2.85(3)
3.03(4)
2.08(2)
2.13(1)
2.95(6)
2.02(6)
2.20(2)
2.46(4)
3.02(5)

σ2 (×103 Å-2) ∆E° (eV) reduced χ2 R-factor
1(2)
0(4)
10(4)
7(1)
3(5)

-3.4
-3.2
-17(3)

N/A

0.64c

22.8

0.11

5(2)
3(1)
6(4)
4(4)
5(4)

-7(2)

22.2

0.06

-10(2)

11.2

0.04

-7(1)

9.04

0.04

-5(3)

14.7

0.09

5(2)
2(2)
2.3(9)
8(3)
12(8)
12(6)
2(1)
6(3)
6(6)

a
WT reduced NiSOD from ref 48. b WT reduced NiSOD from this
work and fit using SixPack. c GOF parameter calculated by EXAFS123
(39).

X-ray Absorption Spectroscopy. XAS studies were used
to confirm that the nickel center was bound to the correct
protein site in the reconstituted WT protein and to characterize the nickel site in the mutant NiSODs, as well as to
supplement the results of the crystallographic investigations
of the nickel sites in Y9F-NiSOD and D3A-NiSOD and
allow comparisons with other mutants. Since the oxidized
enzymes always contain a mixture of oxidized and reduced
nickel centers, the samples studied were all reduced with
sodium dithionite prior to XAS data collection and were EPR
silent. The results for the XAS experiments on the tyrosine
mutants of NiSOD are summarized in Tables 4 and Tables
5 and Figure 2.
XANES. XANES (X-ray absorption near edge structure)
yields information about the coordination number and
geometry of the nickel site. Nickel has vacancies in the 3d
manifold, which give rise to transitions in the XANES region
of the XAS spectrum that are dependent on the geometry
and coordination number of the metal site. These transitions
include the 1s f 3d and 1s f 4pz (plus shakedown
contributions), which occur near 8331 and 8336 eV, respectively, in Ni(II) complexes (50). In WT-NiSOD and in the
mutant NiSODs, both transitions are observed, which
indicates either a square planar or five-coordinate pyramidal
nickel center geometry (50). The peak areas of the 1s f 3d
transition (Table 4) lie on the line between four-coordinate
planar species (0-0.04 eV) and five-coordinate pyramidal
species (0.04-0.09 eV) and indicate the sites that are most
likely distorted four-coordinate planar in nature, consistent
with what was previously reported for native Streptomyces
seoulensis reduced NiSOD (47). The edge energies observed
for the reduced species compare well with those of the native
S. seoulensis enzyme.
EXAFS. The EXAFS (extended X-ray absorption fine
structure) region of the XAS spectrum provides information
regarding the type of scattering atoms present and their
distance from the central metal ion. Table 5 and Figure 2
compare the best fits obtained for WT-NiSOD and mutant
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FIGURE 2: Comparison of XAS data for tyrosine mutant NiSODs:
WT (yellow), Y9F (blue), Y62F (purple), Y9F/Y62F (red), and D3A
(green). The main panels show normalized XANES spectra. The
insets show unfiltered EXAFS data in solid colored lines and fits
(black) from Table 5. The range of the k space fits is 2-12.5 Å-1
for all data.
Table 6: Redox Potentials
sample

E° (mV) (vs NHE)

Aox

Ared

Na

WT, reduction
WT, oxidation
D3A, reduction
D3A, oxidation
Y9F, reduction
Y9F, oxidation

290(4)
279(6)
308(3)
290(7)
297(5)
299(8)

0.76(1)
0.91(2)
0.815(9)
0.91(3)
0.54(2)
1.12(9)

0.19(1)
0.16(5)
0.24(1)
0.16(6)
0.15(2)
0.06(6)

1
1
1
1
1
1

a
N is the number of electrons per Ni(III) center. This value was held
constant in fitting the absorption data to obtain E°.

NiSODs. To evaluate the change in fitting method, we
collected data for reduced WT-NiSOD and compared them
to previously published data (47). The fit is quite similar
except that the Ni-N bond length is ∼0.08 Å shorter than
previously found. However, prior model studies indicate that
it can be difficult to obtain a distance with low error for
N-scattering atoms in a complex where the EXAFS is
dominated by scattering from S atoms (50). The new fits
include atoms in the second coordination sphere, which are
main chain carbon atoms from His1 and Cys2 as well as the
β-carbon from Cys2 as seen in the two crystal structures of
NiSOD (17, 21). These atoms are rigidly positioned by
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chelate rings, and their inclusion improves the fits. The single
mutation, Y9F-NiSOD, alters the structure around the Ni
center. The best fit for Y9F-NiSOD contains two shells of
sulfur donors at different distances. The first sulfur donor
lies at 2.23 Å, while the other sulfur ligand is longer and
lies at 2.52 Å. This splitting of the two sulfur ligands into
two distances is also seen in the double mutation Y9F/Y62FNiSOD, which has a fit similar to that of Y9F-NiSOD (Table
5). D3A- and Y62F-NiSOD have fits that are more similar
to that of WT-NiSOD with both S donors at the same Ni-S
distance. For D3A-NiSOD, the Ni-S bond distance found
was similar to that in WT-NiSOD (0.03 Å shorter), where
Y62F-NiSOD had a slightly longer Ni-S bond (0.07 Å) than
WT-NiSOD (Table 5). The WT- and D3A-NiSOD fits differ
by the addition of one Ni-N vector in the D3A-NiSOD fit,
and the Ni-N bonds are longer in D3A-NiSOD [2.08(2) Å
vs 1.83(4) Å in WT-NiSOD]. The fit obtained for Y62FNiSOD is slightly different in that the best fit splits the two
nitrogen scatterers into different shells with one ligand at
1.90 Å and the other at 2.2 Å.
The data indicate that when Tyr9 is altered by loss of the
OH group, different Ni-S distances are obtained. This
structural perturbation is confirmed by single-crystal diffraction studies (vide infra) and may result from the alteration
of a H-bonding network in the Ni hook domain. Alternatively, the results may indicate that the nickel site is a mixture
of low- and high-spin Ni centers, given the similarity of the
two distances to low-spin (51) and high spin (50, 51) nickel
thiolate model complexes.
PROTEIN STRUCTURE
NiSOD Crystallographic Results. The crystal structures of
two NiSOD mutants, Y9F and D3A, were determined to 1.9
Å. Both the Y9F- and D3A-NiSOD mutant structures are
present as hexamers with a trimer in the crystallographic
asymmetric unit. In an effort to understand the structure and
function of NiSOD, the structures of Y9F- and D3A-NiSOD
were compared to WT-NiSOD, including both the holo and
apo forms (PDB entries 1T6U, 1T6I, and 1T6Q).
Y9F Crystal Structure. The Y9F crystal structure revealed
the presence of an anion-binding site near the active site in
NiSOD. The WT-NiSOD structure showed the presence of
two water molecules making hydrogen bonds to the hydroxyl
of the Tyr9 side chain (17). In our Y9F-NiSOD mutant,
electron density appears at locations similar to those of two
water molecules in the WT-NiSOD structure. During the
initial interpretation of the electron density, water molecules
were placed at these locations in the structure. However,
when a water molecule was refined in one of these locations,
Fo - Fc electron density maps showed residual electron
density and positive peaks. When that water molecule was
replaced with a chloride ion, the refinement then led to lower
Rfree values and the positive peak in the Fo - Fc map
disappeared. The location of the chloride ion is ideally suited
to anion binding, with the main chain amide nitrogen atoms
of residues 3, 6, and 7 pointing toward the chloride and <4
Å away.
To confirm the identity of the chloride and to probe the
specificity of the putative anion-binding pocket, chloride was
substituted with bromide in the crystallization of Y9FNiSOD. Diffraction data were collected above the bromine
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absorption edge energy from crystals of both bromide and
chloride containing Y9F-NiSOD [NiSOD (Br) and NiSOD
(Cl), respectively]. The anomalous difference electron density
maps from NiSOD (Br) diffraction data revealed strong
density (more than eight standard deviations) in the anionbinding site, unambiguously identifying the bromide ion. In
the NiSOD (Cl) crystals, no peak appeared at this location,
as chloride has a negligible anomalous signal at this energy.
As an internal control, the nickel ion appears in both
anomalous maps, because nickel has a slight anomalous
contribution (∼2 e- vs ∼4 e- for bromine) at this energy.
To test if the anion-binding site is a feature of the Y9F
structure alone, the same location in the WT-NiSOD structure
was examined. Intriguingly, the coordinates of WT-NiSOD
contain a water molecule at this position, but Fo - Fc maps
from those diffraction data show a positive peak, suggesting
that the wild-type crystals may also contain some amount
of chloride ion in the anion-binding pocket (Figure 3).
D3A Crystal Structure. The D3A mutation leads to the
loss of two ion pairs across the interface between neighboring
molecules in the hexamer. As a result, 12 ionic interactions
are lost when comparing the WT structure to the D3A
mutant, providing a plausible explanation for the lower
thermal stability of the D3A mutant protein. The carboxyl
group of Asp3 lost upon mutation to Ala leads to the loss of
a salt bridge between Asp3 of one chain and Lys89 of a
neighboring chain. The loss of the carboxyl group from the
side chain of residue 3 produces a gap in the interface
between monomers, allowing the Nζ atom of Lys89 to move
toward Ala3 ∼2.0 Å to fill the space. Lys89 is critical to the
network of salt bridges across the interface between monomers in the hexamer. The movement of the Lys89 side chain
causes the neighboring Glu49 side chain to move by ∼2.0
Å toward Lys89. This movement of Glu49 weakens the ionic
interaction between Glu49 and His53 across the interface
between monomers. Therefore, mutating Asp3 to Ala results
in the loss of two ionic interactions across each interchain
interface (Asp3-Lys89 and Glu49-His53). With six of these
interfaces in the hexamer, the loss of 12 ion pairs per
hexamer could account for the decrease in the melting
temperature of the mutant from 84.8 to 73.9 °C.
As a result of the disruption in the intersubunit salt bridges
in the D3A structure, the “nickel hook” region is subtly
perturbed. Most notably, Tyr9 has moved ∼1 Å closer to
the nickel (Tyr9-O-Ni; WT-NiSOD distance of 5.47 Å; D3ANiSOD distance of 4.26 Å), and a water molecule (W1) has
been displaced from the anion-binding pocket (Figure 4).
Redox Chemistry. EPR and MCD spectroscopic methods
have been used to demonstrate that the nickel centers in the
resting oxidized and reduced proteins are low-spin Ni(III)
and diamagnetic Ni(II) centers, respectively (25). We have
used potentiometric titrations monitoring the absorbance at
380 nm assigned to a CysS f Ni LMCT transition in the
Ni(III) complex (25) to measure the potential of this redox
process (Figure 5). Using samples that were preoxidized with
KMnO4, the data from the initial reductive titrations were
fit to eq 4 to yield values of E° that are listed in Table 6.
Reoxidation of the reduced protein with KMnO4 shows that
the process is reversible. The potentials obtained from fitting
the oxiditative titrations are within experimental error of those
obtained from the reductive titrations (Table 6). The slight
increase in absorbance in the reoxidized enzyme likely
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FIGURE 3: NiSOD hook domain. (A) WT-NiSOD N-terminal region showing the active site Ni ion (green sphere) and two water molecules
(red spheres). (B) Same region of the Y9F-NiSOD mutant. A chloride ion (orange sphere) at the anion-binding site replaces a water molecule.
(C) Same region of the Y9F-NiSOD (Br) structure. An anomalous difference map (red cage), contoured at 4σ, from data measured above
the bromide absorption edge energy. Only the bromide and nickel show an anomalous signal. (D) Same region of the Y9F-NiSOD (Cl)
structure. An anomalous difference map (black cage), contoured at 4σ, from data measured above the bromide absorption edge. Only the
nickel shows an anomalous signal. The Ni centers are modeled as the His-off state; the actual state is most likely a mixture of His-on and
His-off, but higher B-factors led to poorly resolved electron density at the N-terminus. Images were generated in PyMOL (75).

FIGURE 4: Salt bridge changes in the D3A-NiSOD mutant. (A) The D3A-NiSOD mutant is shown at the interface between neighboring
monomers (blue and cyan) in the hexamer. A weighted 2Fo - Fc map shows the electron density in the interface. (B) Superposition of this
interface from D3A-NiSOD (blue and cyan) onto the wild type (pink and magenta) shows the movement of Glu49 and Lys89. Images were
generated with PyMOL (75).

The E° value obtained for WT-NiSOD [290(4) mV vs NHE]
is approximately midway between the potentials for the
oxidation of O2- to O2.
These values are quite similar to the potentials obtained
from other SODs (see Discussion). The potentials obtained
for the Y9F- and D3A-NiSOD mutants are very similar to
the potential of WT-NiSOD, consistent with the high catalytic
rates observed for these mutants (vide infra). This result is
similar to that found for MnSOD, where mutation of Tyr34
does not affect the redox potential of the Mn center (52).
Kinetics. The rate of dismutation of superoxide by NiSOD
was determined by monitoring the decrease in the absorbance
of the superoxide anion at 260 nm (ε ) 2000 M-1 cm-1)
(53) generated by pulse radiolysis. Table 3 shows the
calculated catalytic rate constant for the different tyrosine
mutants of NiSOD as compared to WT. Y9F-NiSOD exhibits
a slightly perturbed value of kcalc that is ∼63% of the activity

FIGURE 5: Redox titrations of WT-NiSOD. The green points are
the initial reduction of oxidized to reduced NiSOD, and the red
points were obtained by reoxidation of the same sample. The black
line depicts the best fit of the reductive titration (green dots) using
eq 4.

reflects a small concentration of the protein due to solvent
loss during the long incubation under Ar that was required
to stabilize the potential at each point (ca. 30 min per point).
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FIGURE 6: Ionic strength dependence of NiSOD catalysis. Y9F- and
WT-NiSOD were reacted with both NaCl (red for WT and yellow
for Y9F) and NaClO4 (blue for WT and green for Y9F), while Y62F
was reacted with only NaCl (black). Pulse radiolytic conditions
were the same as those mentioned in Experimental Procedures,
except 0.5-0.0156 M NaCl or NaClO4 was added to the solution
being monitored to probe the effect of ionic strength.

of WT-NiSOD. This value is slightly lower than the value
obtained from S. seoulensis Y9F-NiSOD (21) (78%) using
a construct in which the SOD from Streptomyces liVidans
was knocked out and replaced with a mutated copy of S.
seoulensis (21). The SOD activity in that study was measured
by the standard cytochrome c assay in cell extract (21).
However, the studies presented here reveal that at high
substrate concentrations (above a 5-fold excess), Y9F-NiSOD
begins to exhibit saturation behavior. The disappearance of
the absorbance at 260 nm at high superoxide concentrations
relative to the enzyme concentration no longer fits a firstorder process and begins to exhibit a linear component
suggesting saturation behavior. The half-life for superoxide
disappearance at high substrate concentrations in the presence
of Y9F-NiSOD is lowered to ∼41% of that in the presence
of lower superoxide concentrations. Saturation kinetics is not
a feature of WT-NiSOD, which cannot be saturated under
these conditions. Saturation behavior is seen in MnSODs,
although in that case for both the WT and mutants (54, 55).
The other Tyr mutant, Y62F-NiSOD, has a catalytic rate
similar to that of WT-NiSOD and does not saturate,
demonstrating that this residue is not intimately involved in
the redox mechanism of NiSOD. This is not surprising
as Tyr62 sits approximately 13 Å from the Ni center (17, 21).
The double mutant, Y9F/Y62F-NiSOD, is generally similar
to the Y9F mutant (kcalc ∼ 35% of that of WT) and displays
evidence of saturation at high substrate concentrations,
consistent with the mutation at Tyr9.
The crystal structure of Y9F-NiSOD (vide supra) shows
that one of the water molecules found in the active site pocket
near the metal site of WT-NiSOD has been replaced with a
small anion (Cl- or Br-) from the buffer solution. Mutation
of Tyr9 may lead to an opening of the binding pocket, which
would allow small anions to compete for the binding site,
placing a negative charge in the path of the negatively
charged superoxide and leading to diminished catalytic rates
or a modification of the electrostatic component of the rate
constant. To test this hypothesis, ionic strength measurements
were carried out using Cl- and ClO4-. Figure 6 shows a
plot of the log of the calculated rate versus the square root
of the ionic strength for WT, Y9F, and Y62F. The results
are similar to those found for native NiSOD from S.
seoulensis (47) and do not show a change from WT-NiSOD
behavior as the ionic strength increases. These results suggest
that small anions are not competing with superoxide during
catalysis for the binding site.
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FIGURE 7: X-Band EPR data from D3A-NiSOD. (A) As-isolated
D3A. (B) H2O2-treated D3A. (C) Enlargement of the region near g
) 2.00 expanded (solid line) and a simulation with parameters gx
) gy ) gz ) 2.004, Axx ) Ayy ) 5 G, and Azz ) 20 G (red dashed
line). (D) H2O2-treated D3A-NiSOD (d4-Tyr), showing alteration
of hyperfine splitting due to tyrosine ring protons. All spectra are
shown with the same intensity scale with the exception of panel
D, which has a scale half as large.

Mutation of Asp3 to Ala results in a 50% decrease in
activity at pH 7.5 when compared to that of WT-NiSOD.
Upon further investigation, it was also determined that D3ANiSOD was much more sensitive to peroxide than WTNiSOD. To examine the nature of this sensitivity, both D3Aand WT-NiSOD were incubated with H2O2 for 5 min, and
then the reductant or inhibitor was dialyzed away. These
samples were then tested for SOD activity using pulse
radiolytic generation of O2-. WT-NiSOD retained full
activity, whereas the activity of D3A-NiSOD was below the
detectable limit (data not shown). ESI-MS of D3A-NiSOD
before and after H2O2 incubation were identical (Supporting
Information), ruling out the possibility that the peroxide was
causing an oxidative modification of the protein, such as
conversion of the cysteine thiolate ligands to sulfinates (24),
which would likely result in a loss of activity. However,
incubation of D3A-NiSOD with peroxide did result in the
production of a tyrosyl radical EPR signal (vide infra), an
oxidative modification that does not affect the MW of the
enzyme.
As isolated, D3A-NiSOD has the same EPR parameters
as WT-NiSOD (Table 3). However, when treated with H2O2
[a reductant and inhibitor of NiSOD (56)] under anaerobic
conditions, a signal attributable to a protein-based radical at
g ) 2.004 emerges with a 1H hyperfine splitting pattern that
resembles a tyrosine radical (Figure 7) (57). Integration of
this signal versus Ni(PDTC) showed that ∼8% of the enzyme
possessed the tyrosine radical. This assignment was confirmed by replacing all four tyrosine residues with d4-tyrosine,
where the protons on the aromatic ring are substituted with
deuterons. The resulting hyperfine splitting is clearly altered,
consistent with the assignment of the hyperfine to a tyrosyl
radical. (The deuterated sample is ∼50% less concentrated
than the nondeuterated sample.) This signal is not observed
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to any significant extent in WT-NiSOD or any of the other
mutants and indicates that the interaction of the enzyme with
peroxide is fundamentally altered by the D3A mutation.
DISCUSSION
Redox Chemistry of the Nickel Site. The protein environments of the catalytic metal sites in SODs are responsible
for achieving at least three features of these enzymes:
adjusting the redox potential of the metal to a value that is
optimum for catalysis (ca. 300 mV) (8), controlling anion
access to the active site (27), and providing a source of
protons for formation of H2O2 (17, 21). The O2/O2- reduction
potential has been determined to be -160 mV (vs NHE),
and the O2-/H2O2 potential lies at 870 mV (vs NHE) (58).
The midpoint of these two potentials (365 mV vs NHE) is
the potential at which an optimal SOD catalyst would lie.
Nickel is an unusual choice of metal for an SOD because
the reduction potential of Niaq(III)/(II) is g2 V [1.94 V for
low-spin Ni(III) and 2.24 for high-spin Ni(III)] (6) and lies
well outside the biologically relevant range. Nonetheless, the
redox titrations of NiSOD presented above establish that the
redox potential of the nickel site is ∼290 mV, appropriate
for SOD catalysis. The other classes of SODs (Cu/Zn, Mn,
and Fe) all have reduction potentials near 300 mV (vs NHE)
with deviations up to ∼100 mV (59-63). This demonstrates
that the protein environment is critical for tuning the
reduction potential of each metal to the optimal potential
for SOD catalysis. The reduction potential for hexa-aqua
complexes of Mn (1.5 V) and Fe (0.77 V) (8, 64) requires
a smaller adjustment by the protein than Ni does. The
suppression of the Em in Mn- and FeSOD is achieved by a
hydrogen bonding network that couples the protonation state
of an aqua ligand to the redox process of the metal (8). In
the case of NiSOD, no aqua ligand exists in any crystal
structure, and thus, the protonation state of such a ligand is
not available for adjusting the redox potential of Ni(III)/(II).
Furthermore, the shift in potential for the Fe(III)/(II) redox
couple in FeSOD has been attributed to the protonation state
of the aqua/hydroxo ligand (65); such a shift would not be
adequate for optimizing the potential of a nickel center in a
similar ligand environment. Instead, NiSOD relies on a
different ligand environment, one that includes cysteine
ligands, a feature of every redox active nickel enzyme that
utilizes the Ni(III)/(II) redox couple (66). Thus, NiSOD uses
a unique strategy to accomplish the same goal, a ∼300 mV
redox potential, that is found in every other SOD.
EPR integration of the Ni(III) signals in the resting,
oxidized enzyme accounts for only 50% of the Ni present
in WT-NiSOD and in the mutant enzymes, indicating that
NiSOD contains a 50:50 mixture of Ni(II) and Ni(III). The
amount of Ni present in NiSOD was determined by ICPOES (see Experimental Procedures) after extensive buffer
exchanging and treatment with Chelex to remove any
nonspecifically bound metal. EXAFS analysis confirms that
all of the Ni is bound in the active site, since each Ni center
has two S donor ligands, and there are only two cysteine
residues in the protein. Oxidation of resting, oxidized WTNiSOD with KMnO4 failed to increase the intensity of the
EPR signal arising from the five-coordinate Ni(III) center
(Supporting Information), indicating that the 50:50 mixture
is, in fact, the fully oxidized enzyme. Although these data
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do not show why one nickel center is redox active and the
other one is not, a likely possibility is that the apical His1
imidazole ligand plays a role. The two nickel centers differ
by coordination of the imidazole ligand (His-on vs His-off),
and it seems likely that the Ni(II/III) redox potential of the
four-coordinate planar center is much higher than for the
five-coordinate complex. In this regard, it is noteworthy that
mutation of the apical His ligand to Gln (49) or Ala (67)
yields mutants that have a resting oxidation state that contains
only EPR-silent Ni(II). Other than a possible role in
maintaining charge neutrality in the hexamer during catalysis,
the biochemical rationale for the equal mix of the two
oxidation states remains to be elucidated but would seem to
require some cooperativity between active site centers to
maintain the equal balance of oxidized and reduced nickel
ions. Until now, the mechanism of communication between
active sites within the hexamer that are spaced ∼25 Å apart
has not been clear, but the structure of D3A-NiSOD suggests
a mode for maintaining the redox balance. As described
above, a network of ion pairs connect Asp3 to Lys89 to
Glu49 to His53 across the interface between neighboring
monomers (Figure 4) derived from different trimer subunits.
His53 also lies near a 2-fold symmetry axis of the hexamer
(which contains 32-point symmetry). The Nδ atom of His53
hydrogen bonds to a water molecule that lies directly on the
molecular 2-fold axis. Thus, the His53 side chains from two
monomers related by a molecular dyad make a watermediated hydrogen bond, raising the possibility that information about one active site nickel may be communicated to a
neighboring active site nickel.
Human MnSOD (hMnSOD) is a homotetramer and forms
a dimer of dimers. A recent study examined the H-bonding
network between Glu162 and His163 (a metal ligand) by
mutating Glu162 to both an Ala and Asp. This H-bonding
network connects neighboring monomers across a dimer
interface and links two Mn centers (54). Both mutations
retained tetrameric structure and specificity for Mn over Fe
[in contrast, studies of the analogous mutation made in E.
coli MnSOD (EcMnSOD), a homodimer, show the mutant
enzyme preferred Fe over Mn (55)]. Both the human Glu162
mutations have diminished activity compared to WThMnSOD (54), but each helps to elucidate fine points of how
hMnSOD carries out O2- dismutation. By performing pH
titrations on the enzyme and monitoring the electronic
absorption spectrum, the pKa of the system can be determined. WT-hMnSOD has a pKa of ∼9.5, which has been
attributed to ionization of Tyr34 (32, 68, 69). In the E162DhMnSOD mutant, the pKa decreases slightly to 8.7(2), while
the E162A-hMnSOD pKa is closer to the pKa of Tyr in water
[10.1(1)] (54). This can be explained by the interaction of
Glu162 and Tyr34, which are 6.2 Å apart. The H-bonding
network extends from the carboxylate of Glu162 to His143
through a solvent molecule to Tyr34. This network is
maintained in the E162D-hMnSOD mutant but is disrupted
in the E162A-hMnSOD mutant. This is analogous to the
backbone amide of Asp3 in NiSOD, which is connected to
the phenol proton on Tyr9 through a H-bonding network
involving ordered water in the pocket. This network is
perturbed in the D3A-NiSOD mutant, and perturbed kinetics
and peroxide sensitivity are observed. (It is noteworthy that
in hMnSOD, there is no functional difference between
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E162A and E162D mutants despite the structural difference.
In NiSOD, there is a functional difference.)
Roles of Tyr9 in NiSOD Catalysis. Mutations of conserved
second-coordination sphere residues, Tyr9, Asp3, and the
more distant Tyr62, do not lead to major perturbations of
the protein structure, or of either the electronic structure or
redox chemistry of the nickel site. However, both the Tyr9
and Asp3 mutations have significant effects on catalysis. In
the case of Y9F, there is a small decrease in kcalc and the
enzyme shows the onset of saturation behavior that is not a
feature of WT-NiSOD under the conditions studied. In the
case of D3A-NiSOD, the loss of activity is more pronounced;
the enzyme is somewhat less thermally stable and exhibits
distinct reactivity with H2O2.
The roles played by the Tyr9 residue in catalysis can
account for much of the altered functions of Y9F- and D3ANiSOD. The structure of WT-NiSOD reveals no water
molecules coordinated to either the five-coordinate pyramidal
His-on Ni(III) center or the reduced four-coordinate planar
His-off Ni(II) center. Tyr9 lies near the vacant sixth
coordination position with a Ni-O-Tyr9 distance of 5.47
Å. The position of Tyr9 is such that the phenol proton is
engaged in hydrogen bonds with two ordered water molecules, W1 at 2.56 Å and W2 at 2.84 Å, that also accept
hydrogen bonds from amide protons from Cys6 (W1) and
Asp3 (W2) (17, 21). In the Y9F mutant, loss of the phenol
group leads to a small perturbation in the position of the
phenyl ring, opening up the existing anion binding pocket
(Figure 3), and W1 is replaced with Cl-. This is the first
crystallographic characterization of an anion complex of
NiSOD and clearly identifies a likely binding site for the
substrate, O2-. That Cl- is not a nickel ligand is evidenced
by the 3.5 Å distance, the absence of a Ni-Cl vector in the
EXAFS spectrum, and the lack of chlorine hyperfine splitting
(even at 200 mM Cl-) in the EPR spectrum, particularly on
gz which exhibits large N hyperfine splitting (Az ) 25 G)
from the apical H1 imidazole ligand in the dz21 ground state.
Hyperfine splitting from the enzyme (likely due to the amide
and or N-terminal amine N-donor ligands) is partially
resolved on gy in Y9F-NiSOD. Similar hyperfine splitting
on the gy feature has also been observed in azide-inhibited
NiSOD (17). When 15N-labeled azide was used, the same
EPR spectrum was observed, indicating that the splitting was
due to an electronic and/or structural perturbation rather than
to azide binding (17). Further, the Cl- in the Y9F-NiSOD
structure is in the same location that was previously
suggested for azide (anion) binding (17). The Cl- anion has
hydrogen bonding interactions with both of the amides from
Cys6 (N-Cl distance of 3.4 Å) and Asp3 (N-Cl distance
of 3.4 Å), which provide a mechanism for a small perturbation of the nickel site. The Cl- is positioned such that it could
interact with the phenol group of Tyr9 in WT-NiSOD, which
suggests possible roles for Tyr9 in the release of H2O2, and
in controlling access of anions to the active site. The size of
the pocket in WT-NiSOD is appropriate for only small anions
and is positioned near the nickel site but does not allow
anions to bind to the metal. Since there is no evidence of
anion binding to Ni in either His-on [Ni(III)] or His-off
[Ni(II)] sites, and assuming that O2- binds to the same site,
the structural data support an outer-sphere redox reaction
for both half-reactions as illustrated in Scheme 1.
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In an outer-sphere mechanism, the superoxide would
displace the two water molecules (Scheme 1, I) and sit
between the backbone amides of Asp3 and Cys6 (Scheme
1, II). Electron transfer would occur, yielding molecular
oxygen and Ni(II) (Scheme 1, II f III). The second half of
the reaction starts the same as the first half, with superoxide
binding in the substrate binding pocket (Scheme 1, IV).
Electron transfer occurs concomitant with proton transfers,
leading to formation of peroxide and Ni(III). Loss of the
phenol group and opening of the anion-binding pocket lead
to a small perturbation in the position of the phenyl ring
and increased occupancy of the site by Cl- and Br- in the
absence of O2- (Figure 3). When the bound peroxide is
protonated, the phenol group could play a role in destabilizing
the binding of the product, H2O2, in the anion binding site
and inhibiting the direct interaction with the nickel site and
its oxidation-sensitive cysteine thiolate ligands. Slower
peroxide release in the absence of the phenol group could
account for the decrease in activity and the saturation
behavior observed in Y9F-NiSOD kinetics.
It has been shown that binding of azide to EcMnSOD is
temperature-dependent. At low temperatures, a six-coordinate
complex derived from complexation of azide is formed,
whereas at room temperature, the active site is five-coordinate
andlacksanazideligand,resemblingtherestingenzyme(31,70,71).
One hypothesis speculates that a “dead-end” complex of
EcMnSOD forms when superoxide binds to Mn2+-SOD,
causing oxidation of the Mn center and reduction of
superoxide to peroxide with concomitant transfer of a proton
from the bound water to yield a Mn center with bound
hydroperoxide and OH- (31). The Y34F mutation changes
the way the enzyme interacts with anions. When azide is
added to Y34F-Mn3+-SOD, the enzyme resembles the lowtemperature six-coordinate N3-Mn3+-SOD complex and
exhibits no temperature dependence (71). Thus, the “gateway” tyrosine seems to play a critical role in controlling
access of anions to the metal site in both Fe- and
MnSODs (15, 16, 71) by inhibiting anion binding at the metal
center. The same function for Tyr9 appears to be a feature
of NiSOD catalysis. Second-sphere residues such as Tyr34
also tune the lability of the peroxide product in MnSOD.
This is seen in the fact that the activity of Y34F-MnSOD is
more product-inhibited than that of WT-MnSOD (68).
Another possible explanation might be that mutation of
Tyr9 and loss of W1 from the active site perturb a hydrogen
bonding network that is important for supplying protons for
the formation of H2O2 (17, 21). This has also been proposed
for MnSOD, where the H-bonding network in the second
coordination sphere has been implicated as the source of
protons for the release of H2O2 (68, 72). Studies of Tyr34
from hMnSOD shows that replacing the Tyr with a Phe has
little effect on the protein fold or the geometry at the active
site; in fact, the thermal stability of the mutant is increased
when compared to that of WT-hMnSOD (68). Tyr34 is not
essential for MnSOD catalysis, as at low substrate concentrations (compared to Km) Y34F-MnSOD has catalytic rates
similar to that of WT-MnSOD. This is shown by the fact
that the steady state constant, kcat/Km, is the nearly identical
for both Y34F- and WT-MnSOD and is near the diffusion
limit of 109 M-1 s-1. The only major perturbation is the
decrease in the maximal rate, kcat, which is approximately
10-fold lower for the mutant enzyme (68). This implies that
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Scheme 1: Proposed Outer-Sphere Mechanism for NiSODa

a
Ni(III) is indicated by the His-on complex, while Ni(II) is denoted as a His-off complex, although removal of His1 during turnover may not
occur. Superoxide is denoted by the orange molecule, and water is denoted by red spheres. Images were generated with PyMOL (75).

Tyr34 may be involved in peroxide release or proton
donation either directly to the metal site or indirectly through
a H-bonding network that ties the Tyr34 to the Mn active
site (68). Mutation of Tyr34 has also been examined in
FeSOD from E. coli (EcFeSOD), and Y34F-FeSOD results
in a rate decrease of ∼60% when compared to that of WTFeSOD (33). The gateway Tyr residue in FeSOD also seems
to play a key role in controlling anion binding to the metal
site, which differs between the reduced and oxidized state
in FeSOD (15).
The importance of Tyr9 in controlling the access of H2O2
to the active site is supported by studies of D3A-NiSOD.
Although this mutant exhibits reduced activity relative to
WT-NiSOD, redox titration shows that this is not due to
alteration of the redox potential of the nickel site. Further,
the similar EPR spectrum obtained from Ni(III) centers in
the oxidized enzyme shows that the electronic structure of the
nickel site is not perturbed by the D3A mutation. Nonetheless, this mutant exhibits a drastically altered interaction with
H2O2. Unlike WT-NiSOD, which shows inhibition (activity
can be restored to normal levels upon removal of peroxide)
by H2O2, D3A-NiSOD is inactivated (loss of activity is
irreversible) by exposure to H2O2. This inactivation does not
result from oxygenation of the cysteine residues but appears
to involve the oxidation of Tyr9 to a tyrosyl radical as
detected by EPR. The crystal structure of D3A-NiSOD
reveals that in addition to the loss of two intersubunit
interactions per monomer resulting in a hexamer with lower
thermal stability, the position of Tyr9 is altered. In D3ANiSOD, the tyrosine is positioned such that the phenol group
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FIGURE 8: Superposition of the Ni hook domains of WT-NiSOD
(blue), Y9F-NiSOD (purple), and D3A-NiSOD (orange) showing
the position of Y9 in each. This image was generated with PyMOL
(75).

is ∼1 Å closer to the nickel site (Figure 8). In this
configuration, it is in a position that would be less effective
in inhibiting access of H2O2 to the nickel site and could even
stabilize formation of a Ni-OOH peroxo or superoxo adduct
that results in oxidation of Tyr9.
Mutation of Tyr34 in MnSOD leads to a more productinhibited form of the enzyme, which is pronounced in
hMnSOD and not as evident in E. coli MnSOD (EcMnSOD)
(73). To probe this inhibition further, Phe66 from hMnSOD
was studied because it contributes to the local environment
of Tyr34 (74). Phe66 also lies at a dimer interface of
hMnSOD, and when this was mutated to an Ala, there were
no major perturbations as the enzyme acted in a manner very
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similar to that of WT-hMnSOD. F66L-hMnSOD exhibited
a decrease in the level of product inhibition and had
characteristics similar to that of EcMnSOD. Crystallographic
characterization of F66L-hMnSOD has provided insight into
why this particular mutant had a decreased level of product
inhibition. The substitution of Phe66 with Leu had an effect
on two residues. First, Gln119 moved approximately 1 Å
farther from the Mn site but maintained the same distance
between residues 66 and 119 as seen in WT-hMnSOD. Tyr34
also had a subtle movement of 0.3 Å away from the Mn
center. This movement is small and has a high uncertainty
due to the resolution of the structure (2.2 Å). This is
consistent with the data presented here in that inward
movement of the gateway tyrosine (Tyr9 of NiSOD and
Tyr34 of MnSOD) leads to a more product sensitive enzyme.
When the corresponding residue swings away from the metal
center, this inhibition is attenuated in hMnSOD and is not
seen in NiSOD.
The angle of the aromatic ring plane of residue 9 (Figure
8) may also act as a sensor for the presence of bound metal.
When the locations of Tyr9 in the holo- and apo-NiSOD
structures are compared, the angle of the residue 9 aromatic
ring plane changes by 15° between the two structures. This
difference is consistent in all 12 copies of the holoenzyme
monomer in PDB entry 1T6U and all six copies of the
apoenzyme in 1T6I and 1T6Q. Thus, the aromatic ring may
also be a sensor for the presence of a metal in the active site
of the enzyme. In the case of the Y9F-NiSOD mutant
structure, the angle of the aromatic ring of residue 9 is more
consistent with the apo structures, producing a structure
intermediate between the active holoenzyme and the inactive
apoenzyme. The Y9F mutant is the first structure in which
the angle of the residue 9 side chain is decoupled from the
presence of metal in the active site of the enzyme. This
observation is consistent with the result that the Y9F mutant
does not bind nickel as efficiently as the wild-type enzyme
(the crystals have only 60% occupancy). Additionally, the
eight N-terminal residues that comprise the Ni hook domain
have higher B-factors and lower quality density than the rest
of the structure, suggesting some heterogeneity in the region
around the Ni center. It appears that the Ni is required to
properly form a well-ordered static Ni hook region at the
N-terminus.
Structural Homology between MnSOD and NiSOD. The
analogous functional roles ascribed to Tyr9 in NiSOD and
Tyr34 in MnSOD are also reflected in their structural
relationship with their respective metal centers. Both tyrosine
phenol oxygen atoms lie at a M-O distance of ca. 5.5 Å
and are engaged in well-defined hydrogen bonding interactions. In addition, both are close to a second aromatic residue.
In the case of MnSOD, Tyr34 lies between Phe66 and the
manganese center. The F66L-MnSOD mutation in hMnSOD
results in perturbation of the positions of water molecules
and hydrogen bonding interactions that leads to a mutant
enzyme that is less sensitive to peroxide inhibition (74). In
WT-NiSOD, Tyr62 lies ∼13 Å from the nickel center and
Tyr9 lies between it and the metal. Neither the structure of
the nickel site (XAS and EPR) nor the kinetic properties of
Y62F-NiSOD differ from significantly from those of WTNiSOD. Although no similar function has been found for
NiSOD Tyr62 and human MnSOD Phe66, they share the
same spatial relationship to the respective Tyr residues near

FIGURE 9: Superposition of the active site structures of hMnSOD
(pink) and S. coelicolor NiSOD (green) showing the positions of
aromatic residues. This image was generated with PyMOL (75).

the metal sites. This is clearly shown in Figure 9, which
shows a superposition of the active site of the human
MnSOD structure (PDB entry 1LUV) and WT-NiSOD (PDB
entry 1T6U), where Phe66 from MnSOD and Tyr62 from
NiSOD were constrained to overlap. Thus, it can be seen
that despite the lack of any primary, secondary, tertiary, or
quaternary structure, the two enzymes have arrived at the
same mechanism for controlling access of anions and H2O2
to the active site.
SUPPORTING INFORMATION AVAILABLE
Amino acid sequence alignments for selected NiSODs,
DSC thermograms, ESI-MS under nondenaturing conditions,
EPR spectra of WT-NiSOD and mutant NiSODs and asisolated and KMnO4-oxidized WT-NiSOD, and tables of
EXAFS fits. This material is available free of charge via the
Internet at http://pubs.acs.org.
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